Microtubule-associated protein Tau (MAPT) iRNA agent compositions and methods of use thereof
By designing RNAi compositions targeting the MAPT gene, silencing the 4R-tau RNA transcripts, the problem of ineffective treatment of 4R-tau-related diseases in the prior art was solved, and the effect of significantly reducing 4R-tau expression was achieved. 4R-tau-related disorders provide new treatment pathways.
Patent Information
- Application Number
- CN202380029685.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-22
- Filing Date
- 2023-02-10
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art has not been effective in treating 4R-tau-related neurodegenerative conditions, such as progressive supranuclear palsy and cortical basal syndrome, and lacks agents that preferentially inhibit or regulate 4R-tau expression.
An RNAi composition was designed to achieve RNA-induced silencing complex-mediated cleavage of 4R-tau RNA transcripts by targeting specific hot spot regions within exon 10 of the MAPT gene, reducing the expression of 4R-tau mRNA. The composition includes a double-stranded ribonucleic acid (dsRNA) agent, which is able to degrade the 4R-tau mRNA of the corresponding gene in the cell and significantly inhibit the expression of 4R-tau.
This method can significantly reduce 4R-tau expression in cells to achieve inhibitory effects of at least 25% to 95%, providing a potential treatment for 4R-tau-related disorders to improve the quality of life of patients.
Smart Images

Figure BDA0005055575920000161 
Figure BDA0005055575920000301 
Figure BDA0005055575920000451
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of priority to U.S. Provisional Application No. 63 / 309,399, filed on February 11, 2022, and U.S. Provisional Application No. 63 / 322,618, filed on March 22, 2022. The entire contents of the above applications are incorporated herein by reference.
[0003] Sequence Listing
[0004] This application contains a sequence listing that has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. The XML copy created on February 10, 2023 is named A108868_1580WO_SL_XML and is 4,839,728 bytes in size. Background Art
[0005] The microtubule-associated protein tau (MAPT) gene encoding the protein microtubule-associated protein Tau (MAPT), which is a member of the microtubule-associated protein family, is located in the chromosome region 17q21.31 (base pairs 45,894,382 to 46,028,334 on chromosome 17). The MAPT gene consists of 16 exons. Variable mRNA splicing produces six MAPT subtypes, totaling 352-441 amino acids. In three of the six MAPT subtypes, the microtubule binding domain of MAPT contains three repeat segments (3R-tau subtype), while in the other three MAPT subtypes, the corresponding domain contains four repeat segments (4R-tau subtype).
[0006] MAPT transcripts are differentially expressed throughout the body, mainly in the central and peripheral nervous systems. Wild-type Tau is involved in stabilizing microtubules in neuronal axons, maintaining dendritic spines, and regulating axonal transport, microtubule dynamics, and cell division. Pathogenic variants of MAPT have been found in approximately 10% of patients with primary tauopathy. Variants are mainly missense mutations and are located in exons 9-13 (microtubule binding domains), many of which affect the alternative splicing of exon 10.
[0007] Tauopathy is a class of heterogeneous progressive neurodegenerative disorders, which is pathologically characterized by the presence of Tau aggregates in the brain. Phenotypically, tauopathy shows variable progression of movement, cognition and behavioral disorders. People usually express 3R-tau and 4R-tau at equal ratios. In some tauopathy such as Alzheimer's disease, experimental evidence from postmortem brain tissue shows that the insoluble aggregates of tau are composed of 3R-tau and 4R-tau. However, sporadic (spAD) and rapidly progressive (rpAD) Alzheimer's disease have recently been characterized by 4R-tau enriched aggregates (see Kim et al., Science Translational Med.2022 14, eabg025). In other 4R-tauopathy, such as progressive supranuclear palsy (PSP) and cortical basal degeneration (CBD), 4R-tau protein is the type of aggregation tendency of tau. The causes of these different types of aggregates in the disease are unknown.
[0008] There is currently no curative therapy for 4R-tauopathy, and treatment is only intended to relieve symptoms and improve the patient's quality of life. Therefore, there is a need for an agent that can effectively and preferably preferentially inhibit or regulate the expression of 4R-tau, so that subjects with 4R-tau-related disorders such as progressive supranuclear palsy (PSP), corticobasal syndrome (CBD), argyrophilic grain disease (AGD), multisystem tauopathy with Alzheimer's disease (MSTD), globular glial tauopathy (GGT), sporadic Alzheimer's disease (spAD), rapidly progressive Alzheimer's disease (rpAD) or another 4R-tauopathy can be effectively treated. Summary of the invention
[0009] The present disclosure provides RNAi compositions, which achieve RNA-induced silencing complex (RISC)-mediated cutting of the 4R-tau RNA transcript of the MAPT gene by targeting a specific hotspot region in exon 10 of the MAPT gene. The MAPT gene can be in a cell, for example, a cell in a subject (such as a human). The use of these iRNAs enables targeted degradation of the 4R-tau mRNA of the corresponding gene (MAPT gene) in mammals.
[0010] iRNA of the present disclosure has been designed to target the hotspot in exon 10 of MAPT gene, for example, there is missense and / or deletion mutation in the exon of gene and there is the MAPT gene of the combination of nucleotide modification.Relative to control level, iRNA of the present disclosure suppresses the expression of 4R-tau transcript by at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 95%, and reduces the level of the locus containing sense and antisense.It is not intended to be limited by theory, it is believed that the combination or subcombination of the above-mentioned characteristics and specific target sites, or the specific modification of these iRNAs give the efficacy, stability, efficacy, persistence and safety of the iRNA of the present disclosure improvement.The combination or subcombination of the aforementioned characteristics and specific target sites, or the specific modification in these iRNAs can also give the iRNA of the present disclosure the enhanced specificity of the 4R-tau subtype of MAPT gene relative to the 3R-tau subtype.
[0011] In one aspect, the present disclosure provides a double-stranded ribonucleic acid (dsRNA) agent for inhibiting the expression of 4R-tau, wherein the dsRNA agent includes a sense strand and an antisense strand forming a double-stranded region, and wherein the sense strand comprises at least 15 consecutive nucleotides that differ by no more than 3 nucleotides from the nucleotide sequence of nucleotides 1009-1053 of SEQ ID NO: 3, and the antisense strand comprises at least 15 consecutive nucleotides that differ by no more than 3 nucleotides from the nucleotide sequence of nucleotides 1007-1053 of SEQ ID NO: 4. In a specific embodiment, the sense strand comprises at least 15 consecutive nucleotides of nucleotides 1009-1053 of SEQ ID NO: 3, and the antisense strand comprises at least 15 consecutive nucleotides of nucleotides 1007-1053 of SEQ ID NO: 4.
[0012] On the other hand, the present disclosure provides a dsRNA agent for inhibiting the expression of 4R-tau, wherein the dsRNA agent includes a sense strand and an antisense strand forming a double-stranded region, wherein the antisense strand comprises a complementary region to an mRNA encoding 4R-tau, and wherein the complementary region comprises at least 15 consecutive nucleotides that differ by no more than 3 nucleotides from the nucleotide sequence of nucleotides 1007-1053 of SEQ ID NO: 4. In a specific embodiment, the complementary region comprises at least 15 consecutive nucleotides of nucleotides 1007-1053 of SEQ ID NO: 4. The complementary region may be entirely present within nucleotides 1007-1053 of SEQ ID NO: 4.
[0013] In yet another aspect, the present disclosure provides a dsRNA agent for inhibiting the expression of 4R-tau, wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double-stranded region, wherein the antisense strand comprises a complementary region to an mRNA encoding 4R-tau, and wherein the complementary region comprises at least 15 consecutive nucleotides that differ by no more than 3 nucleotides from any antisense nucleotide sequence in Table 7 or 8. In a specific embodiment, the nucleotide sequences of the sense strand and the antisense strand comprise any sense and antisense nucleotide sequences of any duplex in Table 7 or 8.
[0014] In some embodiments of the dsRNA agent according to any of the preceding aspects, the sense strand comprises at least 15 consecutive nucleotides that differ by no more than three nucleotides from any of the following nucleotide sequences: nucleotides 1009-1029, 1016-1036, 1018-1038, 1020-1040, 1021-1041, 1022-1042, 1024-1044, 1027-1047, 1028-1048, 1029-1049, 1030-1050, 1032-1052, 1033-1053, 1014-1048, and 1022-1048 of SEQ ID NO:3, and the antisense strand comprises at least 15 consecutive nucleotides of the corresponding nucleotide sequence of SEQ ID NO:4.
[0015] In some embodiments, the antisense strand comprises at least 15 consecutive nucleotides that differ by no more than three nucleotides from any antisense strand nucleotide sequence of a duplex selected from the group consisting of AD-1423276, AD-1423283, AD-1423285, AD-1423287, AD-1423288, AD-1423289, AD-1423291, AD-1423294, AD-1423295, AD-1423296, AD-1423297, AD-1423299, and AD-1423300. In specific embodiments, the antisense strand comprises at least 15 consecutive nucleotides that differ by no more than three nucleotides from any antisense strand nucleotide sequence of a duplex selected from the group consisting of AD-1423283, AD-1423291, AD-1423294, and AD-1423295.
[0016] In some embodiments, the dsRNA agent is capable of reducing 4R-tau isoform mRNA expression by at least about 50%, 55%, 60%, 65%, 70%, or 75% in cells expressing both 3R-tau and 4R-tau isoforms, while reducing 3R-tau isoform mRNA expression by no more than about 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5%.
[0017] In some embodiments, the dsRNA agent is capable of reducing 4R-tau isoform mRNA expression by at least about 70% while reducing 3R-tau isoform mRNA expression by no more than about 30% in cells expressing both 3R-tau and 4R-tau isoforms.
[0018] In one embodiment, the sense strand, the antisense strand, or both the sense strand and the antisense strand described herein are conjugated to one or more lipophilic moieties.
[0019] In one embodiment, the lipophilic moiety is conjugated to one or more internal positions in the double-stranded region of the dsRNA agent.
[0020] In one embodiment, the lipophilic moiety is conjugated via a linker or a carrier.
[0021] In one embodiment, the lipophilic moiety has a lipophilicity, as measured by logKow, of greater than zero.
[0022] In one embodiment, the hydrophobicity of the double-stranded RNA agent as measured by the unbound fraction in a plasma protein binding assay of the double-stranded RNA agent exceeds 0.2.
[0023] In one embodiment, the plasma protein binding assay is an electrophoretic mobility shift assay using human serum albumin.
[0024] In some embodiments, the dsRNA agent comprises at least one modified nucleotide.
[0025] In one embodiment, no more than five sense strand nucleotides and no more than five antisense strand nucleotides in a dsRNA agent of the present disclosure are unmodified nucleotides.
[0026] In one embodiment, all nucleotides of the sense strand and all nucleotides of the antisense strand in the dsRNA agent are modified nucleotides.
[0027] In some embodiments, at least one modified nucleotide of the dsRNA agent is selected from deoxynucleotides, 3'-terminal deoxythymidine (dT) nucleotides, 2'-O-methyl modified nucleotides, 2'-fluoro modified nucleotides, 2'-deoxy modified nucleotides, locked nucleotides, unlocked nucleotides, conformationally restricted nucleotides, constrained ethyl nucleotides, abasic nucleotides, 2'-amino modified nucleotides, 2'-O-allyl modified nucleotides, 2'-C-alkyl modified nucleotides, 2'-hydroxy modified nucleotides, 2'-methoxyethyl modified nucleotides, 2'-O-alkyl modified nucleotides, morpholino nucleotides, phosphoramidates, nucleotides containing non-natural bases, tetrahydropyran modified nucleotides, Nucleotides, 1,5-anhydrohexitol-modified nucleotides, cyclohexenyl-modified nucleotides, nucleotides containing 5'-phosphorothioate groups, nucleotides containing 5'-methylphosphonate groups, nucleotides containing 5'-phosphate or 5'-phosphate mimetics, nucleotides containing vinylphosphonate, nucleotides containing adenosine-diol nucleic acid (GNA), nucleotides containing thymidine-diol nucleic acid (GNA) S-isomers, nucleotides containing 2-hydroxymethyl-tetrahydrofuran-5-phosphate, nucleotides containing 2'-deoxythymidine-3'-phosphate, nucleotides containing 2'-deoxyguanosine-3'-phosphate, and terminal nucleotides connected to cholesteryl derivatives and dodecanoic acid bisdecylamide groups; and combinations thereof.
[0028] In one embodiment, the modified nucleotides of the dsRNA agent are selected from 2'-deoxy-2'-fluoro modified nucleotides, 2'-deoxy modified nucleotides, 3'-terminal deoxythymidine nucleotides (dT), locked nucleotides, abasic nucleotides, 2'-amino modified nucleotides, 2'-alkyl modified nucleotides, morpholino nucleotides, phosphoramidates, and nucleotides containing non-natural bases.
[0029] In one embodiment, the modified nucleotides of the dsRNA agent include a short sequence of 3'-terminal deoxythymidine nucleotides (dT).
[0030] In one embodiment, the modifications on the nucleotides of the dsRNA agent are 2'-O-methyl, 3-RNA, and 2'-deoxy-2'-fluoro modifications.
[0031] In one embodiment, the modifications on the nucleotides of the dsRNA agent are selected from 2'-O-methyl, 2'-deoxy, GNA, and 2'-deoxy-2'-fluoro modifications.
[0032] In some embodiments, the dsRNA agent further comprises at least one phosphorothioate internucleotide linkage.
[0033] In one embodiment, the dsRNA agent comprises 6-8 phosphorothioate internucleotide linkages.
[0034] In one embodiment, each strand of the dsRNA is no more than 30 nucleotides in length.
[0035] In one embodiment, at least one strand of the dsRNA agent comprises a 3'-overhang of at least 1 nucleotide. In another embodiment, at least one strand of the dsRNA agent comprises a 3'-overhang of at least 2 nucleotides.
[0036] In some embodiments, the double-stranded region of the dsRNA agent can be 15-30 nucleotide pairs in length; 17-23 nucleotide pairs in length; 17-25 nucleotide pairs in length; 23-27 nucleotide pairs in length; 19-21 nucleotide pairs in length; or 21-23 nucleotide pairs in length.
[0037] In some embodiments, each strand of the dsRNA agent can have 19-30 nucleotides; 19-23 nucleotides; or 21-23 nucleotides.
[0038] In one embodiment, one or more lipophilic moieties are conjugated to one or more internal positions on at least one chain, such as via a linker or carrier.
[0039] In one embodiment, the internal positions include all positions except the terminal two positions at each end of at least one strand.
[0040] In another embodiment, the internal positions include all positions except the terminal three positions at each end of at least one strand.
[0041] In one embodiment, the internal position does not include the cleavage site region of the sense strand.
[0042] In one embodiment, internal positions include all positions except positions 9-12 counted from the 5 '-end of the sense strand.
[0043] In another embodiment, internal positions include all positions except positions 11-13 counted from the 3 '-end of the sense strand.
[0044] In one embodiment, the internal position does not include the cleavage site region of the antisense strand.
[0045] In one embodiment, internal positions include all positions except positions 12-14 counted from the 5 '-end of the antisense strand.
[0046] In one embodiment, the internal positions include all positions except positions 11-13 on the sense strand counted from the 3'-end and positions 12-14 on the antisense strand counted from the 5'-end.
[0047] In one embodiment, one or more lipophilic moieties are conjugated to one or more internal positions selected from positions 4-8 and 13-18 on the sense strand, and positions 6-10 and 15-18 on the antisense strand, counted from the 5'-end of each strand.
[0048] In another embodiment, one or more lipophilic moieties are conjugated to one or more internal positions selected from positions 5, 6, 7, 15 and 17 on the sense strand, and positions 15 and 17 on the antisense strand, counted from the 5'-end of each strand.
[0049] In one embodiment, the internal position in the double-stranded region does not include the cleavage site region of the sense strand.
[0050] In one embodiment, the sense strand is 21 nucleotides in length, the antisense strand is 23 nucleotides in length, and the lipophilic moiety is conjugated to position 21, position 20, position 15, position 1, position 7, position 6, or position 2 of the sense strand or position 16 of the antisense strand.
[0051] In one embodiment, the lipophilic moiety is conjugated to position 21, position 20, position 15, position 1, or position 7 of the sense strand.
[0052] In another embodiment, the lipophilic moiety is conjugated to position 21, position 20, or position 15 of the sense strand.
[0053] In yet another embodiment, the lipophilic moiety is conjugated to position 20 or position 15 of the sense strand.
[0054] In one embodiment, the lipophilic moiety is conjugated to position 16 of the antisense strand.
[0055] In one embodiment, the lipophilic moiety is an aliphatic, cycloaliphatic, or polycycloaliphatic compound.
[0056] In one embodiment, the lipophilic moiety is selected from a lipid, cholesterol, retinoic acid, cholic acid, adamantaneacetic acid, 1-pyrenebutyric acid, dihydrotestosterone, 1,3-bis-O-(hexadecyl)glycerol, geranyloxyhexanol, hexadecylglycerol, borneol, menthol, 1,3-propylene glycol, heptadecanyl, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl or phenoxazine.
[0057] In one embodiment, the lipophilic moiety contains a saturated or unsaturated C4-C30 hydrocarbon chain, and an optional functional group selected from the group consisting of hydroxyl, amine, carboxylic acid, sulfonate, phosphate, thiol, azide, and alkyne.
[0058] In one embodiment, the lipophilic moiety contains a saturated or unsaturated C6-C18 hydrocarbon chain.
[0059] In one embodiment, the lipophilic moiety contains a saturated or unsaturated C16 hydrocarbon chain.
[0060] In one embodiment, the saturated or unsaturated C16 hydrocarbon chain is conjugated to position 6 counted from the 5'-end of the chain.
[0061] In one embodiment, modifications on the nucleotides of the dsRNA agent are selected from 2'-O-methyl, 2'-deoxy, 3-RNA, and 2'-deoxy-2'-fluoro modifications; and at least one nucleotide comprising a lipophilic moiety (eg, 2'-hexadecyloxy).
[0062] In one embodiment, modifications on the nucleotides of the dsRNA agent are selected from 2'-O-methyl, 2'-deoxy, GNA, and 2'-deoxy-2'-fluoro modifications; and at least one nucleotide comprising a lipophilic moiety (eg, 2'-hexadecyloxy).
[0063] In one embodiment, the lipophilic moiety is conjugated via a carrier that replaces one or more nucleotides at an internal position or in a double-stranded region.
[0064] In one embodiment, the carrier is a cyclic group selected from the group consisting of pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, [1,3]dioxolanyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinone, tetrahydrofuranyl and decahydronaphthyl; or an acyclic moiety based on a serinol backbone or a diethanolamine backbone.
[0065] In one embodiment, the lipophilic moiety is conjugated to the double-stranded iRNA agent through a linker containing an ether, thioether, urea, carbonate, amine, amide, maleimide-thioether, disulfide, phosphodiester, sulfonamide bond, the product of a click reaction, or a carbamate.
[0066] In one embodiment, the lipophilic moiety is conjugated to a nucleobase, a sugar moiety or an internucleoside linkage.
[0067] In one embodiment, the lipophilic moiety or targeting ligand is conjugated via a biolinker selected from the group consisting of DNA, RNA, disulfide, amide, functionalized monosaccharide or oligosaccharide of galactosamine, glucosamine, glucose, galactose, mannose, and combinations thereof.
[0068] In one embodiment, the 3'-end of the sense strand is protected by an end cap, which is a cyclic group with an amine selected from pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, [1,3]dioxolanyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinone, tetrahydrofuranyl and decahydronaphthyl.
[0069] In one embodiment, the dsRNA agent further comprises a targeting ligand that targets neuronal cells.
[0070] In one embodiment, the dsRNA agent further comprises a terminal chiral modification of the first internucleotide bond present at the 3'-end of the antisense strand with a bond phosphorus atom having an Sp configuration; a terminal chiral modification of the first internucleotide bond present at the 5'-end of the antisense strand with a bond phosphorus atom having an Rp configuration; and
[0071] The first internucleotide bond present at the 5'-end of the sense strand has a terminal chiral modification of the phosphorus atom of the bond with either an Rp configuration or an Sp configuration.
[0072] In another embodiment, the dsRNA agent further comprises a terminal chiral modification of the bond phosphorus atom with an Sp configuration at the first internucleotide bond and the second internucleotide bond present at the 3'-end of the antisense strand; a terminal chiral modification of the bond phosphorus atom with an Rp configuration at the first internucleotide bond present at the 5'-end of the antisense strand; and a terminal chiral modification of the bond phosphorus atom with an Rp or Sp configuration at the first internucleotide bond present at the 5'-end of the sense strand.
[0073] In yet another embodiment, the dsRNA agent further comprises a terminal chiral modification of the bond phosphorus atom with an Sp configuration at the first internucleotide bond, the second internucleotide bond, and the third internucleotide bond present at the 3'-end of the antisense strand; a terminal chiral modification of the bond phosphorus atom with an Rp configuration at the first internucleotide bond present at the 5'-end of the antisense strand; and a terminal chiral modification of the bond phosphorus atom with an Rp or Sp configuration at the first internucleotide bond present at the 5'-end of the sense strand.
[0074] In another embodiment, the dsRNA agent further comprises a terminal chiral modification of the bond phosphorus atom with an Sp configuration at the first and second internucleotide bonds present at the 3'-end of the antisense strand; a terminal chiral modification of the bond phosphorus atom with an Rp configuration at the third internucleotide bond present at the 3'-end of the antisense strand; a terminal chiral modification of the bond phosphorus atom with an Rp configuration at the first internucleotide bond present at the 5'-end of the antisense strand; and a terminal chiral modification of the bond phosphorus atom with an Rp or Sp configuration at the first internucleotide bond present at the 5'-end of the sense strand.
[0075] In another embodiment, the dsRNA agent further comprises a terminal chiral modification of the bond phosphorus atom with an Sp configuration at the first internucleotide bond and the second internucleotide bond present at the 3'-end of the antisense strand; a terminal chiral modification of the bond phosphorus atom with an Rp configuration at the first internucleotide bond and the second internucleotide bond present at the 5'-end of the antisense strand; and a terminal chiral modification of the bond phosphorus atom with an Rp or Sp configuration at the first internucleotide bond present at the 5'-end of the sense strand.
[0076] In one embodiment, the dsRNA agent further comprises a phosphate or a phosphate mimetic at the 5 '-end of the antisense strand.
[0077] In one embodiment, the phosphate mimetic is 5'-vinylphosphonate (VP).
[0078] In one embodiment, the base pair at position 1 of the 5'-end of the antisense strand of the duplex is an AU base pair.
[0079] In one embodiment, the sense strand has a total of 21 nucleotides and the antisense strand has a total of 23 nucleotides.
[0080] The present disclosure also provides cells and pharmaceutical compositions comprising the dsRNA agents of the present disclosure and lipid formulations.
[0081] The present disclosure also provides a pharmaceutical composition for inhibiting the expression of a gene encoding 4R-tau, comprising the dsRNA agent of the present disclosure.
[0082] The present disclosure also provides a pharmaceutical composition for reducing abnormal expression (eg, overexpression) of MAPT transcripts containing exon 10, comprising a dsRNA agent of the present disclosure.
[0083] In one embodiment, the dsRNA agent is in an unbuffered solution, such as saline or water.
[0084] In another embodiment, the dsRNA agent is in a buffered solution, such as a buffered solution comprising acetate, citrate, prolamine, carbonate, or phosphate, or any combination thereof; or phosphate buffered saline (PBS).
[0085] In one aspect, the present disclosure provides a method of inhibiting or reducing the expression of 4R-tau in a cell, the method comprising contacting the cell with a dsRNA agent of the present disclosure or a pharmaceutical composition of the present disclosure, thereby inhibiting the expression of 4R-tau in the cell.
[0086] In another aspect, the present disclosure provides a method for reducing abnormal expression (overexpression) of a MAPT transcript containing exon 10 in a cell, the method comprising contacting the cell with a dsRNA agent of the present disclosure or a pharmaceutical composition of the present disclosure, thereby degrading the MAPT transcript containing exon 10 in the cell.
[0087] In one embodiment, the cell is located in a subject.
[0088] In one embodiment, the subject is a human.
[0089] In one embodiment, the subject suffers from a 4R-tau associated disorder.
[0090] In one embodiment, the subject has a 4R-tau associated disorder that is a neurodegenerative disorder.
[0091] In one embodiment, the subject's neurodegenerative disorder is associated with abnormalities in 4R-tau, a protein encoded by the MAPT gene.
[0092] In one embodiment, abnormality in the protein 4R-tau encoded by the MAPT gene results in aggregation of 4R-tau in the brain of the subject.
[0093] In one embodiment, the neurodegenerative disorder is a familial disorder.
[0094] In one embodiment, the neurodegenerative disorder is a sporadic disorder.
[0095] In one embodiment, the 4R-tau-associated disorder is selected from progressive supranuclear palsy (PSP), progressive supranuclear palsy-Richardson syndrome (PSP-RS), corticobasal syndrome (CBD), argyrophilic grain disease (AGD), frontotemporal lobar degeneration caused by tau (FTLD-tau), FTLD-tau caused by MAPT mutations (e.g., mutations selected from N279K, L284L, DN296, N296N, N296H, P301L, P301S, S305N and S305S), multisystem tauopathy with Alzheimer's disease (MSTD), globular glial tauopathy (GGT), Parkinsonism similar to Parkinson's disease, nonfluent variant of primary progressive aphasia (nfvPPA), behavioral variant of frontotemporal dementia (bvFTD), primary akinesia with freezing of gait (PAGF), primary lateral sclerosis (PLS), familial multisystem tauopathy with Alzheimer's disease (FMSTD), familial progressive subcortical gliosis (familial pSG), globus pallidus-ponto-nigral degeneration (pPND), familial frontotemporal dementia (e.g., FTD-Kumamoto), and 4R-tauopathy with N279K tauopathy.
[0096] In one embodiment, the 4R-tau-associated disorder is a 4R-tauopathy that is rapidly progressive Alzheimer's disease (rpAD). In one embodiment, the 4R-tau-associated disorder is a 4R-tauopathy that is sporadic Alzheimer's disease (spAD).
[0097] In one embodiment, the 4R-tau-related disorder is 4R-tauopathy progressive supranuclear palsy (PSP) and progressive supranuclear palsy-Richardson syndrome (PSP-RS). In one embodiment, the 4R-tau-related disorder is 4R-tauopathy progressive supranuclear palsy (PSP).
[0098] In some embodiments, contacting a cell with a dsRNA agent inhibits expression of 4R-tau by at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95%, relative to a control level. In one embodiment, the dsRNA agent inhibits expression of 4R-tau by at least about 25%.
[0099] In some embodiments, inhibition of 4R-tau expression reduces 4R-tau protein levels in the serum of a subject by at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95%, relative to control levels. In one embodiment, the dsRNA agent reduces 4R-tau protein levels in the serum of a subject by at least about 25%.
[0100] In one aspect, the present disclosure provides a method of treating a subject suffering from a disorder that benefits from reduced expression of 4R-tau, comprising administering to the subject a therapeutically effective amount of a dsRNA agent of the present disclosure or a pharmaceutical composition of the present disclosure, thereby treating the subject suffering from a disorder that benefits from reduced expression of 4R-tau.
[0101] In another aspect, the present disclosure provides a method of preventing at least one symptom in a subject suffering from a disorder that benefits from reduced expression of 4R-tau, comprising administering to the subject a prophylactically effective amount of a dsRNA agent of the present disclosure or a pharmaceutical composition of the present disclosure, thereby preventing at least one symptom in the subject suffering from a disorder that benefits from reduced expression of 4R-tau.
[0102] In one embodiment, the disorder is a 4R-tau associated disorder.
[0103] In one embodiment, the disorder is associated with abnormalities in the protein 4R-tau encoded by the MAPT gene.
[0104] In one embodiment, abnormality in the protein 4R-tau encoded by the MAPT gene results in aggregation of 4R-tau in the brain of the subject.
[0105] In one embodiment, the 4R-tau-associated disorder is selected from progressive supranuclear palsy (PSP), progressive supranuclear palsy-Richardson syndrome (PSP-RS), corticobasal syndrome (CBD), argyrophilic grain disease (AGD), frontotemporal lobar degeneration caused by tau (FTLD-tau), FTLD-tau caused by MAPT mutations (e.g., mutations selected from N279K, L284L, DN296, N296N, N296H, P301L, P301S, S305N and S305S), multisystem tauopathy with Alzheimer's disease (MSTD), globular glial tauopathy (GGT), Parkinsonism similar to Parkinson's disease, nonfluent variant of primary progressive aphasia (nfvPPA), behavioral variant of frontotemporal dementia (bvFTD), primary akinesia with freezing of gait (PAGF), primary lateral sclerosis (PLS), familial multisystem tauopathy with Alzheimer's disease (FMSTD), familial progressive subcortical gliosis (familial pSG), globus pallidus-ponto-nigral degeneration (pPND), familial frontotemporal dementia (e.g., FTD-Kumamoto), and 4R-tauopathy with N279K tauopathy.
[0106] In certain embodiments, a 4R-tau-associated disorder is a 4R-tauopathy, e.g., selected from progressive supranuclear palsy (PSP), corticobasal syndrome (CBD), argyrophilic grain disease (AGD), multisystem tauopathy with Alzheimer's disease (MSTD), globular glial tauopathy (GGT), sporadic (spAD) Alzheimer's disease, rapidly progressive (rpAD) Alzheimer's disease.
[0107] In one embodiment, the subject is a human.
[0108] In one embodiment, administration of a dsRNA agent of the disclosure or a pharmaceutical composition of the disclosure results in a reduction in 4R-tau aggregation in the brain of a subject.
[0109] In one embodiment, administering the agent to the subject results in a reduction in 4R-tau aggregation.
[0110] In one embodiment, the dsRNA agent is administered to a subject at a dose of about 0.01 mg / kg to about 50 mg / kg.
[0111] In another embodiment, the dsRNA agent is administered to the subject intrathecally (IT) or intracerebroventricularly (ICV).
[0112] In yet another embodiment, the dsRNA agent is administered intracisternal to the subject. Non-limiting exemplary intracisternal administration includes injection into the cisterna magna (cerebellomedullary cistern) via suboccipital puncture.
[0113] In one embodiment, the methods of the present disclosure further comprise determining the level of 4R-tau in a sample from the subject.
[0114] In one embodiment, the level of 4R-tau in a sample from a subject is the level of 4R-tau protein in a blood, serum, or cerebrospinal fluid sample.
[0115] In one embodiment, the methods of the present disclosure further comprise administering to the subject an additional therapeutic agent.
[0116] In one aspect, the present disclosure provides a kit comprising a dsRNA agent of the present disclosure or a pharmaceutical composition of the present disclosure.
[0117] In another aspect, the present disclosure provides a vial comprising a dsRNA agent of the present disclosure or a pharmaceutical composition of the present disclosure.
[0118] In yet another aspect, the present disclosure provides a syringe comprising a dsRNA agent of the present disclosure or a pharmaceutical composition of the present disclosure.
[0119] In another aspect, the present disclosure provides an intrathecal pump comprising a dsRNA agent of the present disclosure or a pharmaceutical composition of the present disclosure. BRIEF DESCRIPTION OF THE DRAWINGS
[0120] Figure 1 Shown are the percentage RNA knockdown by 4R-tau and mCherry TaqMan assays for 65 candidate 4R-tau siRNAs.
[0121] Figure 2 Relative 4R-tau and mCherry expression of 13 4R-preferred siRNAs (1 nM and 0.1 nM) are shown. Lipofectamine was used as a negative control. Two total tau siRNAs were also used as controls.
[0122] Figure 3TaqMan qPCR data of the expression levels of 4R-tau and mCherry (3Rtau surrogate) after treating HEK293-2N4R-YFP+2N3R-mCherry dual reporter cells with 1 nM of 65 different GalNAc-conjugated siRNAs generated by walking exon 10 of the MAPT gene as a whole. Lipofectamine was used as a negative control. Total tau siRNA was also used as a control.
[0123] Figure 4 Shown are the locations where 13 4R-preferential siRNAs bind in exon 10 of the MAPT gene. The lower panel depicts the sequence homology of the R2 domain to the other repeat domains (R1, R3, R4), where asterisks indicate nucleotide homology, and the boxed regions are identified hotspots where 13 siRNAs showed preferential activity against 4R-tau.
[0124] Figure 5 A summary of the IC50 (potency) of the siRNA and the percent knockdown at a concentration of 100 pM is shown. The dose of the siRNA treatment was an 8-point dose curve and ranged from 0.01 pM to 10 nM depending on the experiment. The table is sorted on the 4R-tau column.
[0125] Figure 6A-6B IC50 graphs are shown for the first four siRNAs selected for in vivo testing (AD-1423291.2, AD-1423283.2, AD-1423294.2, AD-1423295.2). siRNAs were tested at 8 different concentrations in HEK293 dual reporter cells, HEK293-2N3R-mCherry cells only, and HEK293-2N4R-YFP cells only.
[0126] Figure 7 The 4R preferential knockdown of the duplex is confirmed using a protein dot blot. The left figure shows the specificity of commercially available total tau antibodies (mouse monoclonal; clone Tau12), 4R-tau antibodies (mouse monoclonal, clone 7D12.1) and 3R-tau antibodies (mouse monoclonal, clone 8E6\C11) confirmed by blot hybridization with recombinant 1N3R or 1N4R proteins. The right figure shows the use of the same antibodies in HEK293 dual reporter cells treated with vehicle control or siRNA (AD-1091966 = total tau reduction siRNA; AD-1423291.2, AD-1423283.2 and AD-1423294.2 = 4R preferential siRNA; AD-1423295.2 = mixed selective siRNA). The experimental setup is shown at the top.
[0127] Figure 8 The 4R preferential knockdown of siRNA duplexes using a protein ELISA-type assay is shown. In Figure A, a commercially available total tau ALPHALISA (Perkin Elmer, catalog number: AL271C) was used to measure total soluble tau according to the manufacturer's instructions. In Figure B, 4R-tau protein was measured using a PathScan ELISA kit from Cell Signaling Technologies (catalog number: 29443). The experimental setup is shown at the top.
[0128] Fig. 9 In vivo validation of tau knockdown using 4R-tau siRNA is shown. The table shows the sample size of the C16-conjugated duplexes used for in vivo administration, the corresponding GalNAc-conjugated duplexes used for in vitro experiments, and the number of mouse samples for RT-qPCR assays. The graph shows RT-qPCR data for total tau and 4R-tau expression levels on RNA extracted from mouse brains treated with 4R-tau siRNA. Values are given as relative expression (1 / 2 ΔΔCt ) were plotted and normalized to mouse GAPDH.
[0129] Fig.10 Shown are dose-response curves for the dual reporter cell line (HEK293-2N4R-YFP+2N3R-mCherry) for the three TaqMan assays performed (mCherry, YFP, 4R-tau).
[0130] Fig.11 Shown are dose-response curves for the 3R reporter cell line only (HEK293-2N3R-mCherry) for the three TaqMan assays performed (mCherry, YFP, 4R tau).
[0131] Fig.12 Shown are dose-response curves for the 4R reporter cell line only (HEK293-2N4R-YFP) for the three TaqMan assays performed (mCherry, YFP, 4R tau). DETAILED DESCRIPTION
[0132] The present disclosure provides a "hotspot" region of exon 10 targeting the MAPT gene (mapped to nucleotides 1007-1053 of NM_005910.6), which achieves RNA-induced silencing complex (RISC)-mediated cutting of the 4R-tau RNA transcript of the MAPT gene. The MAPT gene can be in cells, for example, cells in a subject (such as a human). The use of these iRNAs enables targeted degradation of the 4R-tau mRNA of the corresponding gene (MAPT gene) in mammals.
[0133] The iRNA disclosed herein has been designed to target the hotspot region of exon 10 of the MAPT gene (e.g., a MAPT gene with or without nucleotide modifications). The iRNA disclosed herein inhibits the expression of 4R-tau subtypes by at least about 25%, and reduces the level of loci containing sense and antisense. It is not intended to be limited by theory, but it is believed that the combination or subcombination of the above-mentioned characteristics and specific target sites or the specific modifications in these iRNAs give the iRNA disclosed herein improved efficacy, stability, effectiveness, persistence and safety.
[0134] Therefore, the present disclosure also provides methods of using the RNAi compositions of the present disclosure to inhibit the expression of 4R-tau subtypes or treat subjects with disorders that benefit from inhibiting or reducing the expression of 4R-tau subtypes, such as 4R-tau-related diseases, such as 4R-tau protein diseases, such as PSP, CBD, AGD, MSTD, GGT, spAD or rpAD. In certain embodiments, the present disclosure provides methods of preferentially inhibiting the expression of 4R-tau subtypes relative to the inhibition of 3R-tau subtypes using the RNAi compositions of the present disclosure.
[0135] The RNAi agents of the present disclosure comprise an RNA strand (antisense strand) having a region of about 30 nucleotides in length or less, e.g., 15-30, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29 , 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23 or 21-22 nucleotides, which region is substantially complementary to a hotspot within exon 10 of the mRNA transcript of the MAPT gene. In certain embodiments, the RNAi agent of the present disclosure comprises an RNA strand (antisense strand) having a region of about 21-23 nucleotides in length that is substantially complementary to a hotspot within exon 10 of the mRNA transcript of the MAPT gene.
[0136] In certain embodiments, the RNAi agent of the present disclosure comprises an RNA strand (antisense strand) that may comprise a longer length, e.g., up to 66 nucleotides, e.g., 36-66, 26-36, 25-36, 31-60, 22-43, 27-53 nucleotides in length, having a region of at least 19 consecutive nucleotides substantially complementary to a hotspot within exon 10 of an mRNA transcript of a MAPT gene. These RNAi agents with a longer antisense strand preferably comprise a second RNA strand (sense strand) of 20-60 nucleotides in length, wherein the sense strand and the antisense strand form a duplex of 18-30 consecutive nucleotides.
[0137] The use of these RNAi agents enables targeted degradation and / or suppression of the 4R-tauumRNA of MAPT gene in mammals.Therefore, the method and composition comprising these RNAi agents can be used for treating the subject whose level or activity is reduced and benefits from 4R-tau, such as suffering from MAPT related diseases, such as 4R-tau protein disease, such as the subject of PSP, CBD, AGD, MSTD, GGT, spAD or rpAD.In certain embodiments, the method and composition comprising these RNAi agents can be used for treating the subject whose level or activity is preferentially reduced relative to 3R-tau and benefits from 4R-tau.
[0138] The following detailed description discloses how to prepare and use compositions containing RNAi agents to inhibit expression of the 4R-tau isoform of the MAPT gene, as well as compositions and methods for treating subjects suffering from diseases and disorders that benefit from inhibition or reduction of gene expression.
[0139] I. Definitions
[0140] In order that the present disclosure may be more readily understood, certain terms are first defined. Additionally, it should be noted that whenever a value or range of values for a parameter is stated, it is intended that values and ranges intermediate to the stated values are also intended to be part of the present disclosure.
[0141] The articles "a" and "an" herein refer to one or to more than one (ie, to at least one) of the grammatical object of the article. For example, "an element" refers to one element or more than one element, e.g., a plurality of elements.
[0142] The term "including" is used herein to mean, and can be used interchangeably with, the phrase "including but not limited to". Unless the context clearly indicates otherwise, the term "or" is used herein to mean, and can be used interchangeably with, the term "and / or".
[0143] The term "about" is used herein to mean within the typical tolerance range in the art. For example, "about" can be understood as about 2 standard deviations of the mean. In certain embodiments, "about" means ± 10%. In certain embodiments, "about" means ± 5%. When "about" appears before a series of numbers or ranges, it should be understood that "about" can modify each number in the series or range.
[0144] The term "at least" before a number or series of numbers should be understood to include the number adjacent to the term "at least", as well as all subsequent numbers or integers that can be logically included, as can be clearly seen from the context. For example, the number of nucleotides in a nucleic acid molecule must be an integer. For example, "at least 18 nucleotides in a nucleic acid molecule of 21 nucleotides" means that 18, 19, 20 or 21 nucleotides have the indicated characteristics. When "at least" appears before a series of numbers or ranges, it should be understood that "at least" can modify each number in the series or range.
[0145] As used herein, "no more than" or "less than" is understood to refer to the value adjacent to the phrase and the logically lower value or integer, with zero being seen logically from the context. For example, a duplex having an overhang of "no more than 2 nucleotides" has an overhang of 2, 1, or 0 nucleotides. When "no more than" appears before a series of numbers or a range, it should be understood that "no more than" can modify each number in the series or range.
[0146] As used herein, when referring to a measurable value such as a parameter, amount, etc., the term "at least about" is meant to encompass variations of + / -20%, preferably + / -10%, more preferably + / -5%, and still more preferably + / -1% from the specified value, as long as such variations are suitable for implementation in the disclosed invention. For example, inhibition of expression of the MAPT gene by "at least about 25%" means that the inhibition of expression of the MAPT gene can be measured as any value of + / -20% of the specified 25%, i.e., 20%, 30%, or any intermediate value between 20-30%.
[0147] As used herein, "control level" refers to the expression level of a gene, the expression level of an RNA molecule, or the expression level of one or more proteins or protein subunits in the same non-regulated cell, tissue, or system as the cell, tissue, or system in which the RNAi agent described herein is expressed. The cell, tissue, or system in which the RNAi agent is expressed has at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 4-fold, 5-fold or higher expression of the above-mentioned gene, RNA, and / or protein compared to the expression of the gene, RNA, and / or protein observed in the absence of the RNAi agent. % and / or fold differences can be calculated relative to the control level, for example,
[0148]
[0149] As used herein, a detection method may include determining that an analyte is present in an amount below the detection level of the method.
[0150] In the event of a conflict between the indicated target site and the nucleotide sequence of the sense or antisense strand, the indicated sequence takes precedence.
[0151] In the event of a conflict between a chemical structure and a chemical name, the chemical structure shall prevail.
[0152] The term "MAPT" gene, also known as "DDPAC", "FTDP-17", "MAPTL", "MSTD", "MTBT1", "MTBT2", "PPND", "PPP1R103", "TAU" and "microtubule-associated protein tau", refers to the gene encoding a protein called microtubule-associated protein tau (MAPT).
[0153] MAPT mRNA is expressed throughout the body, primarily in the central nervous system (i.e., brain and spinal cord) and the peripheral nervous system. Wild-type Tau is involved in stabilizing microtubules in neuronal axons, regulating axonal transport and microtubule dynamics, maintaining dendritic spines, and contributing to the integrity of genomic DNA.
[0154] Tauopathies are a heterogeneous class of progressive neurodegenerative disorders pathologically characterized by the presence of Tau aggregates in the brain. Intracellular and extracellular neural Tau aggregates lead to microtubule disassembly and axonal degeneration, impaired synaptic vesicle release, and prion-like interneuronal spread of Tau aggregates known as "seeding."
[0155] Phenotypically, tauopathies present with different progressions of motor, cognitive and behavioral disorders. Tauopathies include, but are not limited to: Alzheimer's disease, the most common form of Alzheimer's disease, which begins primarily with selective memory impairment and is associated with degeneration of the frontal, temporal (including hippocampus) and parietal lobes of the brain; frontotemporal dementia (FTD), the second most common form of Alzheimer's disease associated with neuronal atrophy in the frontal and temporal lobes, presenting with a range of behavioral, language and motor disorders; and progressive supranuclear palsy (PSP), a degeneration of the brainstem and basal ganglia, presenting with gaze dysfunction, extrapyramidal symptoms (Parkinson's symptoms, including limb apraxia, akinesia / bradykinesia, spasticity and dystonia) and cognitive dysfunction, affecting approximately 20,000 people in the United States.
[0156] FTD further includes, but is not limited to, behavioral variant frontotemporal dementia (bvFTD), pathologically associated with progressive atrophy of the frontal and anterior temporal lobes and clinically associated with complex changes in thinking, personality, and behavior, affecting approximately 30,000 people in the United States; primary progressive aphasia-semantic (PPA-S), degeneration of the frontal and temporal lobes associated with difficulty comprehension and naming words; nonfluent variant primary progressive aphasia (nfvPPA), degeneration involving the left posterior frontal lobe and insula and manifested by poor grammar and inability to comprehend complex sentences, affecting approximately 1,000 people in the United States; primary progressive aphasia-logopenic (PPA-L), degeneration of the left posterior temporal lobe / spur temporal lobe. The following are the most common dementias: frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), pathologically associated with degeneration of the frontal and temporal lobes and clinically associated with speech and movement disorders; Pick's disease (PiD), degeneration of the frontal and temporal lobes, associated with difficulties with language and changes in thinking and behavior; FTD with motor neuron disease, involving degeneration of the cortex and motor neurons; and corticobasal syndrome (CBS), degeneration of the posterior frontal and temporal lobes and basal ganglia [i.e., corticobasal degeneration (CBD)], manifesting with extrapyramidal symptoms (similar to those of Parkinson's disease and PSP) and cognitive impairment, affecting approximately 2,000 people in the United States. MAPT mutations are reported in approximately 10% of patients with bvFTD, nfvPPA, CBS, and PSP, respectively. MAPT is the major component of neurofibrillary tangles in the cytoplasm of neurons, a hallmark of Alzheimer's disease. Aggregation and deposition of MAPT are also observed in the brains of approximately 50% of patients with Parkinson's disease. This suggests that Tau is involved in the pathogenesis of other diseases, including but not limited to argyrophilic grain disease (AGD), multisystem tauopathy (MSTD) with Alzheimer's disease, white matter tauopathy with globulin glial inclusions (FTLD with GGI), FTLD with MAPT mutations, neurofibrillary tangles (NFT) dementia, FTD with motor neuron disease, amyotrophic lateral sclerosis (ALS), postencephalitic Parkinson's disease, Niemann-Pick disease, Huntington's disease, myotonic dystrophy type 1, and Down syndrome (DS).
[0157] The MAPT gene consists of 16 exons (E1-E16). Alternative mRNA splicing of E2, E3, and E10 produces six tau isoforms (352-441 amino acids). E1, E4, E5, E7, E9, E11, E12, E13 are constitutively spliced exons. E6 and E8 are not transcribed in the human brain. E4a is only expressed in the peripheral nervous system. E0 (part of the promoter) and E14 are non-coding exons.
[0158] Pathogenic variants of MAPT are found in approximately 10% of patients with primary tauopathy. Variants are mainly missense and localize to exons 9-13 (microtubule binding domain), with many of them affecting alternative splicing of exon 10. Examples of coding region mutations include R5H and R5L in E1 of the MAPT gene; K257T, I260V, L266V, G272V, and G273R in E9; N279K, K280del, L284L, ΔN296, N296N, N296H, ΔN298, P301L, P301S, P301T, G303V, G304S in E10. , S305I, S305N, and S305S in E11; L315R, K317M, S320F, P332S in E11; G335S, G335V, Q336R, V337M, E342V, S352L, S356T, V363I, P364S, G366R, and K369I in E12; G389R, R406W, and T427M in E13. Humans null (- / -) for MAPT(tau) are likely to be nonviable. Humans heterozygous (+ / -) for MAPT have unclear or unknown phenotypes. Humans overexpressing (+ / + / +) MAPT are associated with early-onset dementia, FTD, PSP, and CBD.
[0159] Each of the six subtypes of MAPT (tau) protein contains three or four repeat segments (R1, R2, R3 and R4) in its microtubule binding domain. The length of each repeat is 31 or 32 amino acids. The splicing of E9, E10, E11 and E12 produces R1, R2, R3 and R4 of the repeat segments in the microtubule binding domain of MAPT, respectively. Among them, the three MAPT (tau) subtypes ("4R-tau subtypes") in which E10 is spliced contain four repeat segments (4R), while the other three MAPT subtypes ("3R-tau subtypes") in which E10 is spliced contain three repeat segments (3R).
[0160] Translation of E2 and E3 produces N1 segment and N2 segment, respectively. Variable splicing of E2 and E3 produces tau subtypes 0N (E2 and E3 are spliced out, resulting in no N segment), 1N (E2 is spliced in, and E3 is spliced out, resulting in one N segment) and 2N (E2 and E3 are spliced in, resulting in two N segments). Therefore, the six MAPT (tau) subtypes produced by variable splicing are 2N4R, 1N4R, 0N4R, 2N3R, 1N3R and 0N3R.
[0161] In healthy individuals, 3R and 4R MAPT transcript subtypes exist in a ratio of 1: 1. The 3R / 4R subtype ratio is skewed in disease states, and the ratio predicts tau aggregate types. For example, certain intronic mutations and coding region mutations (N279K, L284L, DN296, N296N, N296H, S305N, and S305S) in exon 10 of MAPT can increase the splicing of exon 10, which leads to a change in the ratio between three and four repeat subtypes, and excessive production of four repeat tau.
[0162] Four-repeat tau assembly into filaments is characteristic of PSP, CBD, argyrophilic grain disease (AGD), multisystem tauopathy with Alzheimer's disease (MSTD), and white matter tauopathies with globular glial inclusions (FTD with GGI or "globular glial tauopathies (CGT)", which belong to the FTD spectrum (4R tauopathies).
[0163] In contrast, in Pick's disease, triple-repeat tau predominates in neuronal inclusions (3R tauopathy).
[0164] In Alzheimer's disease or other neurodegenerative diseases with neurofibrillary tangles (NFT dementia), both three-repeat and four-repeat tau subtypes can constitute neurofibrillary pathology (3 / 4R tauopathy). However, in some Alzheimer's disease pathologies, four-repeat tau subtypes may be the dominant subtype in neurofibrillary pathology. FTLD with MAPT mutations can be 3R, 4R or 3 / 4R tauopathy.
[0165] FTD with motor neuron disease is associated with FTLD-TDP43 and FTLD-FUS pathologies, which are associated with mutations in the genes C9ORF72, FUS, TARDBP, and VCP.
[0166] bvFTD is associated with FTLD-Tau(3R) and FTLD-TDP43 pathologies. Ten percent of cases involve MAPT mutations. It is associated with mutations in the genes C9ORF72, GRN, and VCP.
[0167] PPA-S can be sporadic. It is associated with FTLD-TDP43 pathology.
[0168] nfvPPA was associated with FTLD-Tau(4R), Alzheimer's disease, and FTLD-TDP43 pathologies, in order of significance. Ten percent of cases involved MAPT mutations. nfvPPA was further associated with mutations in GRN.
[0169] PPA-L can be sporadic. It is associated with Alzheimer's disease and FTLD-Tau pathology, in order of significance.
[0170] CBS is associated with FTLD-Tau (4R) and Alzheimer's disease pathology in order of significance. Ten percent of cases are associated with MAPT mutations. The remainder are likely sporadic cases.
[0171] PSP involves FTLD Tau(4R) pathology. Ten percent of cases are associated with MAPT mutations. The remainder are likely sporadic cases.
[0172] Tau disease usually starts at 60-80 years old and affects the remaining life span of 6-10 years. Tau disease is heterogeneous in phenotype, and it involves movement, cognition and behavioral disorders to varying degrees. Specifically, the progression of motor symptoms is variable.
[0173] There are currently no approved disease-modifying therapies for tauopathies. Available treatments are intended only to relieve symptoms and improve the patient's quality of life as the disease progresses. Agents in preclinical or clinical development include active and passive immunotherapy; inhibitors of O-deglycosylation, aggregation, kinases, acetylation, caspases, or tau expression; phosphatase activators; microtubule stabilizers; and modulators of autophagy or proteasomal degradation. Biomarkers and tests used in clinical trials to assess tauopathies include tau phosphorylated at threonine 181 (pTau), total tau (tTau), neurofilament light chain (NfL), volumetric MRI (vMRI), and 18 F-diagnostic PET markers (e.g., 18 F-flortaucipir (AV-1451, TAUVID TM )).
[0174] Exemplary nucleotide and amino acid sequences of MAPT can be found, for example, in GenBank Accession No. NM_016841.4 (Homo sapiens MAPT variant 4, SEQ ID NO: 1, reverse complement, SEQ ID NO: 2); GenBank Accession No. NM_005910 (Homo sapiens MAPT variant 2, SEQ ID NO: 3, reverse complement, SEQ ID NO: 4); GenBank Accession No. NM_001038609.2 (Mus musculus MAPT, SEQ ID NO: 5; reverse complement, SEQ ID NO: 6); GenBank Accession No. XM_005584540.1 (Macaca fascicularis MAPT variant X13, SEQ ID NO: 7, reverse complement, SEQ ID NO: 8); GenBank Accession No. XM_008768277.2 (Rattus norvegicus MAPT, variant X7, SEQ ID NO: 9); ID NO:9, reverse complementary sequence, SEQ ID NO:10) and GenBank Accession No.: XM_005624183.3 (Canis lupus MAPT variant X23, SEQ ID NO:11, reverse complementary sequence, SEQ ID NO:12).
[0175] The nucleotide sequence of the genomic region of the human chromosome that carries the MAPT gene can be found in the Genome Reference Consortium Human Build 38 (also referred to as human genome builds 38 or GRCh38) obtainable on for example GenBank. The nucleotide sequence of the genomic region of the human chromosome 17 that carries the MAPT gene can also be found in for example GenBank accession number NC_000017.11, corresponding to the nucleotide 45894382-46028334 of human chromosome 17. The nucleotide sequence of mankind MAPT gene can be found in for example GenBank accession number NG_007398.2.
[0176] Further examples of MAPT sequences can be found in publicly available databases such as GenBank, OMIM and UniProt.
[0177] For example, additional information about MAPT can be found on the NCBI webpage relating to gene 100128977. As used herein, the term MAPT also refers to variants of the MAPT gene, including variants provided in clinical variant databases, such as on the NCBI clinical variants website relating to the term mapt.
[0178] As of the filing date of this application, each of the above-mentioned GenBank Accession Numbers and Gene Database Numbers are incorporated herein by reference in their entirety.
[0179] As used herein, "target sequence" refers to a continuous portion of the nucleotide sequence of exon 10 (SEQ ID NO: 13) in the 4R-tau mRNA molecule formed during MAPT gene transcription, including mRNA (e.g., MAPT mRNA produced by alternative splicing) as an RNA processing product of the primary transcription product. In one embodiment, the target portion of the sequence is at least long enough to be used as a substrate for RNAi-guided cleavage at or near the portion of the nucleotide sequence of the mRNA molecule formed during MAPT gene transcription.
[0180] The target sequence may be about 15-30 nucleotides in length. For example, the target sequence may be about 15-30 nucleotides in length, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19 In some embodiments, the target sequence is 19-23 nucleotides in length, optionally 21-23 nucleotides in length. Ranges and lengths intermediate to the above ranges and lengths are also considered to be part of the present disclosure.
[0181] As used herein, the term "chain comprising a sequence" refers to an oligonucleotide comprising a chain of nucleotides, which is described by a sequence referred to using standard nucleotide nomenclature. In the context of modified or unmodified nucleotides, "G", "C", "A", "T" and "U" each typically represent a nucleotide containing guanine, cytosine, adenine, thymine and uracil as a base. However, it should be understood that the term "ribonucleotide" or "nucleotide" may also refer to a modified nucleotide, as further described below, or an alternative portion of an agent (see, e.g., Table 2). It is well known to those skilled in the art that guanine, cytosine, adenine, thymine and uracil may be replaced by other portions without significantly changing the base pairing properties of the oligonucleotide comprising the nucleotide containing such alternative portions. For example, but not limited to, a nucleotide comprising inosine as its base may be base paired with a nucleotide containing adenine, cytosine or uracil. Therefore, in the nucleotide sequence of the dsRNA described in the present disclosure, nucleotides containing uracil, guanine or adenine can be replaced by nucleotides containing, for example, inosine. In another example, adenine and cytosine at any position in the oligonucleotide can be replaced by guanine and uracil, respectively, to form GU wobble base pairing with the target mRNA. Sequences containing such replacement parts are suitable for use in the compositions and methods described in the present disclosure.
[0182] The terms "iRNA", "RNAi agent", "iRNA agent" and "RNA interfering agent" as used interchangeably herein refer to agents containing RNA as that term is defined herein, and which mediate targeted cleavage of RNA transcripts through the RNA-induced silencing complex (RISC) pathway. RNA interference (RNAi) is a process that directs sequence-specific degradation of mRNA. RNAi regulates, for example, inhibits expression of 4R-tau in a cell, for example, a cell in a subject (such as a mammalian subject).
[0183] In one embodiment, the RNAi agent of the present disclosure includes single-stranded RNAi, which interacts with a target RNA sequence (e.g., 4R-tau target mRNA sequence) to guide the cutting of the target RNA. Without wishing to be bound by theory, it is believed that the long double-stranded RNA introduced into the cell is degraded into a double-stranded short interfering RNA (siRNA) including a sense strand and an antisense strand by a type III nuclease called Dicer (Sharp et al., (2001) Genes Dev. 15: 485). Dicer, i.e., ribonuclease-III-like enzyme, processes this dsRNA into a short interfering RNA of 19-23 base pairs with a characteristic two-base 3' overhang (Bernstein et al., (2001) Nature 409: 363). These siRNAs are then incorporated into an RNA-induced silencing complex (RISC), where one or more helicases unwind the siRNA duplex, thereby enabling the complementary antisense strand to guide target recognition (Nykanen et al., (2001) Cell 107: 309). When combined with appropriate target mRNA, one or more endonucleases in RISC cut the target to induce silencing (Elbashir et al., (2001) Genes Dev. 15: 188). Therefore, in one aspect, the disclosure relates to single-stranded RNA (ssRNA) (antisense strand of siRNA duplex) produced in cells, and it promotes the formation of RISC complex to achieve target gene, i.e., silencing of MAPT gene. Therefore, the term "siRNA" is also used herein to refer to RNAi as described above.
[0184] In another embodiment, the RNAi agent can be a single-stranded RNA, which is introduced into a cell or organism to inhibit target mRNA. The single-stranded RNAi agent is combined with RISC endonuclease Argonaute 2, which then cuts the target mRNA. Single-stranded siRNA is generally 15-30 nucleotides and is chemically modified. The design and testing of single-stranded RNA is described in U.S. Patent No. 8,101,348 and Lima et al., (2012) Cell 150: 883-894, and the entire contents of each of them are incorporated herein by reference. Any antisense nucleotide sequence described herein can be used as single-stranded siRNA described herein, or by Lima et al., (2012) Cell 150: 883-894 The method described is chemically modified.
[0185] In another embodiment, the "RNAi agent" used in the compositions and methods of the present disclosure is a double-stranded RNA, and is referred to herein as a "double-stranded RNAi agent," "double-stranded RNA (dsRNA) molecule," "dsRNA agent," or "dsRNA." The term "dsRNA" refers to a complex of ribonucleic acid molecules having a duplex structure comprising two antiparallel and substantially complementary nucleic acid chains, which are referred to as having "sense" and "antisense" orientations relative to the target RNA (i.e., MAPT gene). In some embodiments of the present disclosure, double-stranded RNA (dsRNA) triggers degradation of a target RNA (e.g., mRNA) by a post-transcriptional gene silencing mechanism referred to herein as RNA interference or RNAi.
[0186] Typically, dsRNA molecules may include ribonucleotides, but as described in detail herein, each chain or both chains may also include one or more non-ribonucleotides, for example, deoxyribonucleotides, modified nucleotides. In addition, as used in this specification, "RNAi agents" may include ribonucleotides with chemical modifications; RNAi agents may include substantial modifications at multiple nucleotides. As used herein, the term "modified nucleotides" refers to nucleotides independently having modified sugar moieties, modified internucleotide bonds, or modified nucleobases. Therefore, the term "modified nucleotides" encompasses substitutions, additions, or removals of, for example, functional groups or atoms of internucleoside bonds, sugar moieties, or nucleobases. Modifications suitable for use in the present invention include all types of modifications disclosed herein or known in the art. For the purposes of this specification and claims, any such modifications, as used in siRNA type molecules, are covered by "RNAi agents".
[0187] In certain embodiments of the present disclosure, the inclusion of deoxynucleotides may be considered to constitute modified nucleotides if present within a RNAi agent.
[0188] The duplex region can be any length that allows for specific degradation of the desired target RNA by the RISC pathway, and can be in the range of about 15-36 base pairs in length, such as about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 base pairs in length, such as about 15-30, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-19, 15-23, 15-24, 15-25, 15-26, 15-27, 15-28, 15-29, 15-21, 15-20, 15-19, 15-18, 15-19, 15-23, 15-24, 15-25 0, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 1 In some embodiments, the duplex region has a length of 19-21 base pairs, for example, 21 base pairs in length. Ranges and lengths intermediate to the above ranges and lengths are also considered to be part of the present disclosure.
[0189] The two chains forming the duplex structure can be different parts of a larger RNA molecule, or it can be a separate RNA molecule. If these two chains are part of a larger molecule and are therefore connected by an uninterrupted nucleotide chain between the 3'-end of a chain forming the duplex structure and the 5'-end of the corresponding other chain, the connecting RNA chain is referred to as a "hairpin loop". The hairpin loop may include at least one unpaired nucleotide. In some embodiments, the hairpin loop may include at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 20, at least 23 or more unpaired nucleotides or non-target sites of dsRNA. In some embodiments, the hairpin loop may be 10 or less nucleotides. In some embodiments, the hairpin may be 8 or less unpaired nucleotides. In some embodiments, the hairpin loop may be 4-10 unpaired nucleotides. In some embodiments, the hairpin loop may be 4-8 nucleotides.
[0190] In the case where the two substantially complementary chains of dsRNA are composed of separate RNA molecules, those molecules do not need to be but can be covalently linked. In certain embodiments where the two chains are covalently linked by means other than the uninterrupted nucleotide chain between the 3'-end of one chain forming a duplex structure and the 5'-end of the corresponding other chain, the connecting structure is referred to as a "joint" (although it should be noted that certain other structures defined elsewhere herein may also be referred to as "joints"). RNA chains may have the same or different numbers of nucleotides. The maximum number of base pairs is the number of nucleotides in the shortest chain of the dsRNA minus any overhangs present in the duplex. In addition to the duplex structure, RNAi may include one or more nucleotide overhangs. In one embodiment of the RNAi agent, at least one chain includes a 3' overhang of at least 1 nucleotide. In another embodiment, at least one chain includes a 3' overhang of at least 2 nucleotides, for example, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14 or 15 nucleotides. In other embodiments, at least one strand of the RNAi agent includes a 5' overhang of at least 1 nucleotide. In certain embodiments, at least one strand includes a 5' overhang of at least 2 nucleotides, e.g., 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, or 15 nucleotides. In still other embodiments, both the 3' end and the 5' end of one strand of the RNAi agent include an overhang of at least 1 nucleotide.
[0191] In one embodiment, the RNAi agent of the present disclosure is a dsRNA, each strand of which independently comprises 19-23 nucleotides, which interacts with a target RNA sequence (eg, a MAPT target mRNA sequence) to direct the cleavage of the target RNA.
[0192] In some embodiments, the iRNA of the present disclosure is a 24-30 nucleotide dsRNA that interacts with a target RNA sequence (eg, a MAPT target mRNA sequence) to direct the cleavage of the target RNA.
[0193] As used herein, the term "nucleotide overhang" refers to at least one unpaired nucleotide that protrudes from the duplex structure of an RNAi agent (e.g., dsRNA). For example, when the 3'-end of one strand of a dsRNA extends beyond the 5'-end of the other strand, or vice versa, a nucleotide overhang is present. The dsRNA may include an overhang of at least one nucleotide; alternatively, the overhang may include at least two nucleotides, at least three nucleotides, at least four nucleotides, at least five nucleotides or more. The nucleotide overhang may include or consist of: nucleotide / nucleoside analogs, including deoxynucleotides / nucleosides. The overhang may be on the sense strand, the antisense strand, or any combination thereof. In addition, the nucleotides of the overhang may be present on the 5'-end, the 3'-end, or both of the antisense strand or the sense strand of the dsRNA.
[0194] In one embodiment, the antisense strand of the dsRNA has an overhang of 1-10 nucleotides, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides at the 3'-end or 5'-end. In one embodiment, the sense strand of the dsRNA has an overhang of 1-10 nucleotides, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides at the 3'-end or 5'-end. In another embodiment, one or more nucleotides in the overhang are replaced by nucleoside phosphorothioates.
[0195] In certain embodiments, the antisense strand of the dsRNA has an overhang of 1-10 nucleotides, e.g., 0-3, 1-3, 2-4, 2-5, 4-10, 5-10, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides at the 3'-end or 5'-end. In one embodiment, the sense strand of the dsRNA has an overhang of 1-10 nucleotides, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides at the 3'-end or 5'-end. In another embodiment, one or more nucleotides in the overhang are replaced by nucleoside phosphorothioates.
[0196] In certain embodiments, the overhang on the sense strand or antisense strand may include an extended length longer than 10 nucleotides, for example, 1-30 nucleotides, 2-30 nucleotides, 10-30 nucleotides, or 10-15 nucleotides in length. In certain embodiments, the overhang of the extension is on the sense strand of the duplex. In certain embodiments, the overhang of the extension exists on the 3'-end of the sense strand of the duplex. In certain embodiments, the overhang of the extension exists on the 5'-end of the sense strand of the duplex. In certain embodiments, the overhang of the extension is on the antisense strand of the duplex. In certain embodiments, the overhang of the extension exists on the 3'-end of the antisense strand of the duplex. In certain embodiments, the overhang of the extension exists on the 5'-end of the antisense strand of the duplex. In certain embodiments, one or more nucleotides in the overhang are replaced by nucleoside thiophosphates. In certain embodiments, the overhang includes a self-complementary portion so that the overhang can form a hairpin structure that is stable under physiological conditions.
[0197] As used herein, the term "flat end" or "flat end" with respect to dsRNA refers to the absence of unpaired nucleotides or nucleotide analogs at a given end of the dsRNA, i.e., no nucleotide overhangs. One or both ends of the dsRNA may be flat-ended. In the case where both ends of the dsRNA are flat-ended, the dsRNA is referred to as flat-ended. For clarity, a "flat-ended" dsRNA is a dsRNA with both ends being flat-ended, i.e., no nucleotide overhangs at either end of the molecule. The most common such molecules are double-stranded over their entire length.
[0198] The term "antisense strand" or "guide strand" refers to the strand of a RNAi agent (eg, dsRNA) that comprises a region that is substantially complementary to a target sequence (eg, MAPT mRNA).
[0199] As used herein, the term "complementary region" refers to a region substantially complementary to a sequence defined herein (e.g., a target sequence, such as a MAPT nucleotide sequence) on the antisense strand. In the case where the complementary region is not completely complementary to the target sequence, mispairing may be in the interior or terminal region of the molecule. Typically, the most tolerable mispairing is in the terminal region, e.g., in 5, 4, 3 or 2 nucleotides at the 5'- or 3'-end of the RNAi agent. In some embodiments, the double-stranded RNA agent of the present disclosure comprises a nucleotide mispairing in the antisense strand. In some embodiments, the antisense strand of a double-stranded RNA agent of the present disclosure comprises no more than 4 mispairings with target mRNA, e.g., the antisense strand comprises 4, 3, 2, 1 or 0 mispairings with target mRNA. In some embodiments, the antisense strand of a double-stranded RNA agent of the present disclosure comprises no more than 4 mispairings with sense strand, e.g., the antisense strand comprises 4, 3, 2, 1 or 0 mispairings with sense strand. In some embodiments, the double-stranded RNA agent of the present disclosure comprises a nucleotide mismatch in the sense strand. In some embodiments, the sense strand of the double-stranded RNA agent of the present disclosure comprises no more than 4 mismatches with the antisense strand, for example, the sense strand comprises 4, 3, 2, 1 or 0 mismatches with the antisense strand. In some embodiments, the nucleotide mismatch is within 5, 4, 3 nucleotides of the 3'-end of the iRNA, for example. In another embodiment, the nucleotide mismatch is in the 3'-terminal nucleotide of the iRNA agent, for example. In some embodiments, the mismatch is not in the seed region.
[0200] Therefore, RNAi agent as described herein may contain one or more mispairings with the target sequence. In one embodiment, RNAi agent as described herein contains no more than 3 mispairings (i.e., 3, 2, 1 or 0 mispairings). In one embodiment, RNAi agent as described herein contains no more than 2 mispairings. In one embodiment, RNAi agent as described herein contains no more than 1 mispairing. In one embodiment, RNAi agent as described herein contains 0 mispairings. In certain embodiments, if the antisense strand of RNAi agent contains a mispairing with the target sequence, the mispairing may be optionally limited to the last 5 nucleotides of the 5'- or 3'-end of the complementary region. For example, in such an embodiment, for the RNAi agent of 23 nucleotides, the strand complementary to the region of MAPT gene is generally not contained in the central 13 nucleotides. Methods described herein or methods known in the art can be used to determine whether the RNAi agent comprising a mispairing with the target sequence effectively suppresses the expression of 4R-tau subtypes. For example, Jackson et al., (Nat. Biotechnol. 2003; 21: 635-637) described an expression profile study, in which the expression of a small group of genes with sequence identity to MAPK14 siRNA at only 12-18nt of the sense strand was downregulated with kinetics similar to MAPK14. Similarly, Lin et al. (Nucleic Acids Res. 2005; 33 (14): 4527-4535) used qPCR and reporter gene assays to prove that the 7nt complementation between siRNA and target is sufficient to cause target mRNA degradation. It is important to consider the efficacy of RNAi agents with mismatches in suppressing the expression of 4R-tau subtypes, especially if it is known that the specific complementary region in the MAPT gene has polymorphic sequence variation within the population.
[0201] As used herein, "substantially all nucleotides are modified" are modified to a large extent but not completely, and may include no more than 5, 4, 3, 2 or 1 unmodified nucleotides.
[0202] As used herein, the term "sense strand" or "follower strand" refers to the strand of a RNAi agent that comprises a region that is substantially complementary to a region of the antisense strand, as that term is defined herein.
[0203] As used herein, the term "cleavage zone" refers to the region adjacent to the cleavage site. The cleavage site is the site where cleavage occurs on the target. In some embodiments, the cleavage zone is included in three bases on either end of the cleavage site and adjacent to the cleavage site. In some embodiments, the cleavage zone is included in two bases on either end of the cleavage site and adjacent to the cleavage site. In some embodiments, the cleavage site specifically occurs at the site where nucleotides 10 and 11 of the antisense strand bind, and the cleavage zone includes nucleotides 11, 12, and 13.
[0204] As used herein, and unless otherwise indicated, the term "complementary" when used to describe a first nucleotide sequence relative to a second nucleotide sequence refers to the ability of an oligonucleotide or polynucleotide comprising a first nucleotide sequence to hybridize with an oligonucleotide or polynucleotide comprising a second nucleotide sequence and form a duplex structure under certain conditions, as will be understood by the skilled person. Such conditions may be, for example, "stringent conditions", including but not limited to: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50 ° C or 70 ° C, for 12 to 16 hours, followed by washing (see, for example, Molecular Cloning: A Laboratory Manual, Sambrook et al., (1989) Cold Spring Harbor Laboratory Press). As used herein, "stringent conditions" or "stringent hybridization conditions" refer to conditions under which an antisense compound hybridizes with its target sequence, but hybridizes with a minimum number of other sequences. Stringent conditions are sequence-dependent and are different in different situations, and the "stringent conditions" under which an antisense compound hybridizes with a target sequence are determined by the properties and composition of the antisense compound and the assay method for studying it. Other conditions may be applied, such as physiologically relevant conditions that may be encountered inside an organism. The skilled artisan is able to determine the most appropriate set of conditions for testing the complementarity of two sequences depending on the ultimate application of the hybridizing nucleotides.
[0205] The complementary sequence in RNAi agent (for example, in dsRNA as described herein) includes the base pairing of the oligonucleotide or polynucleotide comprising the first nucleotide sequence and the oligonucleotide or polynucleotide comprising the second nucleotide sequence in the total length of one or two nucleotide sequences. Such sequences may be referred to as "completely complementary" to each other in this article. However, when the first sequence is referred to as "substantially complementary" relative to the second sequence in this article, the two sequences may be completely complementary, or for the duplex of up to 30 base pairs, it may form one or more during hybridization, but is usually no more than 5,4,3 or 2 mispaired base pairs. In some embodiments, "substantially complementary" sequence disclosed herein includes at least about 80% complementary to the equivalent region of target exon 10-MAPT sequence in its complete length, such as about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% complementary continuous nucleotide sequence. However, where two oligonucleotides are designed to form one or more single-stranded overhangs upon hybridization, such overhangs should not be considered mismatches for the purpose of complementarity determination. For example, a dsRNA comprising one oligonucleotide of 21 nucleotides in length and another oligonucleotide of 23 nucleotides in length, wherein the longer oligonucleotide comprises a 21 nucleotide sequence that is fully complementary to the shorter oligonucleotide, can still be referred to as "fully complementary" for the purposes described herein.
[0206] As used herein, "complementary" sequences may also include non-Watson-Crick base pairs or base pairs formed by non-natural and modified nucleotides, or be formed entirely by them, as long as the above requirements for their hybridization ability are met. Such non-Watson-Crick base pairs include, but are not limited to, G:U wobble base pairing or Hoogstein base pairing.
[0207] The terms "complementary," "fully complementary," and "substantially complementary" herein can be used with respect to base matching between the sense and antisense strands of a dsRNA or between the antisense strand of a RNAi agent and a target sequence, as understood from the context of their use.
[0208] As used herein, a polynucleotide that is "at least partially substantially complementary" to a messenger RNA (mRNA) refers to a polynucleotide that is substantially complementary to a contiguous portion of an mRNA of interest (e.g., an mRNA encoding Tau). For example, if the sequence is substantially complementary to an uninterrupted portion of an mRNA encoding Tau, then the polynucleotide is complementary to at least a portion of the MAPT mRNA.
[0209] Therefore, in some embodiments, the antisense polynucleotides disclosed herein are fully complementary to the target MAPT sequence. In other embodiments, the antisense polynucleotides disclosed herein are substantially complementary to the target MAPT sequence, and are included in a continuous nucleotide sequence that is at least 80% complementary to the equivalent region of the nucleotide sequence of exon 10 hotspots (mapped to nucleotides 1007-1053 of SEQ ID NO:3) or its fragment over its entire length, such as about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% complementary.
[0210] In some embodiments, the antisense polynucleotides disclosed herein are substantially complementary to a fragment of a target MAPT sequence and comprise a fragment thereof selected from SEQ ID NO: 3 over its entire length. 1042, 1023-1043, 1024-1044, 1025-1045, 1026-1046, 1027-1047, 1028-1048, 1029-1049, 1030-1050, 1031-1051, 1032-1052, 1033-1053, 1014-1048, and 1022-1048 of SEQ ID NO: 3 are at least 80% complementary contiguous nucleotide sequences, such as about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% complementary. Ranges intermediate to the above ranges are also contemplated as part of the present disclosure. In certain embodiments, the antisense polynucleotides disclosed herein are substantially complementary to a fragment of a target MAPT sequence and comprise a sequence selected from SEQ ID NO: 3 over its entire length: 1009-1029, 1016-1036, 1018-1038, 1020-1040, 1021-1041, 1022-1042, 1024-1044, 1027-1047, 1028-1048, 1029-1049, 1030-1050, 1032-1052, 1033-1053, 1014-1048, and 1022-1048. The fragment of NO:3 is at least 80% complementary, such as about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% complementary contiguous nucleotide sequence.
[0211] In other embodiments, the antisense polynucleotides disclosed herein are substantially complementary to the target MAPT sequence and comprise a continuous nucleotide sequence that is at least about 80% complementary to any one of the sense strand nucleotide sequences in Table 7 or 8, or a fragment of any one of the sense strand nucleotide sequences in Table 7 or 8, such as about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or 100% complementary over its entire length.
[0212] In one embodiment, the RNAi agent of the present disclosure comprises a sense strand that is substantially complementary to an antisense polynucleotide, which in turn is complementary to a target MAPT sequence, and wherein the sense strand polynucleotide comprises a contiguous nucleotide sequence that is at least about 80% complementary over its entire length to a nucleotide sequence of nucleotides 1007-1053 of SEQ ID NO:4, or an equivalent region thereof, such as about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% complementary. In some embodiments, the iRNA of the present disclosure comprises a sense strand that is substantially complementary to an antisense polynucleotide, which in turn is complementary to a MAPT sequence, and wherein the sense strand polynucleotide comprises a contiguous nucleotide sequence that is at least about 80% complementary, such as about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% complementary over its entire length to any of the antisense strand nucleotide sequences in Table 7 or 8 or a fragment of any of the antisense strand nucleotide sequences in Table 7 or 8.
[0213] In certain embodiments, the sense strand and the antisense strand are selected from any of the following duplexes: AD-1423276, AD-1423277, AD-1423278, AD-1423279, AD-1423280, AD-1423281, AD-1423282, AD-1423283, AD-1423284, AD-1423285, AD-1423286, AD- 1423287, AD-1423288, AD-1423289, AD-1423290, AD-1423291, AD-1423292, AD-1423293, A D-1423294, AD-1423295, AD-1423296, AD-1423297, AD-1423298, AD-1423299 and AD-1423300. In a specific embodiment, the sense strand and the antisense strand are selected from any of the following duplexes: AD-1423276, AD-1423283, AD-1423285, AD-1423287, AD-1423288, AD-1423289, AD-1423291, AD-1423294, AD-1423295, AD-1423296, AD-1423297, AD-1423299 and AD-1423300. In a further specific embodiment, the sense strand and the antisense strand are selected from any of the following duplexes: AD-1423283, AD-1423291, AD-1423294 and AD-1423295.
[0214] In one embodiment, at least partial inhibition of the expression of a 4R-tau subtype is assessed by a reduction in the amount of a 4R-tau mRNA (e.g., a sense mRNA, an antisense mRNA, a total 4R-tau mRNA), which can be isolated or detected from a first cell or cell group in which the MAPT gene is transcribed and has been treated so that the expression of the 4R-tau subtype is inhibited, as compared to a second cell or cell group (control cells) that is substantially the same as the first cell or cell group but has not been treated in this way. The degree of inhibition can be expressed by the following formula:
[0215]
[0216] As used herein, the phrase "contacting a cell with an RNAi agent (such as a dsRNA)" includes contacting the cell by any possible means. Contacting a cell with an RNAi agent includes contacting the cell with an RNAi agent in vitro or contacting the cell with an RNAi agent in vivo. Contact may be made directly or indirectly. Thus, for example, the RNAi agent may be brought into physical contact with the cell by an individual performing the method, or alternatively, the RNAi agent may be placed in a situation that allows or causes it to subsequently contact the cell.
[0217] Contacting cells in vitro can be carried out by, for example, incubating cells with RNAi agents.Contacting cells in vivo can be carried out by, for example, injecting RNAi agents into the tissue where the cells are located or in the vicinity thereof, or by injecting RNAi agents into another region, such as the central nervous system (CNS), optionally by intrathecal, intravitreal, intracerebral cistern or other injections, or injected into the bloodstream or subcutaneous space, so that the medicament subsequently arrives at the tissue where the cells are to be contacted.For example, RNAi agents can contain ligands or be coupled to ligands, for example, one or more lipophilic moieties, as described below and described in further detail, such as PCT / US2019 / 031170, the document is incorporated herein by reference, and the ligand guides or otherwise stabilizes RNAi agents at the site of interest (e.g., CNS).The combination of in vitro and in vivo contact methods is also possible.For example, cells can also be contacted with RNAi agents in vitro and then transplanted into a subject.
[0218] In one embodiment, contacting a cell with a RNAi agent includes "introducing" or "delivering" the RNAi agent into a cell by promoting or affecting the uptake or absorption of the cell. The absorption or uptake of the RNAi agent can occur by unassisted diffusion or active cellular processes, or by an adjuvant or device. The introduction of the RNAi agent into the cell can be in vitro or in vivo. For example, for in vivo introduction, the RNAi agent can be injected into a tissue site or administered systemically. In vitro introduction into cells includes methods known in the art, such as electroporation and lipofection. Further approaches are described below or are known in the art.
[0219] The term "lipophilic" or "lipophilic moiety" refers broadly to any compound or chemical moiety that has an affinity for lipids. One way to characterize the lipophilicity of a lipophilic moiety is by the octanol-water partition coefficient log K ow , where K ow Is the ratio of the concentration of a chemical in the octanol phase to its concentration in the aqueous phase in a two-phase system in equilibrium. The octanol-water partition coefficient is a laboratory-measured property of a substance. However, it can also be predicted by using coefficients attributed to the structural components of the chemical, which are calculated using first principles or empirical methods (see, e.g., Tetko et al., J. Chem. Inf. Comput. Sci. 41: 1407-21 (2001), which is incorporated herein by reference in its entirety). It provides a thermodynamic measure of the tendency of a substance to prefer a non-aqueous or oily environment rather than water (i.e., its hydrophilic / lipophilic balance). In principle, when the logK of a chemical substance is ow When it is greater than 0, it is lipophilic. Typically, lipophilic moieties have a logK greater than 1, greater than 1.5, greater than 2, greater than 3, greater than 4, greater than 5, or greater than 10.ow For example, the logK of 6-aminohexanol is ow It is predicted to be approximately 0.7. Using the same method, the logK of cholesterol N-(hexan-6-ol)carbamate ow The forecast is 10.7.
[0220] The lipophilicity of a molecule can be altered depending on the functional groups it carries. For example, adding a hydroxyl or amine group to the end of a lipophilic moiety can increase or decrease the partition coefficient (e.g., logK ow )value.
[0221] Alternatively, the hydrophobicity of a double-stranded RNAi agent conjugated to one or more lipophilic moieties can be measured by its protein binding characteristics. For example, in certain embodiments, the unbound fraction in a plasma protein binding assay of a double-stranded RNAi agent can be determined to be positively correlated with the relative hydrophobicity of the double-stranded RNAi agent, which in turn may be positively correlated with the silencing activity of the double-stranded RNAi agent.
[0222] In one embodiment, the determined plasma protein binding assay is an electrophoretic mobility shift assay (EMSA) using human serum albumin. This exemplary scheme for binding assays is described in detail in, for example, PCT / US2019 / 031170. In short, the duplex is incubated with human serum albumin, and the unbound fraction is determined. The exemplary assay scheme comprises a duplex with a reserve concentration of 10 μM, which is diluted to a final concentration of 0.5 μM (total volume 20 μL), containing 0%, 20% or 90% serum in 1x PBS. The samples can be mixed, centrifuged for 30 seconds, and then incubated at room temperature for 10 minutes. Once the incubation step is complete, 4 μL of 6x EMSA gel loading solution can be added to each sample, centrifuged for 30 seconds, and each sample of 12 μL can be loaded onto a 26-well BioRad 10% PAGE (polyacrylamide gel electrophoresis). The gel can be run at 100 volts for 1 hour. After the run is complete, the gel is removed from the shell and washed in 50mL of 10% TBE (Tris base, boric acid and EDTA). After washing is complete, 5 μL SYBR Gold can be added to the gel, which is then incubated at room temperature for 10 minutes and the gel is washed again in 50mL 10% TBE. In this exemplary assay, the Gel Doc XR+ gel recording system can be used to read the gel using the following parameters: the imaging application is set to SYBR Gold, the size is set to Bio-Rad standard gel, the exposure is set to automatic for strong bands, the prominent saturated pixels can be changed to one, and the color is set to gray. Detection, molecular weight analysis and output can all be disabled. Once a clear photo of the gel is obtained, Image Lab 5.2 can be used to process the image. Lanes and bands can be manually set to measure band intensity. The band intensity of each sample can be standardized relative to PBS to obtain a score that is not combined with siRNA. Through this measurement, relative hydrophobicity can be determined. The hydrophobicity of the double stranded RNAi agent as measured by the fraction of unbound siRNA in a binding assay is greater than 0.15, greater than 0.2, greater than 0.25, greater than 0.3, greater than 0.35, greater than 0.4, greater than 0.45, or greater than 0.5 for enhanced in vivo delivery of siRNA.
[0223] Therefore, conjugating a lipophilic moiety to an internal position of a double-stranded RNAi agent provides optimal hydrophobicity for enhanced in vivo delivery of siRNA.
[0224] The term "lipid nanoparticle" or "LNP" is a vesicle comprising a lipid layer that encapsulates a pharmaceutically active molecule, such as a nucleic acid molecule, e.g., an RNAi agent or a plasmid from which an RNAi agent is transcribed. LNPs are described, e.g., in U.S. Patents Nos. 6,858,225, 6,815,432, 8,158,601, and 8,058,069, the entire contents of which are hereby incorporated by reference herein.
[0225] As used herein, a "subject" is an animal, such as a mammal, including a primate (such as a human, a non-human primate, such as a monkey and a chimpanzee) or a non-primate (such as a rat or a mouse). In a preferred embodiment, the subject is a human, such as a person who is being treated or evaluated for a disease, disorder or condition that benefits from reduced expression of 4R-tau; a person at risk of a disease, disorder or condition that benefits from reduced expression of 4R-tau; a person suffering from a disease, disorder or condition that benefits from reduced expression of 4R-tau; or a person who is being treated for a disease, disorder or condition that benefits from reduced expression of 4R-tau, as described herein. In some embodiments, the subject is a female human. In other embodiments, the subject is a male human. In one embodiment, the subject is an adult subject. In one embodiment, the subject is a pediatric subject. In another embodiment, the subject is an adolescent subject, i.e., a subject under 20 years of age.
[0226] As used herein, the term "treatment" or "treatment" refers to a beneficial or desired outcome, including but not limited to mitigation or alleviation of one or more signs or symptoms associated with 4R-tau expression or 4R-tau production in a 4R-tau-related disease (such as 4R-tau protein disease, such as PSP, CBD, AGD, MSTD, GGT, spAD or rpAD). "Treatment" may also refer to a prolonged survival period compared to the expected survival period in the absence of treatment.
[0227] In the context of 4R-tau levels or disease markers or symptoms in a subject, the term "reduction" refers to a statistically significant reduction in this level. The reduction can be, for example, at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more. In certain embodiments, the reduction is at least 20%. In certain embodiments, the reduction is at least 50% reduction in disease markers (e.g., the level of a locus containing sense or antisense and / or the level of an abnormal dipeptide repeat protein), for example, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more reduction. In some embodiments, the reduction is at least about 25% reduction in disease markers, for example, 4R-tau protein and / or gene expression levels are reduced by at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 95%. "Reduction" in the case of a subject's 4R-tau level is preferably reduced to a level that is generally recognized as being within the normal range for individuals without such a disorder. In certain embodiments, "reduction" is a reduction in the difference between the level of a marker or symptom of a subject with a disease and the level that is generally recognized as being within the normal range for an individual, for example, the level of weight reduction between an obese individual and an individual with a weight that is generally recognized as being within the normal range.
[0228] As used herein, "prevention" or "prevention" when used in reference to a disease, disorder, or condition that benefits from a reduction in 4R-tau isoform expression or 4R-tau production refers to a reduction in the likelihood that a subject will experience symptoms associated with such a disease, disorder, or condition (e.g., symptoms of a 4R-tau-related disease). The absence of a disease, disorder, or condition, or a reduction in the occurrence of symptoms associated with such a disease, disorder, or condition (e.g., a reduction of at least about 10% on a clinically accepted scale for the disease or disorder), or a delay in the manifestation of symptoms (e.g., days, weeks, months, or years) is considered effective prevention.
[0229] As used herein, the term "4R-tau related disease" or "4R-tau related condition" includes any disease or condition that benefits from the expression and / or activity reduction of a 4R-tau subtype. Exemplary 4R-tau diseases include 4R-tauopathy. As used herein, "4R-tauopathy" is a tauopathy characterized by tau protein aggregation in which the 4R-tau subtype is the main or dominant Tau subtype. 4R-tauopathy includes, but is not limited to, progressive supranuclear palsy (PSP), corticobasal syndrome (CBD), argyrophilic grain disease (AGD), multisystem tauopathy (MSTD) with Alzheimer's disease, globular glial tauopathy (GGT), sporadic (spAD) Alzheimer's disease, and rapidly progressive (rpAD) Alzheimer's disease.
[0230] As used herein, "therapeutically effective amount" is intended to include an amount of RNAi agent sufficient to affect the treatment of the disease (e.g., by reducing, ameliorating, or maintaining an existing disease or one or more disease symptoms) when administered to a subject with a 4R-tau-related disease. A "therapeutically effective amount" may vary depending on the RNAi agent, how the agent is administered, the disease and its severity, as well as medical history, age, weight, family history, genetic makeup, type of prior or concomitant treatment (if any), and other individual characteristics of the subject to be treated.
[0231] As used herein, a "prophylactically effective amount" is intended to include an amount of an RNAi agent sufficient to prevent or improve a disease or one or more symptoms of a disease when administered to a subject with a 4R-tau-related disorder. Improving a disease includes slowing the progression of the disease or reducing the severity of a disease that occurs later. A "prophylactically effective amount" may vary depending on the RNAi agent, how the agent is administered, the degree of risk of the disease, and medical history, age, weight, family history, genetic makeup, type of prior or concomitant treatment (if any), and other individual characteristics of the patient to be treated.
[0232] "Therapeutically effective amount" or "prophylactically effective amount" also includes the amount of RNAi agent that produces some desired local or systemic effect at a reasonable benefit / risk ratio applicable to any treatment. The RNAi agent used in the method of the present disclosure can be administered in sufficient amount to produce a reasonable benefit / risk ratio applicable to such treatment.
[0233] The phrase "pharmaceutically acceptable" is used herein to refer to those compounds, materials, compositions, or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human and animal subjects without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0234] As used herein, the phrase "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or stearic acid), or solvent encapsulating material, which is involved in carrying or transporting the subject compound from one organ or part of the body to another organ or part of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the subject being treated. Some examples of materials that can be used as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) lubricants, such as magnesium stearate, sodium lauryl sulfate, and talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; (10) glycols, such as propylene glycol; (11) 1) polyols, such as glycerol, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) pH buffered solutions; (21) polyesters, polycarbonates or polyanhydrides; (22) bulking agents, such as polypeptides and amino acids; (23) serum components, such as serum albumin, HDL and LDL; and (22) other non-toxic compatible substances used in pharmaceutical preparations.
[0235] As used herein, the term "sample" comprises a collection of similar fluids, cells or tissues separated from a subject, and fluids, cells or tissues present in a subject. Examples of biological fluids include blood, serum and serosal fluids, plasma, cerebrospinal fluid, ocular fluids, lymph, urine, saliva, etc. Tissue samples can include samples from tissues, organs or local areas. For example, a sample can be derived from a specific organ, a part of an organ or a fluid or cell in these organs. In certain embodiments, a sample can be derived from brain (for example, some sections of the whole brain or brain, such as striatum, or some types of cells in the brain, such as neurons and glial cells (astrocytes, oligodendrocytes, microglia)). In some embodiments, "sample derived from a subject" refers to blood drawn from a subject or plasma or serum derived from it. In further embodiments, "sample derived from a subject" refers to brain tissue (or its subcomponents) or retinal tissue (or its subcomponents) derived from a subject.
[0236] The term "substituted" refers to replacing one or more hydrogen groups in a given structure with a group of a specified substituent, including but not limited to: alkyl, alkenyl, alkynyl, aryl, heterocyclyl, halo, thiol, alkylthio, arylthio, alkylthioalkyl, arylthioalkyl, alkylsulfonyl, alkylsulfonylalkyl, arylsulfonylalkyl, alkoxy, aryloxy, aralkyloxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, trifluoromethyl, cyano, nitro, alkylamino, arylamino, alkylaminoalkyl, arylaminoalkyl, aminoalkylamino, hydroxy, alkoxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, acyl, aralkyloxycarbonyl, carboxylic acid, sulfonic acid, sulfonyl, phosphonic acid, aryl, heteroaryl, heterocyclic and aliphatic. It should be understood that the substituent can be further substituted.
[0237] The term "alkyl" refers to saturated and unsaturated non-aromatic hydrocarbon chains, which may be linear or branched, containing the indicated number of carbon atoms (these include but are not limited to propyl, allyl or propargyl), which may be optionally interrupted by N, O or S. For example, "(C1-C6) alkyl" means a linear or branched arrangement of 1-6 carbon atoms. "(C1-C6) alkyl" includes, for example, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, pentyl and hexyl. In certain embodiments, the lipophilic portion of the present disclosure may comprise a C6-C18 alkyl hydrocarbon chain.
[0238] The term "alkylene" refers to an optionally substituted saturated aliphatic branched or straight chain divalent hydrocarbon group having a specified number of carbon atoms. For example, "(C1-C6)alkylene" means a divalent saturated aliphatic group having a linear arrangement of 1 to 6 carbon atoms, for example, [(CH 2 ) n ], wherein n is an integer from 1 to 6. "(C1-C6) alkylene" includes methylene, ethylene, propylene, butylene, pentylene and hexylene. Alternatively, "(C1-C6) alkylene" means a branched, saturated divalent group having 1 to 6 carbon atoms, for example: [CH 2 CH 2 CH 2 CH 2 CH(CH 3 )]、[CH 2 CH 2 CH 2 CH 2 C(CH 3 ) 2 ]、[(CH 2 C(CH 3 ) 2 CH(CH 3))] etc. The term "alkylenedioxy" refers to a divalent species of the structure -ORO-, wherein R represents an alkylene group.
[0239] The term "mercapto" refers to a -SH group. The term "thioalkoxy" refers to an -S-alkyl group.
[0240] The term "halo" refers to any radical of fluorine, chlorine, bromine or iodine. "Halogen" and "halo" are used interchangeably herein.
[0241] As used herein, unless otherwise indicated, the term "cycloalkyl" means a saturated or unsaturated non-aromatic hydrocarbon ring group with 3-14 carbon atoms. For example, "(C3-C10)cycloalkyl" means a hydrocarbon group of a (3-10)-membered saturated aliphatic cyclic hydrocarbon ring. Examples of cycloalkyl include, but are not limited to, cyclopropyl, methyl-cyclopropyl, 2,2-dimethyl-cyclobutyl, 2-ethyl-cyclopentyl, cyclohexyl, etc. Cycloalkyl may include multiple spiro rings or fused rings. Cycloalkyl may optionally be mono-, di-, tri-, tetra- or penta-substituted at any position as allowed by normal valence.
[0242] As used herein, unless otherwise indicated, the term "alkenyl" refers to a straight or branched non-aromatic hydrocarbon group containing at least one carbon-carbon double bond and having 2-10 carbon atoms. Up to five carbon-carbon double bonds may be present in such groups. For example, "C2-C6" alkenyl is defined as an alkenyl group with 2-6 carbon atoms. Examples of alkenyl groups include, but are not limited to, vinyl, propenyl, butenyl and cyclohexenyl. The linear, branched or cyclic portion of the alkenyl group may contain a double bond, and may optionally be mono-, di-, tri-, tetra- or penta-substituted in any position as allowed by normal valence. The term "cycloalkenyl" means a monocyclic hydrocarbon group with a specified number of carbon atoms and at least one carbon-carbon double bond.
[0243] As used herein, unless otherwise indicated, the term "alkynyl" refers to a straight or branched hydrocarbon group containing 2-10 carbon atoms and at least one carbon-carbon triple bond. There may be up to 5 carbon-carbon triple bonds. Therefore, "C2-C6 alkynyl" means an alkynyl group with 2-6 carbon atoms. Examples of alkynyl include, but are not limited to, ethynyl, 2-propynyl and 2-butynyl. As normal valence allows, the linear or branched portion of the alkynyl may contain a triple bond, and optionally may be mono-, di-, tri-, tetra- or penta-substituted at any position as normal valence allows.
[0244] As used herein, "alkoxyl" or "alkoxy" refers to an alkyl group as defined above with the indicated number of carbon atoms attached by an oxygen bridge. For example, "(C1-C3) alkoxy" includes methoxy, ethoxy and propoxy. For example, "(C1-C6) alkoxy" is intended to include C1, C2, C3, C4, C5 and C6 alkoxy. For example, "(C1-C8) alkoxy" is intended to include C1, C2, C3, C4, C5, C6, C7 and C8 alkoxy. The example of alkoxy includes but is not limited to methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, sec-pentoxy, n-heptyloxy and n-octyloxy. "Alkylthio" means an alkyl group attached by a sulfur linking atom. The term "alkylamino" or "aminoalkyl" means an alkyl group connected by an NH bond. "Dialkylamino" means two alkyl groups connected by a nitrogen linking atom. The amino group may be unsubstituted, monosubstituted or disubstituted. In some embodiments, the two alkyl groups are identical (e.g., N,N-dimethylamino). In some embodiments, the two alkyl groups are different (e.g., N-ethyl-N-methylamino).
[0245] As used herein, "aryl" or "aromatic" means any stable monocyclic or polycyclic carbocyclic ring of up to 7 atoms in each ring, wherein at least one ring is aromatic. Examples of aryl include, but are not limited to, phenyl, naphthyl, anthracenyl, tetrahydronaphthyl, indanyl, and biphenyl. In cases where the aryl substituent is bicyclic and one ring is non-aromatic, it is understood that the connection is through the aromatic ring. Alkyl groups are optionally mono-, di-, tri-, tetra- or penta-substituted in any position as normal valence permits. The term "arylalkyl" or the term "aralkyl" refers to an alkyl group substituted with an aryl group. The term "arylalkoxy" refers to an alkoxy group substituted with an aryl group.
[0246] "Hetero" refers to the replacement of at least one carbon atom in a ring system with at least one heteroatom selected from N, S and O. "Hetero" also refers to the replacement of at least one carbon atom in an acyclic system. A heterocyclic system or heteroacyclic system can have, for example, 1, 2 or 3 carbon atoms replaced by heteroatoms.
[0247] As used herein, the term "heteroaryl" refers to a stable monocyclic or polycyclic ring of up to 7 atoms in each ring, wherein at least one ring is aromatic and contains 1-4 heteroatoms selected from O, N and S. Examples of heteroaryl include, but are not limited to, acridinyl, carbazolyl, cinnolinyl, quinoxalinyl, pyrazolyl, indolyl, benzotriazolyl, furanyl, thienyl, benzothienyl, benzofuranyl, benzimidazolone, benzoxazolinyl, quinolyl, isoquinolyl, dihydroisoindolone, imidazopyridinyl, isoindolinone, indazolyl, oxazolyl, oxadiazolyl, isoxazolyl, indolyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrahydroquinoline. "Heteroaryl" is also understood to include the N-oxide derivatives of any nitrogen-containing heteroaryl. In the case where the heteroaryl substituent is bicyclic and one ring is non-aromatic or contains no heteroatoms, it is understood that attachment is through the aromatic ring or through the heteroatom-containing ring. The heteroaryl group is optionally mono-, di-, tri-, tetra- or penta-substituted at any position as allowed by normal valence.
[0248] As used herein, the term "heterocycle", "heterocyclic" or "heterocyclyl" means a 3- to 14-membered aromatic or non-aromatic heterocycle (including polycyclic groups) containing 1-4 heteroatoms selected from O, N and S. As used herein, the term "heterocyclic" is also considered to be synonymous with the terms "heterocycle" and "heterocyclyl", and is understood to also have the same definition shown herein."Heterocyclyl" includes the above-mentioned heteroaryl and its dihydro and tetrahydro analogs. The example of heterocyclyl includes but is not limited to: azetidinyl, benzimidazolyl, benzofuranyl, benzofuranyl, benzopyrazolyl, benzotriazolyl, benzothienyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolizinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthopyridinyl, oxadiazol ... oxazolidinyl, oxazolyl, oxazoline, oxopiperazinyl, oxopyrrolidinyl, oxomorpholinyl, isoxazoline, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridyl, pyridonyl, pyrimidinyl, pyrimidonyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydrothiopyranyl, tetrahydroisoquinoline yl, tetrazolyl, tetrazolyl, tetrazolopyridinyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, 1,4-dioxanyl, hexahydroazepanyl, piperazinyl, piperidinyl, pyridin-2-one, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisoxazolyl , dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothiophenyl, dihydrotriazolyl, dihydroazetidinyl, dioxythiomorpholinyl, methylenedioxybenzoyl, tetrahydrofuranyl and tetrahydrothiophenyl, and N-oxides thereof. The connection of the heterocyclic substituent can be carried out by a carbon atom or by a heteroatom. The heterocyclic radical is optionally single, di, tri, tetra or pentasubstituted in any position as allowed by normal valence.
[0249] "Heterocycloalkyl" refers to a cycloalkyl residue in which one to four carbons are replaced by heteroatoms such as oxygen, nitrogen or sulfur. Examples of heterocycles that are heterocyclyl groups include tetrahydropyran, morpholine, pyrrolidine, piperidine, thiazolidine, oxazole, oxazoline, isoxazole, dioxane, tetrahydrofuran, and the like.
[0250] The term "heteroaryl" refers to an aromatic 5- to 8-membered monocyclic, 8- to 12-membered bicyclic, or 11- to 14-membered tricyclic ring system having 1 to 3 heteroatoms if monocyclic, 1 to 6 heteroatoms if bicyclic, or 1 to 9 heteroatoms if tricyclic, the heteroatoms being selected from O, N, or S (e.g., carbon atoms and 1 to 3, 1 to 6, or 1 to 9 heteroatoms of N, O, or S, respectively, if monocyclic, bicyclic, or tricyclic), wherein 0, 1, 2, 3, or 4 atoms of each ring may be substituted with substituents. Examples of heteroaryl groups include pyridyl, furyl or furanyl, imidazolyl, benzimidazolyl, pyrimidinyl, phenylthio or thienyl, quinolinyl, indolyl, thiazolyl, and the like. The term "heteroarylalkyl" or the term "heteroaralkyl" refers to an alkyl group substituted by a heteroaryl group. The term "heteroarylalkoxy" refers to an alkoxy group substituted by a heteroaryl group.
[0251] The term "cycloalkyl" as used herein includes saturated and partially unsaturated cyclic hydrocarbon groups having 3-12 carbons, such as 3-8 carbons, and, for example, 3-6 carbons, wherein the cycloalkyl group may be optionally substituted in addition. Cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl.
[0252] The term "acyl" refers to an alkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, heterocyclylcarbonyl or heteroarylcarbonyl substituent, any of which may be further substituted by substituents.
[0253] As used herein, "keto" refers to any alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl or aryl group as defined herein attached through a carbonyl bridge.
[0254] Examples of keto groups include, but are not limited to, alkanoyl (e.g., acetyl, propionyl, butyryl, valeryl, hexanoyl), alkenoyl (e.g., acryloyl), alkynoyl (e.g., ethynyl, propioyl, butynoyl, pentynyl, hexynyl), aroyl (e.g., benzoyl), heteroaroyl (e.g., pyrroloyl, imidazoyl, quinolinyl, pyridinoyl).
[0255] As used herein, "alkoxycarbonyl" refers to any alkoxy group as defined above (i.e., -C(O)O-alkyl) attached through a carbonyl bridge. Examples of alkoxycarbonyl include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, n-propoxycarbonyl, tert-butoxycarbonyl, benzyloxycarbonyl, or n-pentyloxycarbonyl.
[0256] As used herein, "aryloxycarbonyl" refers to any aryl group as defined herein attached through an oxycarbonyl bridge (ie, -C(O)O-aryl). Examples of aryloxycarbonyl groups include, but are not limited to, phenoxycarbonyl and naphthoxycarbonyl.
[0257] As used herein, "heteroaryloxycarbonyl" refers to any heteroaryl group as defined herein attached through an oxycarbonyl bridge (i.e., -C(O)O-heteroaryl). Examples of heteroaryloxycarbonyl include, but are not limited to, 2-pyridyloxycarbonyl, 2-oxazolyloxycarbonyl, 4-thiazolyloxycarbonyl, or pyrimidinyloxycarbonyl.
[0258] The term "oxo" refers to an oxygen atom which when attached to carbon forms a carbonyl, when attached to nitrogen forms an N-oxide, and when attached to sulfur forms a sulfoxide or sulfone.
[0259] Those of ordinary skill in the art will readily understand and appreciate that the compounds and compositions disclosed herein may have certain atoms (e.g., N, O, or S atoms) in a protonated or deprotonated state, depending on the environment in which the compound or composition is located. Thus, as used herein, the structures disclosed herein contemplate that certain functional groups, e.g., OH, SH, or NH, may be protonated or deprotonated. The disclosure herein is intended to cover the disclosed compounds and compositions regardless of their protonation state based on the pH of the environment, as readily understood by those of ordinary skill in the art.
[0260] II. RNAi Agents of the Disclosure
[0261] The RNAi agent for suppressing the expression of 4R-tau subtypes is described herein. In one embodiment, RNAi agent includes double-stranded ribonucleic acid (dsRNA) molecules for suppressing the expression of 4R-tau in cells, such as subjects, for example, mammals, such as cells in the human body suffering from 4R-tau related diseases (such as 4R-tau protein diseases, such as PSP, CBD, AGD, MSTD, GGT, spAD or rpAD). dsRNA includes an antisense strand with a complementary region, which is complementary to at least a portion of the hot spots in exon 10 in the mRNA formed in the expression of 4R-tau subtypes. The length of the complementary region is about 15-30 nucleotides or less. When contacting with cells expressing 4R-tau subtypes, when compared to similar cells not contacted with the RNAi agent or not contacted with the RNAi agent complementary to the MAPT gene, the RNAi agent suppresses the expression of 4R-tau subtypes (for example, human genes, primate genes, non-primate genes) by at least 25% or higher, as described herein. The expression of 4R-tau isoforms can be determined by, for example, PCR or branched DNA (bDNA) based methods, or by protein based methods, such as by immunofluorescence analysis, using, for example, Western blot or flow cytometry. In one embodiment, the knockdown level is determined in BE(2)-C cells using the assay provided in Example 1 below. In some embodiments, the knockdown level is determined in primary mouse hepatocytes. In some embodiments, the knockdown level is determined in Neuro-2a cells.
[0262] dsRNA comprises two complementary RNA chains that hybridize to form a duplex structure under the conditions of using dsRNA. One chain (antisense chain) of dsRNA comprises a complementary region that is substantially complementary to the target sequence and is usually completely complementary. The target sequence may be derived from the sequence of the hotspot within exon 10 in the mRNA formed during the expression of 4R-tau subtypes. The other chain (sense chain) comprises a region complementary to the antisense chain, so that the two chains hybridize and form a duplex structure when combined under appropriate conditions. As described elsewhere herein and as known in the art, the complementary sequence of dsRNA may also be included as a self-complementary region of a single nucleic acid molecule, as opposed to being located on an independent oligonucleotide.
[0263] Typically, the duplex structure has a length of 15-30 base pairs, for example, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs. In certain preferred embodiments, the length of the duplex structure is 18-25 base pairs, for example, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-25, 20-24, 20-23, 20-22, 20-21, 21-25, 21-24, 21-23, 21-22, 22-25, 22-24, 22-23, 23-25, 23-24 or 24-25 base pairs in length, for example, 19-21 base pairs in length. Ranges and lengths intermediate to the above ranges and lengths are also considered to be part of the present disclosure.
[0264] Similarly, the length of the complementary region to the target sequence is 15-30 nucleotides, for example, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 1 21-23 nucleotides, or a length of 21-23 nucleotides. Ranges and lengths intermediate to the above ranges and lengths are also considered to be part of the present disclosure.
[0265] In some embodiments, the length of the duplex structure is 19-30 base pairs. Similarly, the length of the complementary region to the target sequence is 19-30 nucleotides.
[0266] In some embodiments, the length of the dsRNA is 15 to 23 nucleotides, 19-23 nucleotides, or 25-30 nucleotides. In general, the dsRNA is long enough to serve as a substrate for the Dicer enzyme. For example, it is well known in the art that dsRNAs longer than about 21-23 nucleotides can be used as substrates for Dicer. As will also be appreciated by those of ordinary skill, the region of the RNA targeted for cutting is most often a portion of a larger RNA molecule (usually an mRNA molecule). In relevant cases, a "portion" of an mRNA target is a continuous sequence of an mRNA target that is long enough to make it a substrate for RNAi directed cutting (i.e., cutting by the RISC pathway).
[0267] Those skilled in the art will also recognize that the duplex region is the major functional portion of a dsRNA, e.g., about 15-36 base pairs (e.g., 15-36, 15-35, 15-34, 15-33, 15-32, 15-31, 15-30, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-2 22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23 or 21-22 base pairs, for example 19-21 base pairs). Thus, in one embodiment, to the extent that it is processed into a functional duplex of, for example, 15-30 base pairs that targets the desired RNA for cleavage, an RNA molecule or RNA molecule complex having a duplex region greater than 30 base pairs is a dsRNA. Thus, one of ordinary skill will recognize that, in one embodiment, a miRNA is a dsRNA. In another embodiment, a dsRNA is not a naturally occurring miRNA. In another embodiment, an RNAi agent that can be used to target 4R-tau expression is not produced in a target cell by cleaving a larger dsRNA.
[0268] The dsRNA as described herein may further comprise one or more single-stranded nucleotide overhangs, e.g., 1, 2, 3, or 4 nucleotides. The nucleotide overhangs may comprise or consist of nucleotide / nucleoside analogs, including deoxynucleotides / nucleosides. The overhangs may be on the sense strand, the antisense strand, or any combination thereof. In addition, the nucleotides of the overhangs may be present at the 5' end, 3' end, or both ends of the antisense strand or the sense strand of the dsRNA.
[0269] dsRNA can be synthesized by standard methods known in the art. Double-stranded RNAi compounds of the present disclosure can be prepared using a two-step procedure. First, a single strand of a double-stranded RNA molecule is prepared separately. Then, the component strands are annealed. The single strand of the siRNA compound can be prepared using solution phase or solid phase organic synthesis or both. The advantage provided by organic synthesis is that oligonucleotide chains containing non-natural or modified nucleotides can be easily prepared. Similarly, single-stranded oligonucleotides of the present disclosure can be prepared using solution phase or solid phase organic synthesis or both.
[0270] In one aspect, the dsRNA of the present disclosure comprises at least two nucleotide sequences, a sense sequence and an antisense sequence. The sense strand sequence of MAPT can be selected from the sequence group provided in Table 7 or 8, and the corresponding nucleotide sequence of the antisense strand of the sense strand can be selected from the sequence group of Table 7 or 8. In this aspect, one of the two sequences is complementary to the other of the two sequences, wherein one of the sequences is substantially complementary to the mRNA sequence produced in the expression of 4R-tau subtypes. Therefore, in this aspect, the dsRNA comprises two oligonucleotides, one of which is described as a sense strand (follower strand) in Table 7 or 8, and the second oligonucleotide is described as the corresponding antisense strand (guide strand) of the sense strand in Table 7 or 8.
[0271] In one embodiment, the sense strand comprises at least 15 consecutive nucleotides that differ by no more than three nucleotides from any of the following nucleotide sequences: nucleotides 1009-1029, 1010-1030, 1011-1031, 1012-1032, 1013-1033, 1014-1034, 1015-1035, 1016-1036, 1017-1037, 1018-1038, 1019-1039, 1020-1040, 1021-1041, 1022-1043 of SEQ ID NO:3. 42, 1023-1043, 1024-1044, 1025-1045, 1026-1046, 1027-1047, 1028-1048, 1029-1049, 1030-1050, 1031-1051, 1032-1052, 1033-1053, 1014-1048 and 1022-1048, and the antisense strand comprises at least 15 consecutive nucleotides from the corresponding nucleotide sequence of SEQ ID NO:4. In a specific embodiment, the sense strand comprises at least 15 consecutive nucleotides that differ by no more than three nucleotides from any of the following nucleotide sequences: 1009-1029, 1016-1036, 1018-1038, 1020-1040, 1021-1041, 1022-1042, 1024-1044, 1027-1047, 1028-1048, 1029-1049, 1030-1050, 1032-1052, 1033-1053, 1014-1048, and 1022-1048 of SEQ ID NO:3, and the antisense strand comprises at least 15 consecutive nucleotides from the corresponding nucleotide sequence of SEQ ID NO:4.
[0272] In certain embodiments, the antisense polynucleotides disclosed herein are substantially complementary to a fragment of a target MAPT sequence and comprise a contiguous nucleotide sequence that is at least 80% complementary to a fragment of SEQ ID NO: 3 over its entire length, wherein the sense strand comprises nucleotides 1009-1029, 1010-1030, 1011-1031, 1012-1032, 1013-1033, 1014-1034, 1015-1035, 1016-1036, 1017-1037, 1018-1038, 1019-1039, 1020-1040, 1021-1041, 1022-1042, 1023-1043, 1024-1044, 1025-1045, 1026-1046, 1027-1047, 1028-1048, 1029-1050 Any of the nucleotide sequences of SEQ ID NO: 1024-1044, 1025-1045, 1026-1046, 1027-1047, 1028-1048, 1029-1049, 1030-1050, 1031-1051, 1032-1052, 1033-1053, 1014-1048 and 1022-1048 differs by no more than three nucleotides in at least 15 consecutive nucleotides, and the antisense strand comprises at least 15 consecutive nucleotides from the corresponding nucleotide sequence of SEQ ID NO: 4. In some embodiments, the antisense polynucleotides disclosed herein are substantially complementary to a fragment of a target MAPT sequence and comprise a contiguous nucleotide sequence that is complementary to a fragment of SEQ ID NO: 3 over its entire length, wherein the sense strand comprises at least 15 contiguous nucleotides that differ by no more than three nucleotides from any one of nucleotide sequences of nucleotides 1009-1029, 1016-1036, 1018-1038, 1020-1040, 1021-1041, 1022-1042, 1024-1044, 1027-1047, 1028-1048, 1029-1049, 1030-1050, 1032-1052, 1033-1053, 1014-1048 and 1022-1048 of SEQ ID NO: 3, and the antisense strand comprises at least 15 contiguous nucleotides from the corresponding nucleotide sequence of SEQ ID NO: 4.
[0273] In one embodiment, the antisense strand comprises at least 15 consecutive nucleotides that differ by no more than three nucleotides from any antisense strand nucleotide sequence of a duplex selected from the group consisting of AD-1423276, AD-1423277, AD-1423278, AD-1423279, AD-1423280, AD-1423281, AD-1423282, AD-1423283, AD-1423284, AD-1423285 , AD-1423286, AD-1423287, AD-1423288, AD-1423289, AD-1423290, AD-1423291, AD-1423292, AD-14 23293, AD-1423294, AD-1423295, AD-1423296, AD-1423297, AD-1423298, AD-1423299 and AD-1423300. In a specific embodiment, the antisense strand comprises at least 15 consecutive nucleotides that differ by no more than three nucleotides from any antisense strand nucleotide sequence of a duplex selected from the group consisting of AD-1423276, AD-1423283, AD-1423285, AD-1423287, AD-1423288, AD-1423289, AD-1423291, AD-1423294, AD-1423295, AD-1423296, AD-1423297, AD-1423299, and AD-1423300.
[0274] In some embodiments, the present disclosure provides a dsRNA agent for inhibiting the expression of 4R-tau, wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double-stranded region, wherein the antisense strand comprises a complementary region to an mRNA encoding 4R-tau, and wherein the complementary region comprises at least 15 consecutive nucleotides that differ by no more than 3 nucleotides from any one of the antisense nucleotide sequences in Table 7 or 8.
[0275] In one embodiment, the substantially complementary sequences of the dsRNA are contained on separate oligonucleotides. In another embodiment, the substantially complementary sequences of the dsRNA are contained on a single oligonucleotide.
[0276] It should be understood that although the sequences in Tables 7 and 8 are described as modified or conjugated sequences, the RNA of the RNAi agent of the present disclosure (e.g., dsRNA of the present disclosure) may include any of the sequences shown in Tables 7 and 8, which are unmodified, unconjugated, or modified or conjugated differently from those described therein. For example, although the sense strand of the agent of the present disclosure can be conjugated to a GalNAc ligand, these agents can be conjugated to a portion that directs delivery to the CNS, such as a C16 ligand, as described herein. In one embodiment, the lipophilic moiety contains a saturated or unsaturated C16 hydrocarbon chain (e.g., a straight chain C16 alkyl or alkenyl). The lipophilic ligand may be included in any position provided in the present application. In some embodiments, the lipophilic moiety is conjugated to a nucleobase, a sugar moiety, or an internucleoside bond in a double-stranded iRNA agent. For example, the C16 ligand can be conjugated to the 2'-oxygen of a ribonucleotide as shown in the following structure:
[0277]
[0278] Wherein * represents the bond to the adjacent nucleotide, and B is a nucleobase or a nucleobase analog, optionally wherein B is adenine, guanine, cytosine, thymine or uracil. The design and synthesis of the ligands and monomers provided herein are described in, for example, PCT Publication Nos. WO2019 / 217459, WO2020 / 132227, and WO2020 / 257194, the contents of which are incorporated herein by reference in their entirety.
[0279] In some embodiments, the double-stranded iRNA agent further comprises a phosphate or phosphate mimic at the 5'-end of the antisense strand. In one embodiment, the phosphate mimic is 5'-vinylphosphonate (VP). In one embodiment, the phosphate mimic is 5'-cyclopropylphosphonate (VP). In some embodiments, the 5'-end of the antisense strand of the double-stranded iRNA agent does not contain 5'-vinylphosphonate (VP).
[0280] In one embodiment, at least one modified nucleotide is selected from deoxynucleotides, 2'-O-methyl modified nucleotides, 2'-fluoro modified nucleotides, 2'-deoxy modified nucleotides, diol modified nucleotides (GNA) (e.g., Ggn, Cgn, Tgn or Agn), nucleotides with 2'-phosphate (e.g., G2p, C2p, A2p or U2p) and vinyl-phosphonate nucleotides; and combinations thereof.
[0281] In other embodiments, each of the duplexes of Tables 7 and 8 can be specifically modified to provide another double-stranded iRNA agent of the present disclosure. In one example, the 3'-end of each sense duplex can be modified by removing the 3'-terminal L96 ligand and exchanging the two phosphodiester internucleotide bonds between the three 3'-terminal nucleotides with phosphorothioate internucleotide bonds. That is, the three 3'-terminal nucleotides (N) of the sense sequence of the following formula:
[0282] 5'-N 1 -…-N n-2 N n-1 N n L96 3'
[0283] The following can be used instead:
[0284] 5'-N 1 -…-N n-2 s N n-1 s N n 3'.
[0285] That is, for example, for AD-1423297, the sense sequence:
[0286] asasgga(Uhd)aaUfAfUfcaaacacguaL96
[0287] The following can be used instead:
[0288] asasgga(Uhd)aaUfAfUfcaaacac gsusa .
[0289] The antisense sequence remains unchanged to provide another double-stranded iRNA agent of the present disclosure. In other examples, the sense strand of each of the following duplexes is modified according to the foregoing description to provide a duplex of the present disclosure: AD-1423277, AD-1423278, AD-1423279, AD-1423280, AD-1423281, AD-1423282, AD-1423283, AD-1423284, AD-1423285, AD-1423286, AD-1423287, AD-1423288 D-1423287, AD-1423288, AD-1423289, AD-1423290, AD-1423291, AD-1423292, AD-1423293, AD-1423294, AD-1423295, AD-1423296, AD-1423297, AD-1423298, AD-1423299 and AD-1423300.
[0290] It is well known to those skilled in the art that dsRNAs having a duplex structure of about 20-23 base pairs (e.g., 21 base pairs) have been praised as being particularly effective in inducing RNA interference (Elbashir et al., (2001) EMBO J., 20:6877-6888). However, others have found that shorter or longer RNA duplex structures can also be effective (Chu and Rana (2007) RNA 14:1714-1719; Kim et al., (2005) Nat Biotech 23:222-226). In the above embodiments, due to the nature of the oligonucleotide sequences provided herein, the dsRNA described herein may comprise at least one strand having a minimum length of 21 nucleotides. It is reasonable to expect that, compared to the above dsRNAs, shorter duplexes with only a few nucleotides removed at one or both ends may be similarly effective. Thus, a dsRNA having a sequence of at least 15, 16, 17, 18, 19, 20 or more consecutive nucleotides derived from one of the sequences provided herein, and having an ability to inhibit the expression of a 4R-tau isoform that is at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95% inhibition compared to a control level of a dsRNA comprising the full sequence (using in vitro assays and PCR assays with, for example, A549 cells and 10 nM concentrations of RNA agents provided in the Examples herein) is considered to be within the scope of the present disclosure. In some embodiments, inhibition of a dsRNA comprising the full sequence is measured using an in vitro assay with primary mouse hepatocytes.
[0291] In addition, RNA described herein has identified the site of RISC-mediated cutting sensitivity in the MAPT transcript.So, the disclosure is further characterized by the RNAi agent in this site of targeting.As used herein, if the RNAi agent promotes the cutting of transcript in any position in this specific site, then the RNAi agent is referred to as in the specific site of the targeting RNA transcript.This type of RNAi agent usually comprises at least about 15 continuous nucleotides from one of the sequences provided by this paper, preferably at least 19 nucleotides, the other nucleotide sequence coupling of itself and the zone adjacent to the selected sequence taken from the MAPT gene.
[0292] III. Modified RNAi Agents of the Disclosure
[0293] In one embodiment, the RNA of RNAi agent (such as dsRNA) of the present disclosure is unmodified, and does not include chemical modifications or conjugations such as known in the art and described herein. In a preferred embodiment, the RNA of RNAi agent (such as dsRNA) of the present disclosure is chemically modified to enhance stability or other beneficial features. In certain embodiments of the present disclosure, substantially all nucleotides of RNAi agent of the present disclosure are modified. In other embodiments of the present disclosure, all nucleotides of RNAi agent of the present disclosure are modified. Wherein "substantially all nucleotides are modified" RNAi agent of the present disclosure is modified to a great extent but not completely, and may include no more than 5, 4, 3, 2 or unmodified nucleotides. In other embodiments of the present disclosure, RNAi agent of the present disclosure may include no more than 5, 4, 3, 2 or 1 modified nucleotides.
[0294] The nucleic acids described in the present disclosure can be synthesized or modified by methods recognized in the art, such as those described in "Current protocols in nucleic acid chemistry", Beaucage, SL et al. (eds.), John Wiley & Sons, Inc., New York, NY, USA, which are incorporated herein by reference. Modifications include, for example, end modifications, such as 5'-end modifications (phosphorylation, conjugation, reverse connection, etc.) or 3'-end modifications (conjugation, DNA nucleotides, reverse connection, etc.); base modifications, for example, base replacement, base removal (abasic nucleotides) or conjugated bases with stable bases, destabilizing bases, or base pairing with an extended partner library; sugar modifications (e.g., at the 2'-position or 4'-position) or replacement of sugars; or backbone modifications, including modification or replacement of phosphodiester bonds. Specific examples of RNAi agents that can be used in the embodiments described herein include, but are not limited to, RNAs containing modified backbones or containing no natural internucleoside bonds. RNAs with modified backbones particularly include those that do not have phosphorus atoms in the backbone. For the purposes of this specification, and as sometimes referred to in the art, modified RNAs that do not have a phosphorus atom in their internucleoside backbones may also be considered oligonucleosides. In some embodiments, the modified RNAi agent has a phosphorus atom in its internucleoside backbone.
[0295] The RNA backbone of modification comprises for example phosphorothioate, chiral phosphorothioate, phosphorodithioate, phosphotriester, aminoalkylphosphotriester, methyl and other alkylphosphonates (including 3'-alkylenephosphonates and chiral phosphonates), phosphinate, phosphoramidate (including 3'-aminophosphoramidate and aminoalkylphosphoramidate), thionophosphoramidate, thionoalkylphosphonates, thionoalkylphosphotriester and boranephosphate with normal 3'-5' key, analogs of these 2'-5' connections, and those with reverse polarity, wherein adjacent nucleoside units are connected to 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included. In some embodiments of the present disclosure, dsRNA agent of the present disclosure is free acid form. In other embodiments of the present disclosure, dsRNA agent of the present disclosure is salt form. In one embodiment, dsRNA agent of the present disclosure is sodium salt form. In certain embodiments, when the dsRNA agent of the present disclosure is in the form of a sodium salt, sodium ions are present in the agent as counterions for substantially all phosphodiester and / or phosphorothioate groups present in the agent. The agent in which substantially all phosphodiester and / or phosphorothioate bonds have sodium counterions comprises no more than 5, 4, 3, 2, or 1 phosphodiester and / or phosphorothioate bonds without sodium counterions. In some embodiments, when the dsRNA agent of the present disclosure is in the form of a sodium salt, sodium ions are present in the agent as counterions for all phosphodiester and / or phosphorothioate groups present in the agent.
[0296] Representative U.S. patents that teach the preparation of the above-mentioned phosphorus-containing bonds include, but are not limited to, the following U.S. Patents: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,195; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,316; 5,550,111; 5,563,253; 5,571,799; 5, 587,361; 5,625,050; 6,028,188; 6,124,445; 6,160,109; 6,169,170; 6,172,209; 6,239,265; 6,277,603; 6,326,199; 6,346,614; 6,444,423; 6,531,590; 6,5 Nos. 34,639; 6,608,035; 6,683,167; 6,858,715; 6,867,294; 6,878,805; 7,015,315; 7,041,816; 7,273,933; 7,321,029; and U.S. Pat. No. RE39464, each of which is hereby incorporated by reference in its entirety.
[0297] The modified RNA backbones that do not contain phosphorus atoms have backbones formed by short-chain alkyl or cycloalkyl nucleoside bonds, mixed heteroatoms and alkyl or cycloalkyl nucleoside bonds, or one or more short-chain heteroatoms or heterocyclic nucleoside bonds. These include backbones with morpholino linkages (partially formed by the sugar portion of the nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methyleneformacetyl and thioformacetyl backbones; olefin-containing backbones; sulfamic acid ester backbones; methyleneimino and methylenehydrazine backbones; sulfonate and sulfonamide backbones; amide backbones; and other backbones with mixed N, O, S and CH 2 The main chain of the component part.
[0298] Representative U.S. patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Patent Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,64,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5, Nos. 489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, the entire contents of each of which are hereby incorporated herein by reference.
[0299] In other embodiments, suitable RNA mimics are considered for RNAi agents, wherein the sugar and internucleoside bonds (i.e., main chains) of the nucleotide units are replaced by alternative groups. The base units are maintained to hybridize with appropriate nucleic acid target compounds. One such oligomeric compound (an RNA mimic that has been shown to have excellent hybridization properties) is referred to as peptide nucleic acid (PNA). In PNA compounds, the sugar backbone of RNA is replaced by an amide-containing main chain, especially an aminoethylglycine main chain. The core base is retained and directly or indirectly combined with the aza nitrogen atom of the amide portion of the main chain. Representative U.S. patents for teaching the preparation of PNA compounds include, but are not limited to, U.S. Patent No. 5,539,082; No. 5,714,331; and No. 5,719,262, the entire contents of each of which are hereby incorporated herein by reference. Other PNA compounds suitable for RNAi agents of the present disclosure are described in, for example, Nielsen et al., Science, 1991, 254, 1497-1500.
[0300] Some embodiments described in the present disclosure include RNAs having phosphorothioate backbones and oligonucleosides having heteroatom backbones, and in particular -CH 2 -NH-CH 2 -、-CH 2 -N(CH 3 )-O-CH 2 -[called methylene (methylimino) or MMI backbone], -CH 2 -ON(CH 3 )-CH 2 -、-CH 2 -N(CH 3 )-N(CH 3 )-CH 2- and -N(CH 3 )-CH 2 -[where the natural phosphodiester backbone is represented by -OPO-CH 2 -], and the amide backbone of US Pat. No. 5,602,240 cited above. In some embodiments, the RNA described herein has the morpholino backbone structure of US Pat. No. 5,034,506 cited above.
[0301] The modified RNA may also contain one or more substituted sugar moieties. The RNAi agents described herein (e.g., dsRNA) may include one of the following at the 2'-position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S-, or N-alkynyl; or O-alkyl-O-alkyl, wherein alkyl, alkenyl, and alkynyl groups may be substituted or unsubstituted C 1 To C 10 Alkyl or C 2 To C 10 Exemplary suitable modifications include O[(CH 2 ) n O] m CH 3 、O(CH 2 ). n OCH 3 、O(CH 2 ) n NH 2 、O(CH 2 ) n CH 3 、O(CH 2 ) n ONH 2 and O(CH 2 ) n ON[(CH 2 ) n CH 3 )] 2 , wherein n and m are from 1 to about 10. In other embodiments, the dsRNA includes one of the following at the 2'-position: C 1 To C 10 Lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH 3 、OCN、Cl、Br、CN、CF 3 、OCF 3 、SOCH 3 、SO 2 CH 3 、ONO 2 、NO 2 、N 3 NH 2, heterocycloalkyl, heterocycloalkylaryl, aminoalkylamino, polyalkylamino, substituted silyl, RNA cleavage group, reporter group, intercalator, group for improving the pharmacokinetic properties of RNAi agent or group for improving the pharmacodynamic properties of RNAi agent, and other substituents with similar properties. In some embodiments, the modification includes 2'-methoxyethoxy (2'-O-CH 2 CH 2 OCH 3 ), also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., Helv. Chim. Acta, 1995, 78: 486-504), i.e., an alkoxy-alkoxy group. Another exemplary modification is 2'-dimethylaminooxyethoxy, i.e., O(CH 2 ) 2 ON(CH 3 ) 2 The group, also known as 2'-DMAOE, as described in the Examples below, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-O-CH 2 -O-CH 2 -N(CH 2 ) 2 Additional exemplary modifications include: 5'-Me-2'-F nucleotides, 5'-Me-2'-OMe nucleotides, 5'-Me-2'-deoxynucleotides (both R and S isomers in these three families); 2'-alkoxyalkyl; and 2'-NMA (N-methylacetamide).
[0302] Other modifications include 2'-methoxy (2'-OCH 3 ), 2'-aminopropyloxy (2'-OCH 2 CH 2 CH 2 NH 2), 2'-O-hexadecyl and 2'-fluoro (2'-F). Similar modifications can also be made at other positions on the RNA of the RNAi agent, particularly the 3' position of the sugar on the 3'-terminal nucleotide or the 2'-5' linked dsRNA and the 5' position of the 5'-terminal nucleotide. The RNAi agent can also have a sugar mimetic, such as a cyclobutyl moiety replacing the furanopentosyl sugar. Representative U.S. patents that teach the preparation of such modified sugar structures include, but are not limited to, the following U.S. Patents 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, some of which are commonly owned by the present application. The entire contents of each of the above are hereby incorporated herein by reference.
[0303] The RNAi agents of the present disclosure may also include modifications or substitutions of nucleobases (commonly referred to in the art as "bases"). As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C), and uracil (U). Modified nucleobases include other synthetic and natural nucleobases, such as 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyluracil and cytosine, 6-azouracil, cytosine and Thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-sulfanyl, 8-hydroxy and other 8-substituted adenines and guanines, 5-halo, specifically 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in Modified Nucleosides in Biochemistry, Biotechnology and Medicine, Herdewijn, P., ed., Wiley-VCH, 2008; those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pp. 858-859, Kroschwitz, JL, ed., John Wiley & Sons, 1990, those disclosed in Englisch et al., (1991) Angewandte Chemie, International Edition, 30:613, and those disclosed in Sanghvi, Y S., Chapter 15, dsRNA Research and Applications, pp. 289-302, Crooke, ST and Lebleu, B., eds., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds described in the present disclosure. These include 5-substituted pyrimidines, 6-azapyrimidines, and N-2, N-6, and 0-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil, and 5-propynylcytosine.5-Methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6°C to 1.2°C (Sanghvi, YS, Crooke, ST and Lebleu, B., eds., dsRNA Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278), and are exemplary base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.
[0304] Representative U.S. patents that teach the preparation of some of the above modified nucleobases, as well as other modified nucleobases, include, but are not limited to, the above-mentioned U.S. Patents Nos. 3,687,808, 4,845,205; 5,130,30; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,59 Nos. 4,121, 5,596,091; 5,614,617; 5,681,941; 5,750,692; 6,015,886; 6,147,200; 6,166,197; 6,222,025; 6,235,887; 6,380,368; 6,528,640; 6,639,062; 6,617,438; 7,045,610; 7,427,672; and 7,495,088, the entire contents of each of which are hereby incorporated herein by reference.
[0305] The RNAi agents of the present disclosure may also be modified to include one or more locked nucleic acids (LNAs). Locked nucleic acids are nucleotides with modified ribose moieties, wherein the ribose moieties include an additional bridge connecting 2' and 4' carbons. This structure effectively "locks" the ribose in a 3'-endo conformation. Adding locked nucleic acids to siRNA has been shown to improve siRNA stability in serum and reduce off-target effects (Elmen, J. et al., (2005) Nucleic Acids Research 33 (1): 439-447; Mook, OR. et al., (2007) Mol Canc Ther 6 (3): 833-843; Grunweller, A. et al., (2003) Nucleic Acids Research 31 (12): 3185-3193).
[0306] RNAi agents of the present disclosure may also be modified to include one or more bicyclic sugar moieties." Bicyclic sugar " is a furanosyl ring modified by two atoms bridging. "Bicyclic nucleoside" ("BNA") is a nucleoside having a sugar moiety comprising a bridge of two carbon atoms connecting the sugar ring, thereby forming a bicyclic ring system. In certain embodiments, the bridge connects the 4' carbon and 2'-carbon of the sugar ring. Therefore, in some embodiments, the medicament of the present disclosure may include one or more locked nucleic acids (LNA). Locked nucleic acids are nucleotides with modified ribose moieties, wherein the ribose moiety includes an additional bridge connecting 2' and 4' carbons. In other words, LNA is a nucleotide comprising a bicyclic sugar moiety, which includes 4'-CH 2 -O-2' bridge. This structure effectively "locks" the ribose in a 3'-endo conformation. Adding locked nucleic acid to siRNA has been shown to improve siRNA stability in serum and reduce off-target effects (Elmen, J. et al., (2005) Nucleic Acids Research 33(1):439-447; Mook, OR. et al., (2007) Mol Canc Ther 6(3):833-843; Grunweller, A. et al., (2003) Nucleic Acids Research 31(12):3185-3193). Examples of bicyclic nucleosides for use in the polynucleotides of the present disclosure include, but are not limited to, nucleosides comprising a bridge between the 4' and 2' ribosyl ring atoms. In certain embodiments, the antisense polynucleotide agents of the present disclosure comprise one or more bicyclic nucleosides containing a 4' to 2' bridge. Examples of such 4' to 2' bridged bicyclic nucleosides include, but are not limited to, 4'-(CH 2 )-O-2'(LNA); 4'-(CH 2 )-S-2';4'-(CH 2 ) 2 -O-2'(ENA); 4'-CH(CH 3 )-O-2' (also called "constrained ethyl" or "cEt") and 4'-CH(CH 2 OCH 3 )-O-2' (and the like; see, e.g., U.S. Pat. No. 7,399,845); 4'-C(CH 3 )(CH 3 )-O-2' (and the like; see, e.g., U.S. Pat. No. 8,278,283); 4'-CH 2 -N(OCH 3 )-2' (and analogs thereof; see, e.g., U.S. Pat. No. 8,278,425); 4'-CH 2 -ON(CH 3)-2' (see, e.g., U.S. Patent Publication No. 2004 / 0171570); 4'-CH 2 -N(R)-O-2', wherein R is H, C1-C12 alkyl or a protecting group (see, e.g., U.S. Pat. No. 7,427,672); 4'-CH 2 -C(H)(CH 3 )-2' (see, e.g., Chattopadhyaya et al., J. Org. Chem., 2009, 74, 118-134); and 4'-CH 2 -C(═CH 2 )-2' (and analogs thereof; see, eg, US Pat. No. 8,278,426). The entire contents of each of the above are hereby incorporated herein by reference.
[0307] Other representative U.S. patents and U.S. patent publications that teach the preparation of locked nucleic acid nucleotides include, but are not limited to, the following: U.S. Patent Nos. 6,268,490; 6,525,191; 6,670,461; 6,770,748; 6,794,499; 6,998,484; 7,053,207; 7,034,133; 7,084,125; 7,399,845; 7,427,672; 7,569,686; 7,741,457; 8,022,193; 8,030,467; 8,278,425; 8,278,426; 8,278,283; US2008 / 0039618 and US2009 / 0012281, the entire contents of each of which are hereby incorporated herein by reference.
[0308] Any of the foregoing bicyclic nucleosides may be prepared with one or more stereochemical sugar configurations, including, for example, α-L-ribofuranose and β-D-ribofuranose (see WO 99 / 14226).
[0309] The RNAi agents of the present disclosure can also be modified to include one or more constrained ethyl nucleotides. As used herein, "constrained ethyl nucleotides" or "cEt" are nucleotides that include 4'-CH(CH 3 )-O-2' bridge. In one embodiment, the constrained ethyl nucleotide is in an S conformation referred to herein as "S-cEt".
[0310] The RNAi agents of the present disclosure may also comprise one or more "conformation-restricted nucleotides" ("CRNs"). CRNs are nucleotide analogs having a linker connecting the C2' and C4' carbons of ribose or the C3 and -C5' carbons of ribose. CRNs lock the ribose ring into a stable conformation and increase hybridization affinity to mRNA. The linker is of sufficient length to place the oxygen in a position optimal for stability and affinity, resulting in less ribose ring wrinkling.
[0311] Representative publications that teach the preparation of certain of the above-described CRNs include, but are not limited to, US 2013 / 0190383; and WO 2013 / 036868, the entire contents of each of which are hereby incorporated herein by reference.
[0312] In some embodiments, the RNAi agent of the present disclosure includes one or more monomers that are UNA (unlocking nucleic acid) nucleotides. UNA is an unlocking acyclic nucleic acid in which any bond of a sugar has been removed, thereby forming an unlocking "sugar" residue. In one example, UNA also encompasses monomers in which the bond between C1'-C4' has been removed (i.e., a covalent carbon-oxygen-carbon bond between C1' and C4' carbon). In another example, the C2'-C3' bond of a sugar (i.e., a covalent carbon-carbon bond between C2' and C3' carbon) has been removed (see Nuc. Acids Symp. Series, 52, 133-134 (2008) and Fluiter et al., Mol. Biosyst., 2009, 10, 1039, hereby incorporated by reference).
[0313] Representative U.S. publications that teach the preparation of UNA include, but are not limited to, US 8,314,227; and U.S. Patent Publication Nos. 2013 / 0096289; 2013 / 0011922; and 2011 / 0313020, each of which is hereby incorporated by reference in its entirety.
[0314] The RNAi agents of the present disclosure may also comprise one or more "cyclohexene nucleic acids" or ("CeNA"). CeNAs are nucleotide analogs in which the furanose moiety of DNA is replaced with a cyclohexene ring. The incorporation of cyclohexenyl nucleosides into the DNA chain increases the stability of the DNA / RNA hybrid. CeNAs are stable to degradation in serum, and CeNA / RNA hybrids are able to activate E. coli RNase H, resulting in cleavage of the RNA chain (see Wang et al., Am. Chem. Soc. 2000, 122, 36, 8595-8602, hereby incorporated by reference).
[0315] Potential stabilizing modifications to the ends of RNA molecules may include N-(acetylaminohexanoyl)-4-hydroxyprolinol (Hyp-C6-NHAc), N-(hexanoyl-4-hydroxyprolinol) (Hyp-C6), N-(acetyl-4-hydroxyprolinol) (Hyp-NHAc), thymidine-2'-O-deoxythymidine (ether), N-(aminohexanoyl)-4-hydroxyprolinol (Hyp-C6-amino), 2-docosanoyl-uridine-3"-phosphate, inverted base dT (idT), and the like. Disclosure of such modifications may be found in WO 2011 / 005861.
[0316] Other modifications of the RNAi agents of the present disclosure include 5' phosphates or 5' phosphate mimetics, for example, 5'-terminal phosphates or phosphate mimetics on the antisense strand of the RNAi agent. Suitable phosphate mimetics are disclosed, for example, in US2012 / 0157511, the entire contents of which are incorporated herein by reference.
[0317] A. Modified RNAi Agents Comprising Motifs of the Disclosure
[0318] In some aspects of the present disclosure, the double-stranded RNAi agent of the present disclosure includes a medicament with chemical modification, such as disclosed in, for example, WO 2013 / 075035, the entire contents of which are incorporated herein by reference. As shown in this article and WO 2013 / 075035, by introducing one or more motifs of three identical modifications on three consecutive nucleotides into the sense strand or antisense strand of the RNAi agent, particularly at or near the cleavage site, excellent results can be obtained. In some embodiments, the sense strand and antisense strand of the RNAi agent can be modified completely in other ways. The introduction of these motifs interrupts the modification pattern (if any) of the sense or antisense strand. The RNAi agent can optionally be conjugated with a lipophilic ligand, such as a C16 ligand, for example, on the sense strand. The RNAi agent can optionally be modified with (S)-glycol nucleic acid (GNA) modification, for example, on one or more residues of the antisense strand. The resulting RNAi agent presents excellent gene silencing activity.
[0319] Therefore, the disclosure provides the double-stranded RNAi agent that can suppress the expression of target gene (i.e. MAPT gene) in vivo.RNAi agent includes sense strand and antisense strand.Every chain of RNAi agent can be 15-30 nucleotide in length.For example, every chain can be 16-30 nucleotide in length, 17-30 nucleotide in length, 25-30 nucleotide in length, 27-30 nucleotide in length, 17-23 nucleotide in length, 17-21 nucleotide in length, 17-19 nucleotide in length, 19-25 nucleotide in length, 19-23 nucleotide in length, 19-21 nucleotide in length, 21-25 nucleotide in length or 21-23 nucleotide in length.In certain embodiments, the length of every chain is 19-23 nucleotide.
[0320] The sense strand and the antisense strand generally form a duplex double-stranded RNA ("dsRNA"), also referred to herein as a "RNAi agent". The length of the duplex region of the RNAi agent can be 15-30 nucleotide pairs. For example, the duplex region can be 16-30 nucleotide pairs in length, 17-30 nucleotide pairs in length, 27-30 nucleotide pairs in length, 17-23 nucleotide pairs in length, 17-21 nucleotide pairs in length, 17-19 nucleotide pairs in length, 19-25 nucleotide pairs in length, 19-23 nucleotide pairs in length, 19-21 nucleotide pairs in length, 21-25 nucleotide pairs in length, or 21-23 nucleotide pairs in length. In another example, the length of the duplex region is selected from 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, and 27 nucleotides. In preferred embodiments, the duplex region is 19-21 nucleotide pairs in length.
[0321] In one embodiment, the RNAi agent can contain one or more overhang regions or blocking groups at the 3'-end, 5'-end or both ends of one or both chains. The length of the overhang can be 1-6 nucleotides, for example, 2-6 nucleotides in length, 1-5 nucleotides in length, 2-5 nucleotides in length, 1-4 nucleotides in length, 2-4 nucleotides in length, 1-3 nucleotides in length, 2-3 nucleotides in length or 1-2 nucleotides in length. In a preferred embodiment, the length of the nucleotide overhang region is 2 nucleotides. The overhang is the result that one chain is longer than another chain, or the result of two chains of the same length interlacing. The overhang can form a mismatch with the target mRNA, or it can be complementary to the targeted gene sequence, or another sequence. The first chain and the second chain can also be joined, for example, by other bases to form a hairpin, or by other non-basic joints.
[0322] In one embodiment, the nucleotides in the overhang region of the RNAi agent can each independently be a modified or unmodified nucleotide, including but not limited to 2'-sugar modifications such as 2-F, 2'-O-methyl, thymidine (T), and any combination thereof.
[0323] For example, TT can be an overhang sequence at either end of either strand. The overhang can form a mismatch with the target mRNA, or it can be complementary to the targeted gene sequence, or it can be another sequence.
[0324] The sense strand, antisense strand or 5'- or 3'-overhangs on two chains of RNAi agent can be phosphorylated. In some embodiments, the overhang region contains two nucleotides with thiophosphate between two nucleotides, wherein the two nucleotides can be identical or different. In one embodiment, the overhang is present at the 3'-end of the sense strand, antisense strand or two chains. In one embodiment, this 3'-overhang is present in the antisense strand. In one embodiment, this 3'-overhang is present in the sense strand.
[0325] RNAi agent may contain only a single overhang, which can enhance the interference activity of RNAi without affecting its overall stability. For example, a single-stranded overhang can be located at the 3'-end of the sense strand, or alternatively, at the 3'-end of the antisense strand. RNAi may also have a flat end, located at the 5'-end (or 3'-end of the sense strand) of the antisense strand, and vice versa. Typically, the antisense strand of RNAi has a nucleotide overhang at the 3'-end, and the 5'-end is a flat end. Although it is not desired to be bound by theory, the asymmetric flat end at the 5'-end of the antisense strand and the 3'-end overhang of the antisense strand are conducive to the loading of the guide strand into the RISC process.
[0326] In one embodiment, the RNAi agent is double blunt-ended and 19 nucleotides in length, wherein the sense strand contains at least one 2'-F modified motif on three consecutive nucleotides at positions 7, 8, and 9 from the 5'-end. The antisense strand contains at least one 2'-O-methyl modified motif on three consecutive nucleotides at positions 11, 12, and 13 from the 5'-end.
[0327] In another embodiment, the RNAi agent is double blunt-ended and 20 nucleotides in length, wherein the sense strand contains at least one 2'-F modified motif on three consecutive nucleotides at positions 8, 9, 10 at the 5'-end. The antisense strand contains at least one 2'-O-methyl modified motif on three consecutive nucleotides at positions 11, 12, 13 at the 5'-end.
[0328] In yet another embodiment, the RNAi agent is double blunt-ended and 21 nucleotides in length, wherein the sense strand contains at least one 2'-F modified motif on three consecutive nucleotides at positions 9, 10, 11 at the 5'-end. The antisense strand contains at least one 2'-O-methyl modified motif on three consecutive nucleotides at positions 11, 12, 13 at the 5'-end.
[0329] In one embodiment, the RNAi agent includes a sense strand of 21 nucleotides and an antisense strand of 23 nucleotides, wherein the sense strand contains at least one 2'-F modified motif on three consecutive nucleotides at positions 9, 10, and 11 at the 5'-end; the antisense strand contains at least one 2'-O-methyl modified motif on three consecutive nucleotides at positions 11, 12, and 13 at the 5'-end, wherein one end of the RNAi agent is blunt-ended, and the other end includes a 2-nucleotide overhang. Preferably, the 2-nucleotide overhang is located at the 3'-end of the antisense strand. When the 2-nucleotide overhang is located at the 3'-end of the antisense strand, there may be two phosphorothioate internucleotide bonds between the terminal three nucleotides, wherein two of the three nucleotides are overhang nucleotides, and the third nucleotide is a pairing nucleotide next to the overhang nucleotide. In one embodiment, the RNAi agent has two additional phosphorothioate internucleotide bonds between the terminal three nucleotides of the 5'-end of the sense strand and the 5'-end of the antisense strand. In one embodiment, each nucleotide in the sense strand and antisense strand of the RNAi agent (including nucleotides as part of the motif) is a modified nucleotide. In one embodiment, each residue is independently modified with 2'-O-methyl or 3'-fluoro, for example in an alternating motif. Optionally, the RNAi agent further comprises a ligand (e.g., a lipophilic ligand, optionally a C16 ligand).
[0330] In one embodiment, the RNAi agent comprises a sense strand and an antisense strand, wherein the sense strand is 25-30 nucleotide residues in length, wherein starting from the 5'-terminal nucleotide (position 1) position 1, positions 1-23 of the first strand include at least 8 ribonucleotides; the antisense strand is 36-66 nucleotide residues in length and, starting from the 3'-terminal nucleotide, includes at least 8 ribonucleotides in positions that pair with positions 1-23 of the sense strand to form a duplex; wherein at least the 3'-terminal nucleotide of the antisense strand is unpaired with the sense strand, and up to 6 consecutive 3'-terminal nucleotides are unpaired with the sense strand, thereby forming a 3'-single-stranded overhang of 1-6 nucleotides; wherein the 5'- The terminus comprises 10-30 consecutive nucleotides that are not paired with the sense strand, thereby forming a single-stranded 5'-overhang of 10-30 nucleotides; wherein when the sense strand and the antisense strand are aligned for maximum complementarity, at least the 5'-terminal and 3'-terminal nucleotides of the sense strand are base-paired with nucleotides of the antisense strand, thereby forming a substantially double-stranded region between the sense strand and the antisense strand; and at least 19 ribonucleotides along the length of the antisense strand are sufficiently complementary to the target RNA to reduce target gene expression when the double-stranded nucleic acid is introduced into a mammalian cell; and wherein the sense strand contains at least one motif of three 2'-F modifications on three consecutive nucleotides, wherein at least one of the motifs occurs at or near the cleavage site. The antisense strand contains at least one motif of three 2'-O-methyl modifications on three consecutive nucleotides at or near the cleavage site.
[0331] In one embodiment, the RNAi agent includes a sense strand and an antisense strand, wherein the RNAi agent includes a first strand of at least 25 and at most 29 nucleotides in length and a second strand of at most 30 nucleotides in length, having at least one 2'-O-methyl modified motif on three consecutive nucleotides at positions 11, 12, and 13 at the 5' end; wherein the 3'-end of the first strand and the 5'-end of the second strand form a blunt end, and the second strand is 1-4 nucleotides longer than the first strand at its 3'-end, wherein the length of the duplex region is at least 25 nucleotides, and the second strand is fully complementary to the target mRNA along at least 19 nucleotides of the second strand length, so as to reduce target gene expression when the RNAi agent is introduced into a mammalian cell, and wherein dicer cleavage of the RNAi agent preferentially produces siRNA comprising the 3'-end of the second strand, thereby reducing target gene expression in mammals. Optionally, the RNAi agent further comprises a ligand.
[0332] In one embodiment, the sense strand of the RNAi agent contains at least one motif of three identical modifications on three consecutive nucleotides, wherein one of the motifs occurs at the cleavage site in the sense strand.
[0333] In one embodiment, the antisense strand of the RNAi agent may also contain at least one motif of three identical modifications on three consecutive nucleotides, wherein one of the motifs occurs at or near the cleavage site in the antisense strand.
[0334] For RNAi agents with duplex regions of 17-23 nucleotides in length, the cleavage sites of the antisense strand are usually near positions 10, 11, and 12 of the 5'-end. Thus, three identical modified motifs may appear at positions 9, 10, 11 of the antisense strand; positions 10, 11, 12; positions 11, 12, 13; positions 12, 13, 14; or positions 13, 14, 15, counting from the first nucleotide at the 5'-end of the antisense strand, or counting from the first paired nucleotide at the 5'-end of the antisense strand within the duplex region. The cleavage site in the antisense strand may also vary depending on the length of the duplex region of the RNAi from the 5' end.
[0335] The sense strand of the RNAi agent may contain at least one motif of three identical modifications on three consecutive nucleotides at the cleavage site of the strand; and the antisense strand may have at least one motif of three identical modifications on three consecutive nucleotides at or near the cleavage site of the strand. When the sense strand and the antisense strand form a dsRNA duplex, the sense strand and the antisense strand may be aligned so that one motif of three nucleotides on the sense strand overlaps with one motif of three nucleotides on the antisense strand, i.e., at least one of the three nucleotides of the motif in the sense strand forms a base pair with at least one of the three nucleotides of the motif in the antisense strand. Alternatively, at least two nucleotides may overlap, or all three nucleotides may overlap.
[0336] In one embodiment, the sense strand of the RNAi agent can contain more than one motif of three identical modifications on three consecutive nucleotides. The first motif can appear at or near the cleavage site of the chain, and other motifs can be wing modifications. The term "wing modification" herein refers to a motif that appears at another part of the chain, which is separated from a motif at or near the cleavage site of the same chain. The wing modification is adjacent to the first motif, or is separated by at least one or more nucleotides. When the motifs are adjacent to each other, the chemistry of the motif is different from each other, and when the motif is separated by one or more nucleotides, the chemistry can be the same or different. There may be two or more wing modifications. For example, when there are two wing modifications, each wing modification can appear at one end of the first motif relative to being located at or near the cleavage site or on either side of the previous motif.
[0337] As with the sense strand, the antisense strand of a RNAi agent may contain more than one motif of three identical modifications on three consecutive nucleotides, wherein at least one motif occurs at or near the cleavage site of the strand. The antisense strand may also contain one or more wing modifications arranged similarly to the wing modifications that may be present on the sense strand.
[0338] In one embodiment, the wing modifications on the sense or antisense strand of the RNAi agent typically do not include the first one or two terminal nucleotides at the 3 '-end, the 5 '-end, or both ends of the strand.
[0339] In another embodiment, the wing modifications on the sense or antisense strand of the RNAi agent typically do not include the first one or two paired nucleotides within the duplex region at the 3 '-end, 5 '-end, or both ends of the strand.
[0340] When the sense and antisense strands of the RNAi agent each contain at least one wing modification, the wing modifications can fall on the same end of the duplex region and have an overlap of one, two, or three nucleotides.
[0341] When the sense and antisense strands of the RNAi agent each contain at least two wing modifications, the sense and antisense strands can be aligned so that the two modifications each from one strand fall on one end of the duplex region with an overlap of one, two, or three nucleotides; the two modifications each from one strand fall on the other end of the duplex region with an overlap of one, two, or three nucleotides; the two modifications of one strand fall on each side of the previous motif with an overlap of one, two, or three nucleotides in the duplex region.
[0342] In one embodiment, the RNAi agent comprises a mismatch with the target, within a duplex, or a combination thereof. Mismatches may be present in an overhang region or a duplex region. Base pairs can be ranked based on their tendency to promote dissociation or melt (e.g., based on the free energy of association or dissociation of a particular pairing, the simplest way is to check pairing on the basis of a single pairing, although neighbor or similar analysis may also be used). In terms of promoting dissociation: A:U is better than G:C; G:U is better than G:C; and I:C is better than G:C (I = inosine). Mismatches, such as non-canonical or canonical extra-pairing (as described elsewhere herein) are better than canonical (A:T, A:U, G:C) pairings; and pairings comprising universal bases are better than canonical pairings.
[0343] In one embodiment, the RNAi agent includes at least one of the first 1, 2, 3, 4 or 5 base pairs at the 5'-end of the antisense strand within the duplex region, which are independently selected from: A:U, G:U, I:C and mispairing, such as non-canonical or extra-canonical pairing or pairing comprising universal bases, to promote dissociation of the antisense strand at the 5'-end of the duplex.
[0344] In one embodiment, the nucleotide at position 1 of the 5'-end of the antisense strand in the duplex region is selected from: A, dA, dU, U and dT. Optionally, at least one of the first 1, 2 or 3 base pairs at the 5'-end of the antisense strand in the duplex region is an AU base pair. For example, the first base pair at the 5'-end of the antisense strand in the duplex region is an AU base pair.
[0345] In another embodiment, the nucleotide at the 3'-end of the sense strand is deoxythymidine (dT). In another embodiment, the nucleotide at the 3'-end of the antisense strand is deoxythymidine (dT). In one embodiment, there is a short sequence of deoxythymidine nucleotides, for example, two dT nucleotides on the 3' end of the sense strand or the antisense strand.
[0346] In one embodiment, the sense strand sequence can be represented by formula (I):
[0347] 5'n p -N a -(XX) i -N b -Y YN b -(Z) j -N a -n q 3' (I)
[0348] in:
[0349] i and j are each independently 0 or 1;
[0350] p and q are each independently 0 to 6;
[0351] Each N a independently represent oligonucleotide sequences comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified nucleotides;
[0352] Each N b independently represent an oligonucleotide sequence comprising 0-10 modified nucleotides;
[0353] Each n p and n q Overhang nucleotides are represented independently;
[0354] Where N b and Y do not have the same modifications; and
[0355] XXX, YYY and ZZZ each independently represent a motif of three identical modifications on three consecutive nucleotides. Preferably, all YYY are 2'-F modified nucleotides.
[0356] In one embodiment, N a or Nb Includes alternating pattern modifications.
[0357] In one embodiment, the YYY motif appears at or near the cleavage site of the sense strand. For example, when the RNAi agent has a duplex region of 17-23 nucleotides in length, the YYY motif can appear at or near the cleavage site of the sense strand (e.g., can appear at positions 6, 7, 8; 7, 8, 9; 8, 9, 10; 9, 10, 11; 10, 11, 12 or 11, 12, 13), counting from the first nucleotide at the 5'-end; or optionally, counting from the first paired nucleotide at the 5' end within the duplex region.
[0358] In one embodiment, i is 1 and j is 0, or i is 0 and j is 1, or both i and j are 1. Thus, the sense strand can be represented by the formula:
[0359] 5'n p -N a -YYY-N b -ZZZ-N a -n q 3' (Ib);
[0360] 5'n p -N a -XXX-N b -YYY-N a -n q 3' (Ic); or
[0361] 5'n p -N a -XXX-N b -YYY-N b -ZZZ-N a -n q 3' (Id).
[0362] When the sense strand is represented by formula (Ib), N b refers to an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides.
[0363] Each N a Oligonucleotide sequences comprising 2-20, 2-15 or 2-10 modified nucleotides may be independently represented.
[0364] When the sense strand is represented by formula (Ic), N b represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N aOligonucleotide sequences comprising 2-20, 2-15 or 2-10 modified nucleotides may be independently represented.
[0365] When the sense strand is represented by formula (Id), each N b independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. b is 0, 1, 2, 3, 4, 5, or 6. Each N a An oligonucleotide sequence comprising 2-20, 2-15 or 2-10 modified nucleotides may independently be represented.
[0366] Each of X, Y, and Z may be the same as or different from each other.
[0367] In other embodiments, i is 0 and j is 0, and the sense strand can be represented by the formula:
[0368] 5'n p -N a -YYY-N a -n q 3' (Ia).
[0369] When the sense strand is represented by formula (Ia), each N a An oligonucleotide sequence comprising 2-20, 2-15 or 2-10 modified nucleotides may independently be represented.
[0370] In one embodiment, the antisense strand sequence of RNAi can be represented by formula (Ie):
[0371] 5'n q' -N a '-(Z'Z'Z') k -N b '-Y'Y'Y'-N b '-(X'X'X') l -N' a -n p '3' (Ie)
[0372] in:
[0373] k and l are each independently 0 or 1;
[0374] p' and q' are each independently 0 to 6;
[0375] Each N a ' independently represents an oligonucleotide sequence comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified nucleotides;
[0376] Each Nb ' independently represents an oligonucleotide sequence comprising 0-10 modified nucleotides;
[0377] Each n p ' and n q ' independently represent the overhang nucleotides;
[0378] Where N b ' and Y' do not have the same modifications;
[0379] And X'X'X', Y'Y'Y' and Z'Z'Z' each independently represent a motif of three identical modifications on three consecutive nucleotides.
[0380] In one embodiment, N a ' or N b 'Includes alternating pattern modifications.
[0381] The Y'Y'Y' motif occurs at or near the cleavage site of the antisense strand. For example, when the RNAi agent has a duplex region of 17-23 nucleotides in length, the Y'Y'Y' motif may occur at positions 9, 10, 11; 10, 11, 12; 11, 12, 13; 12, 13, 14; or 13, 14, 15 of the antisense strand, counting from the first nucleotide at the 5' end; or optionally, counting from the first paired nucleotide at the 5' end within the duplex region. Preferably, the Y'Y'Y' motif occurs at positions 11, 12, 13.
[0382] In one embodiment, the Y'Y'Y' motif is entirely 2'-OMe modified nucleotides.
[0383] In one embodiment, k is 1 and l is 0, or k is 0 and l is 1, or k and l are both 1.
[0384] Therefore, the antisense strand can be represented by the following formula:
[0385] 5'n q' -N a '-Z'Z'Z'-N b '-Y'Y'Y'-N a '-n p' 3' (If);
[0386] 5'n q' -N a '-Y'Y'Y'-N b '-X'X'X'-n p' 3' (Ig); or
[0387] 5'n q' -N a '-Z'Z'Z'-Nb '-Y'Y'Y'-N b '-X'X'X'-N a '-n p' 3' (Ih).
[0388] When the antisense strand is represented by formula (If), N b ' represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N a ' independently represents an oligonucleotide sequence comprising 2-20, 2-15 or 2-10 modified nucleotides.
[0389] When the antisense strand is represented by formula (Ig), N b represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N a ' independently represents an oligonucleotide sequence comprising 2-20, 2-15 or 2-10 modified nucleotides.
[0390] When the antisense strand is represented by formula (Ih), each N b ' independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N a ' independently represents an oligonucleotide sequence comprising 2-20, 2-15 or 2-10 modified nucleotides. Preferably, N b Is 0, 1, 2, 3, 4, 5, or 6.
[0391] In other embodiments, k is 0 and l is 0, and the antisense strand can be represented by the formula:
[0392] 5'n p' -N a' -Y'Y'Y'-N a' -n q' 3' (Ia).
[0393] When the antisense strand is represented by formula (Ie), each N a ' independently represents an oligonucleotide sequence comprising 2-20, 2-15 or 2-10 modified nucleotides.
[0394] Each of X', Y' and Z' may be the same as or different from each other.
[0395] Each nucleotide of the sense strand and the antisense strand can be independently modified with LNA, HNA, CeNA, 2'-methoxyethyl, 2'-O-methyl, 2'-O-allyl, 2'-C-allyl, 2'-hydroxyl or 2'-fluoro. For example, each nucleotide of the sense strand and the antisense strand is independently modified with 2'-O-methyl or 2'-fluoro. In particular, each of X, Y, Z, X', Y' and Z' can represent a 2'-O-methyl modification or a 2'-fluoro modification.
[0396] In one embodiment, when the duplex region is 21 nt, the sense strand of the RNAi agent may contain a YYY motif appearing at positions 9, 10, and 11 of the strand, with the count starting from the first nucleotide at the 5' end, or optionally, the count starting from the first paired nucleotide at the 5' end within the duplex region; and Y represents a 2'-F modification. The sense strand may additionally contain a XXX motif or a ZZZ motif as a wing modification at the opposite end of the duplex region; and XXX and ZZZ each independently represent a 2'-OMe modification or a 2'-F modification.
[0397] In one embodiment, the antisense strand may contain a Y'Y'Y' motif appearing at positions 11, 12, 13 of the strand, counting from the first nucleotide at the 5' end, or optionally, counting from the first paired nucleotide at the 5' end within the duplex region; and Y' represents a 2'-O-methyl modification. The antisense strand may additionally contain a X'X'X' motif or a Z'Z'Z' motif as wing modifications at opposite ends of the duplex region; and X'X'X' and Z'Z'Z' each independently represent a 2'-OMe modification or a 2'-F modification.
[0398] The sense strand represented by any one of the above formulae (Ia), (Ib), (Ic) and (Id) forms a duplex with the antisense strand represented by any one of the formulae (Ie), (If), (Ig) and (Ih), respectively.
[0399] Thus, the RNAi agent used in the methods of the present disclosure may include a sense strand and an antisense strand, each strand having 14-30 nucleotides, and the RNAi duplex is represented by formula (Ii):
[0400] Meaning: 5'n p -N a -(XXX) i -N b -YY YN b -(ZZZ) j -N a -n q 3'
[0401] Antonym: 3'n p '-N a '-(X'X'X')k -N b '-Y'Y'Y'-N b '-(Z'Z'Z') l -N a '-n q '5' (Ii)
[0402] in:
[0403] i, j, k and l are each independently 0 or 1;
[0404] p, p', q and q' are each independently 0 to 6;
[0405] Each N a and N a ' independently represents an oligonucleotide sequence comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified nucleotides;
[0406] Each N b and N b ' independently represents an oligonucleotide sequence comprising 0-10 modified nucleotides;
[0407] in
[0408] Each may exist or not exist p '、n p 、n q ' and n q each of independently represents an overhang nucleotide; and
[0409] XXX, YYY, ZZZ, X'X'X', Y'Y'Y' and Z'Z'Z' each independently represent a motif of three identical modifications on three consecutive nucleotides.
[0410] In one embodiment, i is 0 and j is 0; or i is 1 and j is 0; or i is 0 and j is 1; or i and j are both 0; or i and j are both 1. In another embodiment, k is 0 and l is 0; or k is 1 and l is 0; k is 0 and l is 1; or k and l are both 0; or k and l are both 1.
[0411] Exemplary combinations of sense and antisense strands that form RNAi duplexes include the following:
[0412] 5'n p -N a -YY YN a -n q 3'
[0413] 3'n p '-N a'-Y'Y'Y'-N a 'n q '5' (Ij)
[0414] 5'n p -N a -YY YN b -ZZ ZN a -n q 3'
[0415] 3'n p '-N a '-Y'Y'Y'-N b '-Z'Z'Z'-N a 'n q '5' (Ik)
[0416] 5'n p -N a -XX XN b -YY YN a -n q 3'
[0417] 3'n p '-N a '-X'X'X'-N b '-Y'Y'Y'-N a '-n q '5' (Il)
[0418] 5'n p -N a -XX XN b -YY YN b -ZZ ZN a -n q 3'
[0419] 3'n p '-N a '-X'X'X'-N b '-Y'Y'Y'-N b '-Z'Z'Z'-N a -n q '5' (Im)
[0420] When the RNAi agent is represented by formula (Ij), each N a Independently refers to an oligonucleotide sequence comprising 2-20, 2-15 or 2-10 modified nucleotides.
[0421] When the RNAi agent is represented by formula (Ik), each N bN independently represents an oligonucleotide sequence comprising 1-10, 1-7, 1-5 or 1-4 modified nucleotides. a Independently refers to an oligonucleotide sequence comprising 2-20, 2-15 or 2-10 modified nucleotides.
[0422] When the RNAi agent is represented by formula (I1), each N b 、N b ' independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N a Independently refers to an oligonucleotide sequence comprising 2-20, 2-15 or 2-10 modified nucleotides.
[0423] When the RNAi agent is represented by formula (Im), each N b 、N b ' independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N a 、N a ' independently represents an oligonucleotide sequence comprising 2-20, 2-15 or 2-10 modified nucleotides. N a 、N a '、N b and N b Each of ' independently comprises an alternating pattern of modifications.
[0424] In one embodiment, when the RNAi agent is represented by formula (Im), N a The modification is a 2'-O-methyl or 2'-fluoro modification. In another embodiment, when the RNAi agent is represented by formula (Im), N a The modification is 2′-O-methyl or 2′-fluoro, and n p '>0, and at least one n p ' is connected to the adjacent nucleotide through a phosphorothioate bond. In another embodiment, when the RNAi agent is represented by formula (Im), N a The modification is 2′-O-methyl or 2′-fluoro, n p '>0, and at least one n p ' is linked to adjacent nucleotides via a phosphorothioate bond, and the sense strand is conjugated to one or more C16 (or related) moieties linked via a divalent or trivalent branched linker (described below). In another embodiment, when the RNAi agent is represented by formula (Im), N a The modification is 2′-O-methyl or 2′-fluoro, n p '>0, and at least one n p' is linked to adjacent nucleotides via phosphorothioate bonds, the sense strand comprises at least one phosphorothioate bond, and the sense strand is conjugated to one or more lipophilic, e.g., C16 (or related) moieties optionally linked via a bivalent or trivalent branched linker.
[0425] In one embodiment, when the RNAi agent is represented by formula (Ij), N a The modification is 2′-O-methyl or 2′-fluoro, n p '>0, and at least one n p ' is linked to adjacent nucleotides via phosphorothioate bonds, the sense strand comprises at least one phosphorothioate bond, and the sense strand is conjugated to one or more lipophilic, e.g., C16 (or related) moieties linked via a divalent or trivalent branched linker.
[0426] In one embodiment, the RNAi agent is a polymer containing at least two duplexes represented by Formula (Ii), (Ij), (Ik), (Il) and (Im), wherein the duplexes are connected by a linker. The linker can be cleavable or non-cleavable. Optionally, the polymer further comprises a ligand. Each duplex can target the same gene or two different genes; or each duplex can target the same gene at two different target sites.
[0427] In one embodiment, the RNAi agent is a polymer containing three, four, five, six or more duplexes represented by Formula (Ii), (Ij), (Ik), (Il) and (Im), wherein the duplexes are connected by a linker. The linker can be cleavable or non-cleavable. Optionally, the polymer further comprises a ligand. Each duplex can target the same gene or two different genes; or each duplex can target the same gene at two different target sites.
[0428] In one embodiment, two RNAi agents represented by formula (Ii), (Ij), (Ik), (Il) and (Im) are linked to each other at the 5'-end and one or both 3'-ends, and are optionally conjugated to a ligand. Each agent can target the same gene or two different genes; or each agent can target the same gene at two different target sites.
[0429] Various disclosures describe poly RNAi agents that can be used in the methods of the present disclosure. Such disclosures include WO2007 / 091269, WO2010 / 141511, WO2007 / 117686, WO2009 / 014887, and WO2011 / 031520; and US7858769, the entire contents of each of which are hereby incorporated herein by reference.
[0430] In certain embodiments, the compositions and methods of the present disclosure comprise vinylphosphonate (VP) modifications of RNAi agents as described herein. In an exemplary embodiment, the 5'-vinylphosphonate modified nucleotides of the present disclosure have the structure:
[0431]
[0432] Where X is O or S;
[0433] R is hydrogen, hydroxy, fluorine or C 1-20 Alkoxy (e.g., methoxy or n-hexadecyloxy);
[0434] R 5 =C(H)-P(O)(OH) 2 , and the double bond between the C5' carbon and R5' is in the E or Z orientation (e.g., the E orientation); and
[0435] B is a nucleobase or a modified nucleobase, optionally wherein B is adenine, guanine, cytosine, thymine or uracil.
[0436] In one embodiment, R 5 ' is = C(H)-P(O)(OH) 2 , and the double bond between the C5' carbon and R5' is in the E orientation. In another embodiment, R is methoxy and R 5 ' is = C(H)-P(O)(OH) 2 , and the double bond between the C5' carbon and R5' is in the E orientation. In another embodiment, X is S, R is methoxy and R 5 ' is = C(H)-P(O)(OH) 2 , and the double bond between the C5' carbon and R5' is in the E orientation.
[0437] The vinyl phosphonates of the present disclosure may be linked to the antisense strand or the sense strand of the dsRNA of the present disclosure. In certain preferred embodiments, the vinyl phosphonates of the present disclosure are linked to the antisense strand of the dsRNA, optionally the 5'-end of the antisense strand of the dsRNA.
[0438] Vinyl phosphate modifications are also contemplated for use in the compositions and methods of the present disclosure. Exemplary vinyl phosphate structures include the preceding structures, wherein R 5 =C(H)-OP(O)(OH) 2 , and the C5' carbon is 5 The double bond between ' is in the E or Z orientation (eg, the E orientation).
[0439] i. Thermal destabilization modification
[0440] In certain embodiments, dsRNA molecules can be optimized RNA interference by incorporating thermal destabilization modifications in the seed region of the antisense strand (i.e., positions 2 to 9 at the 5'-end of the antisense strand) to reduce or inhibit off-target gene silencing. It has been found that dsRNAs with antisense strands (including at least one thermal destabilization modification of the duplex within the first 9 nucleotide positions of the antisense strand counted from the 5' end) have reduced off-target gene silencing activity. Therefore, in some embodiments, the antisense strand is included in at least one (e.g., one, two, three, four, five or more) thermal destabilization modification of the duplex within the first 9 nucleotide positions of the 5' region of the antisense strand. In some embodiments, one or more thermal destabilization modifications of the duplex are located at positions 2 to 9 from the 5'-end of the antisense strand, or preferably positions 4 to 8. In some other embodiments, the thermal destabilization modification of the duplex is located at positions 6, 7 or 8 from the 5' end of the antisense strand. In some other embodiments, the thermal destabilization modification of the duplex is located at positions 7 from the 5' end of the antisense strand. The term "thermal destabilizing modification" includes modifications that result in a lower overall melting temperature (Tm) of the dsRNA (preferably, a Tm that is one, two, three, or four degrees lower than the Tm of the dsRNA without such modification). In some embodiments, the thermal destabilizing modification of the duplex is located at position 2, 3, 4, 5, or 9 from the 5' end of the antisense strand.
[0441] Thermally destabilizing modifications may include, but are not limited to, abasic modifications; mismatches with the opposite nucleotide in the opposite strand; and sugar modifications such as 2'-deoxy modifications or acyclic nucleotides, e.g., unlocked nucleic acids (UNA) or glycol nucleic acids (GNA).
[0442] Exemplary abasic modifications include, but are not limited to, the following:
[0443]
[0444] wherein R=H, Me, Et or OMe; R'=H, Me, Et or OMe; R"=H, Me, Et or OMe.
[0445]
[0446] wherein B is a modified or unmodified nucleobase.
[0447] Exemplary sugar modifications include, but are not limited to, the following:
[0448]
[0449] wherein B is a modified or unmodified nucleobase.
[0450] In some embodiments, the thermal destabilizing modification of the duplex is selected from:
[0451]
[0452] where B is a modified or unmodified nucleobase and the asterisk on each structure indicates R, S or racemic.
[0453] In some embodiments, the thermal destabilizing modification of the duplex is selected from:
[0454]
[0455] wherein B is a modified or unmodified nucleobase and the asterisk indicates R, S or racemic (eg, S).
[0456] The term "acyclic nucleotide" refers to any nucleotide having an acyclic ribose sugar, e.g., wherein any bond between the ribose carbons (e.g., C1'-C2', C2'-C3', C3'-C4', C4'-O4', or C1'-O4') is absent or at least one of the ribose carbons or oxygens (e.g., C1', C2', C3', C4', or O4') is absent, either independently or in combination, in the nucleotide. In some embodiments, an acyclic nucleotide is Wherein B is a modified or unmodified nucleobase, R 1 and R 2 are independently H, halogen, OR 3 or alkyl; and R 3 is H, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl or sugar. Acyclic derivatives provide greater backbone flexibility without affecting Watson-Crick pairing. Acyclic nucleotides can be linked via 2'-5' or 3'-5' bonds.
[0457] The term "GNA" refers to diol nucleic acid, which is a polymer similar to DNA or RNA, but the composition of its "backbone" differs in that it consists of repeating glycerol units linked by phosphodiester bonds:
[0458]
[0459] The heat destabilization modification of the duplex can be a mismatch (i.e., non-complementary base pair) between a heat destabilizing nucleotide and a relative nucleotide in the relative strand within the dsRNA duplex. Exemplary mismatch base pairs include G:G, G:A, G:U, G:T, A:A, A:C, C:C, C:U, C:T, U:U, T:T, U:T, or a combination thereof. Other mismatch base pairs known in the art are also applicable to the present disclosure. Mismatches can be present between nucleotides (naturally occurring nucleotides or modified nucleotides), that is, mismatch base pairing can be present between core bases from corresponding nucleotides, regardless of the modification on the ribose of the nucleotides. In certain embodiments, the dsRNA molecule contains at least one core base in the mismatch pairing, which is a 2'-deoxynucleobase; for example, the 2'-deoxynucleobase is in the sense strand.
[0460] In some embodiments, the thermally destabilizing modification of the duplex in the seed region of the antisense strand comprises nucleotides with impaired WCH-bonding to complementary bases on the target mRNA, such as:
[0461]
[0462] Further examples of abasic nucleotides, acyclic nucleotide modifications (including UNA and GNA), and mismatch modifications are described in detail in WO 2011 / 133876, which is incorporated herein by reference in its entirety.
[0463] Heat destabilizing modifications may also include universal base and phosphate modifications with reduced or eliminated ability to form hydrogen bonds with opposing bases.
[0464] In some embodiments, the thermal destabilizing modification of the duplex includes nucleotides with non-canonical bases, such as, but not limited to, nucleobase modifications with impaired or completely eliminated ability to form hydrogen bonds with bases in the opposite strand. These nucleobase modifications were evaluated for destabilization of the central region of the dsRNA duplex, as described in WO 2010 / 0011895, which is incorporated herein by reference in its entirety. Exemplary nucleobase modifications are:
[0465]
[0466] In some embodiments, the thermally destabilizing modification of the duplex in the seed region of the antisense strand includes one or more α-nucleotides that are complementary to bases on the target mRNA, such as:
[0467]
[0468] Where R is H, OH, OCH 3 , F, NH 2 、NHMe、NMe 2 or O-alkyl.
[0469] Exemplary phosphate modifications known to reduce the thermal stability of dsRNA duplexes compared to native phosphodiester bonds are:
[0470]
[0471] R=alkyl
[0472] The alkyl group of the R group can be C 1 -C 6 Alkyl. Specific alkyl groups for the R group include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, pentyl, and hexyl.
[0473] As recognized by those skilled in the art, in view of the functional role of the core base is to define the specificity of the RNAi agent of the present disclosure, and the core base modification can be carried out in various ways as described herein, such as introducing destabilizing modifications into the RNAi agent of the present disclosure, such as for the purpose of enhancing the on-target effect relative to the off-target effect, for non-core base modifications, such as modifications to the sugar group or phosphate backbone of polyribonucleotides, the scope of modifications available and generally present in the RNAi agent of the present disclosure is often much larger. Such modifications are described in more detail in other parts of the present disclosure, and are clearly considered for RNAi agents of the present disclosure, which have natural core bases or modified core bases as described above or elsewhere herein.
[0474] In addition to the antisense strand including the thermal destabilization modification, the dsRNA can also include one or more stable modifications. For example, the dsRNA can include at least two (e.g., two, three, four, five, six, seven, eight, nine, ten or more) stable modifications. Without limitation, the stable modifications can all be present in one chain. In some embodiments, both the sense strand and the antisense strand include at least two stable modifications. The stable modification can be present on any nucleotide of the sense strand or the antisense strand. For example, the stable modification can be present on each nucleotide on the sense strand or the antisense strand; each stable modification can exist in an alternating pattern on the sense strand or the antisense strand; or the sense strand or the antisense strand both include a stable modification of an alternating pattern. The alternating pattern of the stable modification on the sense strand can be the same or different from the antisense strand, and the alternating pattern of the stable modification on the sense strand can have an offset relative to the alternating pattern of the stable modification on the antisense strand.
[0475] In some embodiments, the antisense strand comprises at least two (e.g., two, three, four, five, six, seven, eight, nine, ten or more) stabilizing modifications. Without limitation, the stabilizing modifications in the antisense strand can be present at any position. In some embodiments, the antisense comprises stabilizing modifications at positions 2, 6, 8, 9, 14, and 16 of the 5' end. In still some other embodiments, the antisense comprises stabilizing modifications at positions 2, 6, 14, and 16 of the 5' end. In still some other embodiments, the antisense comprises stabilizing modifications at positions 2, 14, and 16 of the 5' end.
[0476] In some embodiments, the antisense strand comprises at least one stabilizing modification adjacent to a destabilizing modification. For example, the stabilizing modification can be a nucleotide at the 5'-end or 3'-end of the unstable modification, i.e., at the -1 or +1 position of the position of the unstable modification. In some embodiments, the antisense strand comprises a stabilizing modification at each of the 5'-end and 3'-end of the unstable modification, i.e., at the -1 and +1 positions of the unstable modification position.
[0477] In some embodiments, the antisense strand comprises at least two stabilizing modifications 3'-terminus of the destabilizing modification, ie, at positions +1 or +2 to the position of the destabilizing modification.
[0478] In some embodiments, the sense strand comprises at least two (e.g., two, three, four, five, six, seven, eight, nine, ten or more) stabilizing modifications. Without limitation, the stabilizing modifications in the sense strand may be present at any position. In some embodiments, the sense strand comprises stabilizing modifications at positions 7, 10, and 11 of the 5'-end. In some other embodiments, the sense strand comprises stabilizing modifications at positions 7, 9, 10, and 11 of the 5'-end. In some embodiments, the sense strand comprises stabilizing modifications at positions opposite or complementary to positions 11, 12, and 15 of the antisense strand, counting from the 5' end of the antisense strand. In some other embodiments, the sense strand comprises stabilizing modifications at positions opposite or complementary to positions 11, 12, 13, and 15 of the antisense strand, counting from the 5' end of the antisense strand. In some embodiments, the sense strand comprises two, three, or four blocks of stabilizing modifications.
[0479] In some embodiments, the sense strand does not comprise a stabilizing modification at a position opposite or complementary to a thermal destabilizing modification of the duplex in the antisense strand.
[0480] Exemplary thermostable modifications include, but are not limited to, 2'-fluoro modifications. Other thermostable modifications include, but are not limited to, LNA.
[0481] In some embodiments, the dsRNA of the present disclosure comprises at least four (e.g., four, five, six, seven, eight, nine, ten or more) 2'-fluoro nucleotides. Without limitation, 2'-fluoro nucleotides may all be present in one strand. In some embodiments, both the sense strand and the antisense strand comprise at least two 2'-fluoro nucleotides. The 2'-fluoro modification may be present on any nucleotide of the sense strand or the antisense strand. For example, the 2'-fluoro modification may be present on each nucleotide on the sense strand or the antisense strand; each 2'-fluoro modification may be present in an alternating pattern on the sense strand or the antisense strand; or the sense strand or the antisense strand both comprise an alternating pattern of 2'-fluoro modifications. The alternating pattern of the 2'-fluoro modifications on the sense strand may be the same or different from the antisense strand, and the alternating pattern of the 2'-fluoro modifications on the sense strand may have an offset relative to the alternating pattern of the 2'-fluoro modifications on the antisense strand.
[0482] In some embodiments, the antisense strand comprises at least two (e.g., two, three, four, five, six, seven, eight, nine, ten or more) 2'-fluoro nucleotides. Without limitation, the 2'-fluoro modification in the antisense strand can be present at any position. In some embodiments, the antisense comprises 2'-fluoro nucleotides at positions 2, 6, 8, 9, 14 and 16 of the 5' end. In some other embodiments, the antisense comprises 2'-fluoro nucleotides at positions 2, 6, 14 and 16 of the 5' end. In still some other embodiments, the antisense comprises 2'-fluoro nucleotides at positions 2, 14 and 16 of the 5' end.
[0483] In some embodiments, the antisense strand comprises at least one 2'-fluoro nucleotide adjacent to the destabilizing modification. For example, the 2'-fluoro nucleotide can be a nucleotide at the 5' end or 3' end of the destabilizing modification, i.e., at -1 or +1 position of the destabilizing modification position. In some embodiments, the antisense strand comprises a 2'-fluoro nucleotide at each of the 5' end and the 3' end of the destabilizing modification, i.e., at -1 and +1 position of the destabilizing modification position.
[0484] In some embodiments, the antisense strand comprises at least two 2'-fluoro nucleotides at the 3' end of the destabilizing modification, ie, at position +1 or +2 of the destabilizing modification.
[0485] In some embodiments, the sense strand comprises at least two (e.g., two, three, four, five, six, seven, eight, nine, ten or more) 2'-fluoro nucleotides. Without limitation, the 2'-fluoro modification in the sense strand can be present at any position. In some embodiments, the antisense comprises 2'-fluoro nucleotides at positions 7, 10 and 11 of the 5' end. In some other embodiments, the sense strand comprises 2'-fluoro nucleotides at positions 7, 9, 10 and 11 of the 5' end. In some embodiments, the sense strand comprises 2'-fluoro nucleotides at positions opposite or complementary to positions 11, 12 and 15 of the antisense strand, counting from the 5' end of the antisense strand. In some other embodiments, the sense strand comprises 2'-fluoro nucleotides at positions opposite or complementary to positions 11, 12, 13 and 15 of the antisense strand, counting from the 5' end of the antisense strand. In some embodiments, the sense strand comprises blocks of two, three or four 2'-fluoro nucleotides.
[0486] In some embodiments, the sense strand does not comprise a 2'-fluoro nucleotide at a position opposite or complementary to the thermal destabilizing modification of the duplex in the antisense strand.
[0487] In some embodiments, the dsRNA molecules of the present disclosure include a sense strand of 21 nucleotides (nt) and an antisense strand of 23 nucleotides (nt), wherein the antisense strand contains at least one thermally destabilized nucleotide, wherein the at least one thermally destabilized nucleotide occurs in the seed region of the antisense strand (i.e., positions 2 to 9 at the 5' end of the antisense strand), wherein one end of the dsRNA is blunt and the other end includes a 2 nt overhang, and wherein the dsRNA optionally further has at least one of the following features (e.g., one, two, three, four, five, six or all seven): (i) the antisense comprises 2, 3, 4, 5 or 6 2'-fluoro modifications; (ii) the antisense comprises 1, 2, 3, 4 or 5 phosphorothioate internucleotide bonds; (iii) the sense strand is conjugated to a ligand; (iv) the sense strand comprises 2, 3, 4 or 5 2'-fluoro modifications; (v) the sense strand comprises 1, 2, 3, 4 or 5 phosphorothioate internucleotide bonds; (vi) the dsRNA comprises at least four 2'-fluoro modifications; and (vii) the dsRNA comprises a blunt end at the 5' end of the antisense strand. Preferably, the 2nt overhang is located at the 3' end of the antisense.
[0488] In some embodiments, the dsRNA molecules of the present disclosure include a sense strand and an antisense strand, wherein: the sense strand is 25-30 nucleotide residues in length, wherein starting from the 5'-terminal nucleotide (position 1), positions 1 to 23 of the sense strand include at least 8 ribonucleotides; the antisense strand is 36-66 nucleotide residues in length, and starting from the 3'-terminal nucleotide, at least 8 ribonucleotides in positions that pair with positions 1 to 23 of the sense strand to form a duplex; wherein at least the 3'-terminal nucleotide of the antisense strand is unpaired with the sense strand, and up to 6 consecutive 3'-terminal nucleotides are unpaired with the sense strand, thereby forming a 3' single-stranded overhang of 1-6 nucleotides; wherein the 5'- The terminus comprises 10-30 consecutive nucleotides that are unpaired with the sense strand, thereby forming a single-stranded 5' overhang of 10-30 nucleotides; wherein when the sense strand and the antisense strand are aligned for maximum complementarity, at least the 5'-terminal and 3'-terminal nucleotides of the sense strand base pair with nucleotides of the antisense strand, thereby forming a substantially double-stranded region between the sense strand and the antisense strand; and at least 19 ribonucleotides along the length of the antisense strand are sufficiently complementary to the target RNA to reduce target gene expression when the double-stranded nucleic acid is introduced into a mammalian cell; and wherein the antisense strand contains at least one thermally destabilizing nucleotide, wherein the at least one thermally destabilizing nucleotide is in the seed region of the antisense strand (i.e., positions 2 to 9 at the 5'-end of the antisense strand). For example, the thermally destabilizing nucleotide occurs between positions opposite or complementary to positions 14 to 17 of the 5'-end of the sense strand, and wherein the dsRNA optionally further has at least one (e.g., one, two, three, four, five, six, or all seven) of the following features: (i) the antisense comprises 2, 3, 4, 5, or 6 2'-fluoro modifications; (ii) the antisense comprises 1, 2, 3, 4, or 5 phosphorothioate internucleotide linkages; (iii) the sense strand is conjugated to a ligand; (iv) the sense strand comprises 2, 3, 4, or 5 2'-fluoro modifications; (v) the sense strand comprises 1, 2, 3, 4, or 5 phosphorothioate internucleotide linkages; and (vi) the dsRNA comprises at least four 2'-fluoro modifications; and (vii) the dsRNA comprises a duplex region of 12-30 nucleotide pairs in length.
[0489] In some embodiments, the dsRNA molecules of the present disclosure include a sense strand and an antisense strand, wherein the dsRNA molecule includes a sense strand of at least 25 and at most 29 nucleotides in length and an antisense strand of at most 30 nucleotides in length, wherein the sense strand includes a modified nucleotide at position 11 of the 5' end that is susceptible to enzymatic degradation, wherein the 3'-end of the sense strand and the 5'-end of the antisense strand form a blunt end, and the antisense strand is 1-4 nucleotides longer at its 3'-end than the sense strand, wherein a duplex region of at least 25 nucleotides in length, and the antisense strand is sufficiently complementary to a target mRNA along at least 19 nt of the length of the antisense strand to reduce target gene expression when the dsRNA molecule is introduced into a mammalian cell, and wherein dicer cleavage of the dsRNA preferentially generates an siRNA that includes the 3'-end of the antisense strand, thereby reducing expression of the target gene in the mammal. , wherein the antisense strand contains at least one thermally destabilizing nucleotide, wherein the at least one thermally destabilizing nucleotide is in the seed region of the antisense strand (i.e., positions 2 to 9 at the 5' end of the antisense strand), and wherein the dsRNA optionally further has at least one of the following features (e.g., one, two, three, four, five, six, or all seven): (i) the antisense comprises 2, 3, 4, 5, or 6 2'-fluoro modifications; (ii) the antisense comprises 1, 2, 3, 4, or 5 phosphorothioate internucleotide linkages; (iii) the sense strand is conjugated to a ligand; (iv) the sense strand comprises 2, 3, 4, or 5 2'-fluoro modifications; (v) the sense strand comprises 1, 2, 3, 4, or 5 phosphorothioate internucleotide linkages; and (vi) the dsRNA comprises at least four 2'-fluoro modifications; and (vii) the dsRNA has a duplex region of 12-29 nucleotide pairs in length.
[0490] In some embodiments, each nucleotide in the sense strand and antisense strand of the dsRNA molecule can be modified. Each nucleotide can be modified with the same or different modifications, which can include one or more changes in one or both of the non-linked phosphate oxygens or one or more of the linked phosphate oxygens; changes in the ribose composition, for example, changes in the 2' hydroxyl group on the ribose; wholesale replacement of phosphate moieties with "dephosphorylation" linkers; modification or replacement of naturally occurring bases; and replacement or modification of the ribose-phosphate backbone.
[0491] Because nucleic acid is a polymer of subunits, many modifications are present in the position of repetition in nucleic acid, such as the modification of bases, or phosphate moieties, or the non-connected O of phosphate moieties. In some cases, modification is present in all the positions described in nucleic acid, but it is not in many cases. For example, modification can be present only in 3' or 5' terminal positions, can be present only in the terminal region, for example, at the position on the terminal nucleotide or in the last 2, 3, 4, 5 or 10 nucleotides of the chain. Modification can be present in double-stranded regions, single-stranded regions or both. Modification can be present only in the double-stranded regions of RNA, or can be present only in the single-stranded regions of RNA. For example, the phosphorothioate modification at the non-connected O position can be present only in one or both ends, can be present only in the terminal region, for example, at the position on the terminal nucleotide or in the last 2, 3, 4, 5 or 10 nucleotides of the chain, or can be present in double-stranded and single-stranded regions, particularly at the ends. One or more 5'-ends can be phosphorylated.
[0492] For example, to enhance stability, specific bases can be included in the overhang, or in the single-stranded overhang, for example, in the 5' or 3' overhang or in both, modified nucleotides or nucleotide substitutes. For example, it may be desirable to include purine nucleotides in the overhang. In some embodiments, all or some bases in the 3' or 5' overhang can be modified, for example, by modification described herein. Modification can include, for example, using modification known in the art at the 2' position of ribose, for example, using deoxyribonucleotides, 2'-deoxy-2'-fluorine (2'-F) or 2'-O-methyl modifications to replace the ribose of the core base, and the modification of phosphate groups, for example, phosphorothioate modifications. The overhang does not need to be homologous to the target sequence.
[0493] In some embodiments, each residue of the sense strand and the antisense strand is independently modified with a locked nucleic acid (LNA), an unlocked nucleic acid (UNA), a cyclohexene nucleic acid (CeNA), a 2'-methoxyethyl, a 2'-O-methyl, a 2'-O-allyl, a 2'-C-allyl, a 2'-deoxy, or a 2'-fluoro. A strand may contain more than one modification. In some embodiments, each residue of the sense strand and the antisense strand is independently modified with a 2'-O-methyl or a 2'-fluoro. It is understood that these modifications are in addition to at least one thermal destabilizing modification of the duplex present in the antisense strand.
[0494] There are usually at least two different modifications on the sense strand and the antisense strand. These two modifications can be 2'-deoxy, 2'-O-methyl or 2'-fluoro modifications, acyclic nucleotides or other modifications. In some embodiments, the sense strand and the antisense strand each contain two different modified nucleotides selected from 2'-O-methyl or 2'-deoxy. In some embodiments, each residue of the sense strand and the antisense strand is independently modified with 2'-O-methyl nucleotides, 2'-deoxy nucleotides, 2'-deoxy-2'-fluoro nucleotides, 2'-ON-methylacetamido (2'-O-NMA) nucleotides, 2'-O-dimethylaminoethoxyethyl (2'-O-DMAEOE) nucleotides, 2'-O-aminopropyl (2'-O-AP) nucleotides or 2'-ara-F nucleotides. Similarly, it should be understood that these modifications are outside the at least one thermal destabilization modification of the duplex present in the antisense strand.
[0495] In some embodiments, the dsRNA molecules of the present disclosure include modifications of alternating patterns, particularly in B1, B2, B3, B1', B2', B3', B4' regions. As used herein, the term "alternating motif" or "alternating pattern" refers to a motif with one or more modifications, each modification being present in the alternating nucleotides of a chain. Alternating nucleotides may refer to one every other nucleotide or one every three nucleotides, or a similar pattern. For example, if A, B, and C each represent a type of modification to a nucleotide, the alternating motif may be "ABABABABABAB...", "AABBAABBAABB...", "AABAABAABAAB...", "AAABAAABAAAB...", "AAABBBAAABBB...", or "ABCABCABCABC...", etc.
[0496] The types of modifications contained in the alternating motif can be the same or different. For example, if A, B, C, D each represent a type of modification on a nucleotide, the alternating pattern (i.e., the modification on every other nucleotide) can be the same, but the sense strand or the antisense strand can each be selected from several modification possibilities within the alternating motif, such as "ABABAB...", "ACACAC...", "BDBDBD..." or "CDCDCD...", etc.
[0497] In some embodiments, the dsRNA molecules of the present disclosure include a modification pattern relative to the alternating motif on the antisense strand, and the modification pattern of the alternating motif on the sense strand is offset. The offset can cause the modified groups of the nucleotides of the sense strand to correspond to the differently modified groups of the nucleotides of the antisense strand, and vice versa. For example, when the sense strand is paired with the antisense strand in the dsRNA duplex, the alternating motif in the sense strand can start with "ABABAB" from the 5'-3' of the strand, and the alternating motif in the antisense strand can start with "BABABA" from the 3'-5' of the strand in the duplex region. As another example, the alternating motif in the sense strand can start with "AABBAABB" from the 5'-3' of the strand, and the alternating motif in the antisense strand can start with "BBAABBAA" from the 3'-5' of the strand in the duplex region, so there is a complete or partial transfer of the modification pattern between the sense strand and the antisense strand.
[0498] The dsRNA molecules of the present disclosure may further comprise at least one phosphorothioate or methylphosphonate internucleotide bond. The phosphorothioate or methylphosphonate internucleotide bond modification may be present in any position of the chain on any nucleotide of the sense strand or the antisense strand or both strands. For example, the internucleotide bond modification may be present on each nucleotide on the sense strand or the antisense strand; each internucleotide bond modification may be present in an alternating pattern on the sense strand or the antisense strand; or the sense strand or the antisense strand may comprise two internucleotide bond modifications in an alternating pattern. The alternating pattern of the internucleotide bond modification on the sense strand may be the same or different from the antisense strand, and the alternating pattern of the internucleotide bond modification on the sense strand may have an offset relative to the alternating pattern of the internucleotide bond modification on the antisense strand.
[0499] In some embodiments, the dsRNA molecule comprises a phosphorothioate or methylphosphonate internucleotide bond modification in the overhang region. For example, the overhang region includes two nucleotides, and there is a phosphorothioate or methylphosphonate internucleotide bond between the two nucleotides. It is also possible to carry out internucleotide bond modification to connect the overhang nucleotide to the terminal pairing nucleotide in the duplex region. For example, at least 2, 3, 4 or all overhang nucleotides can be connected by a phosphorothioate or methylphosphonate internucleotide bond, and optionally, there may be another phosphorothioate or methylphosphonate internucleotide bond that connects the overhang nucleotide to the pairing nucleotide next to the overhang nucleotide. For example, there may be at least two phosphorothioate internucleotide bonds between the three nucleotides at the end, wherein two of the three nucleotides are overhang nucleotides, and the third is a pairing nucleotide adjacent to the overhang nucleotide. Preferably, these three nucleotides at the end can be located at the 3'-end of the antisense strand.
[0500] In some embodiments, the sense strand of the dsRNA molecule comprises 1-10 blocks of two to ten phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is located at any position in the oligonucleotide sequence, and the sense strand is paired with an antisense strand comprising any combination of phosphorothioate, methylphosphonate, and phosphate internucleotide linkages, or an antisense strand comprising phosphorothioate or methylphosphonate or phosphate linkages.
[0501] In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of two phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is located at any position in the oligonucleotide sequence, and the antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate, and phosphate internucleotide linkages or an antisense strand comprising phosphorothioate or methylphosphonate or phosphate linkages.
[0502] In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of three phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is located at any position in the oligonucleotide sequence, and the antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate, and phosphate internucleotide linkages or an antisense strand comprising phosphorothioate or methylphosphonate or phosphate linkages.
[0503] In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of four phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is located at any position in the oligonucleotide sequence, and the antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate, and phosphate internucleotide linkages or an antisense strand comprising phosphorothioate or methylphosphonate or phosphate linkages.
[0504] In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of five phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is located at any position in the oligonucleotide sequence, and the antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate, and phosphate internucleotide linkages or an antisense strand comprising phosphorothioate or methylphosphonate or phosphate linkages.
[0505] In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of six phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is located at any position in the oligonucleotide sequence, and the antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate, and phosphate internucleotide linkages or an antisense strand comprising phosphorothioate or methylphosphonate or phosphate linkages.
[0506] In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of seven phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7, or 8 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is located at any position in the oligonucleotide sequence, and the antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate, and phosphate internucleotide linkages or an antisense strand comprising phosphorothioate or methylphosphonate or phosphate linkages.
[0507] In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of eight phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, or 6 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is located at any position in the oligonucleotide sequence, and the antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate, and phosphate internucleotide linkages or an antisense strand comprising phosphorothioate or methylphosphonate or phosphate linkages.
[0508] In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of nine phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, or 4 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is located at any position in the oligonucleotide sequence, and the antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate, and phosphate internucleotide linkages or an antisense strand comprising phosphorothioate or methylphosphonate or phosphate linkages.
[0509] In some embodiments, the dsRNA molecules of the present disclosure further comprise one or more phosphorothioate or methylphosphonate internucleotide linkage modifications within terminal positions 1 to 10 of the sense or antisense strand. For example, at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides may be linked by phosphorothioate or methylphosphonate internucleotide linkages at one or both ends of the sense or antisense strand.
[0510] In some embodiments, the dsRNA molecules of the present disclosure further include one or more phosphorothioate or methylphosphonate internucleotide bond modifications within 1 to 10 of the duplex internal region of each sense or antisense strand. For example, at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides may be linked by phosphorothioate methylphosphonate internucleotide bonds at positions 8 to 16 of the duplex region counted from the 5'-end of the sense strand; the dsRNA molecules may optionally further include one or more phosphorothioate or methylphosphonate internucleotide bond modifications within 1 to 10 of the terminal positions.
[0511] In some embodiments, the dsRNA molecules of the present disclosure further comprise one to five phosphorothioate or methylphosphonate internucleotide linkage modifications within positions 1 to 5 and one to five phosphorothioate or methylphosphonate internucleotide linkage modifications within positions 18 to 23 (counting from the 5'-end) of the sense strand, and one to five phosphorothioate or methylphosphonate internucleotide linkage modifications at positions 1 and 2 and one to five within positions 18 to 23 (counting from the 5'-end) of the antisense strand.
[0512] In some embodiments, the dsRNA molecules of the present disclosure further comprise one phosphorothioate internucleotide linkage modification within positions 1 to 5 and one phosphorothioate or methylphosphonate internucleotide linkage modification within positions 18 to 23 of the sense strand (counting from the 5' end), and one phosphorothioate internucleotide linkage modification at position 1 or 2 and two phosphorothioate or methylphosphonate internucleotide linkage modifications within positions 18 to 23 of the antisense strand (counting from the 5' end).
[0513] In some embodiments, the dsRNA molecules of the present disclosure further comprise two phosphorothioate internucleotide linkage modifications within positions 1 to 5 and one phosphorothioate internucleotide linkage modification within positions 18 to 23 of the sense strand (counting from the 5' end), and one phosphorothioate internucleotide linkage modification at position 1 or 2 and two phosphorothioate internucleotide linkage modifications within positions 18 to 23 of the antisense strand (counting from the 5' end).
[0514] In some embodiments, the dsRNA molecules of the present disclosure further comprise two phosphorothioate internucleotide linkage modifications within positions 1 to 5 and two phosphorothioate internucleotide linkage modifications within positions 18 to 23 of the sense strand (counting from the 5' end), and one phosphorothioate internucleotide linkage modification at position 1 or 2 and two phosphorothioate internucleotide linkage modifications within positions 18 to 23 of the antisense strand (counting from the 5' end).
[0515] In some embodiments, the dsRNA molecules of the present disclosure further comprise two phosphorothioate internucleotide linkage modifications within positions 1 to 5 and two phosphorothioate internucleotide linkage modifications within positions 18 to 23 of the sense strand (counting from the 5' end), and one phosphorothioate internucleotide linkage modification at position 1 or 2 and one phosphorothioate internucleotide linkage modification within positions 18 to 23 of the antisense strand (counting from the 5' end).
[0516] In some embodiments, the dsRNA molecules of the present disclosure further comprise one phosphorothioate internucleotide linkage modification within positions 1 to 5 and one phosphorothioate internucleotide linkage modification within positions 18 to 23 of the sense strand (counting from the 5' end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18 to 23 of the antisense strand (counting from the 5' end).
[0517] In some embodiments, the dsRNA molecules of the present disclosure further comprise one phosphorothioate internucleotide linkage modification within positions 1 to 5 and one within positions 18 to 23 (counting from the 5' end) of the sense strand, and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and one phosphorothioate internucleotide linkage modification within positions 18 to 23 (counting from the 5' end) of the antisense strand.
[0518] In some embodiments, the dsRNA molecules of the present disclosure further comprise one phosphorothioate internucleotide linkage modification within positions 1 to 5 (counting from the 5' end) of the sense strand, and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and one phosphorothioate internucleotide linkage modification within positions 18 to 23 (counting from the 5' end) of the antisense strand.
[0519] In some embodiments, the dsRNA molecules of the present disclosure further comprise two phosphorothioate internucleotide linkage modifications within positions 1 to 5 (counting from the 5' end) of the sense strand, and one phosphorothioate internucleotide linkage modification at position 1 or 2 and two phosphorothioate internucleotide linkage modifications within positions 18 to 23 (counting from the 5' end) of the antisense strand.
[0520] In some embodiments, the dsRNA molecules of the present disclosure further comprise two phosphorothioate internucleotide linkage modifications within positions 1 to 5 and one within positions 18 to 23 (counting from the 5' end) of the sense strand, and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and one phosphorothioate internucleotide linkage modification within positions 18 to 23 (counting from the 5' end) of the antisense strand.
[0521] In some embodiments, the dsRNA molecules of the present disclosure further comprise two phosphorothioate internucleotide linkage modifications within positions 1 to 5 and one phosphorothioate internucleotide linkage modification within positions 18 to 23 of the sense strand (counting from the 5' end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18 to 23 of the antisense strand (counting from the 5' end).
[0522] In some embodiments, the dsRNA molecules of the present disclosure further comprise two phosphorothioate internucleotide linkage modifications within positions 1 to 5 and one phosphorothioate internucleotide linkage modification within positions 18 to 23 of the sense strand (counting from the 5' end), and one phosphorothioate internucleotide linkage modification at position 1 or 2 and two phosphorothioate internucleotide linkage modifications within positions 18 to 23 of the antisense strand (counting from the 5' end).
[0523] In some embodiments, the dsRNA molecules of the present disclosure further comprise two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications at positions 20 and 21 (counting from the 5' end) of the sense strand, and one phosphorothioate internucleotide linkage modification at position 1 and one at position 21 (counting from the 5' end) of the antisense strand.
[0524] In some embodiments, the dsRNA molecules of the present disclosure further comprise one phosphorothioate internucleotide linkage modification at position 1 and one phosphorothioate internucleotide linkage modification at position 21 of the sense strand (counting from the 5' end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications at positions 20 and 21 of the antisense strand (counting from the 5' end).
[0525] In some embodiments, the dsRNA molecules of the present disclosure further comprise two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications at positions 21 and 22 of the sense strand (counting from the 5' end), and one phosphorothioate internucleotide linkage modification at position 1 and one phosphorothioate internucleotide linkage modification at position 21 of the antisense strand (counting from the 5' end).
[0526] In some embodiments, the dsRNA molecules of the present disclosure further comprise one phosphorothioate internucleotide linkage modification at position 1 and one phosphorothioate internucleotide linkage modification at position 21 of the sense strand (counting from the 5' end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications at positions 21 and 22 of the antisense strand (counting from the 5' end).
[0527] In some embodiments, the dsRNA molecules of the present disclosure further comprise two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications at positions 22 and 23 of the sense strand (counting from the 5' end), and one phosphorothioate internucleotide linkage modification at position 1 and one phosphorothioate internucleotide linkage modification at position 21 of the antisense strand (counting from the 5' end).
[0528] In some embodiments, the dsRNA molecules of the present disclosure further comprise one phosphorothioate internucleotide linkage modification at position 1 and one phosphorothioate internucleotide linkage modification at position 21 of the sense strand (counting from the 5' end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications at positions 23 and 23 of the antisense strand (counting from the 5' end).
[0529] In some embodiments, the compounds of the present disclosure include patterns of backbone chiral centers. In some embodiments, the common pattern of backbone chiral centers includes at least 5 internucleotide bonds of Sp configuration. In some embodiments, the common pattern of backbone chiral centers includes at least 6 internucleotide bonds of Sp configuration. In some embodiments, the common pattern of backbone chiral centers includes at least 7 internucleotide bonds of Sp configuration. In some embodiments, the common pattern of backbone chiral centers includes at least 8 internucleotide bonds of Sp configuration. In some embodiments, the common pattern of backbone chiral centers includes at least 9 internucleotide bonds of Sp configuration. In some embodiments, the common pattern of backbone chiral centers includes at least 10 internucleotide bonds of Sp configuration. In some embodiments, the common pattern of backbone chiral centers includes at least 11 internucleotide bonds of Sp configuration. In some embodiments, the common pattern of backbone chiral centers includes at least 12 internucleotide bonds of Sp configuration. In some embodiments, the common pattern of backbone chiral centers includes at least 13 internucleotide bonds of Sp configuration. In some embodiments, the common pattern of the main chain chiral center includes at least 14 internucleotide bonds of the Sp configuration. In some embodiments, the common pattern of the main chain chiral center includes at least 15 internucleotide bonds of the Sp configuration. In some embodiments, the common pattern of the main chain chiral center includes at least 16 internucleotide bonds of the Sp configuration. In some embodiments, the common pattern of the main chain chiral center includes at least 17 internucleotide bonds of the Sp configuration. In some embodiments, the common pattern of the main chain chiral center includes at least 18 internucleotide bonds of the Sp configuration. In some embodiments, the common pattern of the main chain chiral center includes at least 19 internucleotide bonds of the Sp configuration. In some embodiments, the common pattern of the main chain chiral center includes no more than 8 internucleotide bonds of the Rp configuration. In some embodiments, the common pattern of the main chain chiral center includes no more than 7 internucleotide bonds of the Rp configuration. In some embodiments, the common pattern of the main chain chiral center includes no more than 6 internucleotide bonds of the Rp configuration. In some embodiments, the common pattern of the main chain chiral center includes no more than 5 internucleotide bonds of the Rp configuration. In some embodiments, the common pattern of the main chain chiral center includes no more than 4 internucleotide bonds of the Rp configuration. In some embodiments, the common pattern of the main chain chiral center includes no more than 3 internucleotide bonds of the Rp configuration. In some embodiments, the common pattern of the main chain chiral center includes no more than 2 internucleotide bonds of the Rp configuration. In some embodiments, the common pattern of the main chain chiral center includes no more than 1 internucleotide bond of the Rp configuration. In some embodiments, the common pattern of the main chain chiral center includes no more than 8 non-chiral internucleotide bonds (as a non-limiting example, phosphodiester). In some embodiments, the common pattern of the main chain chiral center includes no more than 7 non-chiral internucleotide bonds.In some embodiments, the common pattern of backbone chiral centers includes no more than 6 achiral internucleotide bonds. In some embodiments, the common pattern of backbone chiral centers includes no more than 5 achiral internucleotide bonds. In some embodiments, the common pattern of backbone chiral centers includes no more than 4 achiral internucleotide bonds. In some embodiments, the common pattern of backbone chiral centers includes no more than 3 achiral internucleotide bonds. In some embodiments, the common pattern of backbone chiral centers includes no more than 2 achiral internucleotide bonds. In some embodiments, the common pattern of backbone chiral centers includes no more than 1 achiral internucleotide bond. In some embodiments, the common pattern of backbone chiral centers includes at least 10 internucleotide bonds of Sp configuration and no more than 8 achiral internucleotide bonds. In some embodiments, the common pattern of backbone chiral centers includes at least 11 internucleotide bonds of Sp configuration and no more than 7 achiral internucleotide bonds. In some embodiments, the common pattern of backbone chiral centers includes at least 12 internucleotide bonds of Sp configuration and no more than 6 achiral internucleotide bonds. In some embodiments, the common pattern of the main chain chiral center includes at least 13 internucleotide bonds of the Sp configuration and no more than 6 non-chiral internucleotide bonds. In some embodiments, the common pattern of the main chain chiral center includes at least 14 internucleotide bonds of the Sp configuration and no more than 5 non-chiral internucleotide bonds. In some embodiments, the common pattern of the main chain chiral center includes at least 15 internucleotide bonds of the Sp configuration and no more than 4 non-chiral internucleotide bonds. In some embodiments, the internucleotide bonds of the Sp configuration are optionally continuous or discontinuous. In some embodiments, the internucleotide bonds of the Rp configuration are optionally continuous or discontinuous. In some embodiments, the non-chiral internucleotide bonds are optionally continuous or discontinuous.
[0530] In some embodiments, the compounds of the present disclosure include blocks that are stereochemical blocks. In some embodiments, the block is an Rp block, wherein each internucleotide bond of the block is Rp. In some embodiments, the 5'-block is an Rp block. In some embodiments, the 3'-block is an Rp block. In some embodiments, the block is an Sp block, wherein each internucleotide bond of the block is Sp. In some embodiments, the 5'-block is an Sp block. In some embodiments, the 3'-block is an Sp block. In some embodiments, the oligonucleotides provided include both Rp and Sp blocks. In some embodiments, the oligonucleotides provided include one or more Rp blocks but do not include Sp blocks. In some embodiments, the oligonucleotides provided include one or more Sp blocks but do not include Rp blocks. In some embodiments, the oligonucleotides provided include one or more PO blocks, wherein each internucleotide bond is a natural phosphate bond.
[0531] In some embodiments, the compounds of the present disclosure include a 5'-block as a Sp block, wherein each sugar moiety includes a 2'-F modification. In some embodiments, the 5'-block is a Sp block, wherein each internucleotide bond is a modified internucleotide bond, and each sugar moiety includes a 2'-F modification. In some embodiments, the 5'-block is a Sp block, wherein each internucleotide bond is a phosphorothioate bond, and each sugar moiety includes a 2'-F modification. In some embodiments, the 5'-block includes 4 or more nucleoside units. In some embodiments, the 5'-block includes 5 or more nucleoside units. In some embodiments, the 5'-block includes 6 or more nucleoside units. In some embodiments, the 5'-block includes 7 or more nucleoside units. In some embodiments, the 3'-block is a Sp block, wherein each sugar moiety includes a 2'-F modification. In some embodiments, the 3'-block is a Sp block, wherein each internucleotide bond is a modified internucleotide bond, and each sugar moiety includes a 2'-F modification. In some embodiments, the 3'-block is an Sp block, wherein each internucleotide bond is a phosphorothioate bond, and each sugar moiety includes a 2'-F modification. In some embodiments, the 3'-block includes 4 or more nucleoside units. In some embodiments, the 3'-block includes 5 or more nucleoside units. In some embodiments, the 3'-block includes 6 or more nucleoside units. In some embodiments, the 3'-block includes 7 or more nucleoside units.
[0532] In some embodiments, the compounds of the present disclosure include one type of nucleoside in a region, or the oligonucleotide is followed by a specific type of internucleotide bond, such as a natural phosphate bond, a modified internucleotide bond, an Rp chiral internucleotide bond, a Sp chiral internucleotide bond, etc. In some embodiments, A is followed by Sp. In some embodiments, A is followed by Rp. In some embodiments, A is followed by a natural phosphate bond (PO). In some embodiments, U is followed by Sp. In some embodiments, U is followed by Rp. In some embodiments, U is followed by a natural phosphate bond (PO). In some embodiments, C is followed by Sp. In some embodiments, C is followed by Rp. In some embodiments, C is followed by a natural phosphate bond (PO). In some embodiments, G is followed by Sp. In some embodiments, G is followed by Rp. In some embodiments, G is followed by a natural phosphate bond (PO). In some embodiments, C and U are followed by Sp. In some embodiments, C and U are followed by Rp. In some embodiments, C and U are followed by a natural phosphate bond (PO). In some embodiments, A and G are followed by Sp. In some embodiments, A and G are followed by Rp.
[0533] In some embodiments, the antisense strand comprises phosphorothioate internucleotide linkages between nucleotide positions 21 and 22 and between nucleotide positions 22 and 23, wherein the antisense strand contains at least one thermally destabilizing modification of the duplex located in the seed region of the antisense strand (i.e., positions 2 to 9 at the 5' end of the antisense strand), and wherein the dsRNA optionally further has at least one (e.g., one, two, three, four, five, six, seven, or all eight) of the following features: (i) the antisense strand comprises 2, 3, 4, 5, or 6 2'-fluoro modification; (ii) the antisense comprises 3, 4 or 5 phosphorothioate internucleotide bonds; (iii) the sense strand is conjugated to a ligand; (iv) the sense strand comprises 2, 3, 4 or 5 2'-fluoro modifications; (v) the sense strand comprises 1, 2, 3, 4 or 5 phosphorothioate internucleotide bonds; (vi) the dsRNA comprises at least four 2'-fluoro modifications; (vii) the dsRNA comprises a duplex region of 12-40 nucleotide pairs in length; and (viii) the dsRNA has a blunt end at the 5' end of the antisense strand.
[0534] In some embodiments, the antisense strand comprises phosphorothioate internucleotide bonds between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23, wherein the antisense strand contains at least one thermally destabilizing modification of the duplex located in the seed region of the antisense strand (i.e., positions 2 to 9 at the 5' end of the antisense strand), and wherein the dsRNA optionally further has at least one (e.g., one, two, three, four, five, six, seven, or all eight) of the following features: (i) the antisense strand comprises 2, 3, 4 , 5 or 6 2'-fluoro modifications; (ii) the sense strand is conjugated to a ligand; (iii) the sense strand comprises 2, 3, 4 or 5 2'-fluoro modifications; (iv) the sense strand comprises 1, 2, 3, 4 or 5 phosphorothioate internucleotide bonds; (v) the dsRNA comprises at least four 2'-fluoro modifications; (vi) the dsRNA comprises a duplex region of 12-40 nucleotide pairs in length; (vii) the dsRNA comprises a duplex region of 12-40 nucleotide pairs in length; and (viii) the dsRNA has a blunt end at the 5' end of the antisense strand.
[0535] In some embodiments, the sense strand includes phosphorothioate internucleotide bonds between nucleotide positions 1 and 2 and between nucleotide positions 2 and 3, wherein the antisense strand contains at least one thermally destabilizing modification of the duplex located in the seed region of the antisense strand (i.e., positions 2 to 9 at the 5' end of the antisense strand), and wherein the dsRNA optionally further has at least one (e.g., one, two, three, four, five, six, seven, or all eight) of the following features: (i) the antisense strand includes 2, 3, 4, 5, or 6 2'-fluoro modifications ; (ii) the antisense comprises 1, 2, 3, 4 or 5 phosphorothioate internucleotide bonds; (iii) the sense strand is conjugated to a ligand; (iv) the sense strand comprises 2, 3, 4 or 5 2'-fluoro modifications; (v) the sense strand comprises 3, 4 or 5 phosphorothioate internucleotide bonds; (vi) the dsRNA comprises at least four 2'-fluoro modifications; (vii) the dsRNA comprises a duplex region of 12-40 nucleotide pairs in length; and (viii) the dsRNA has a blunt end at the 5' end of the antisense strand.
[0536] In some embodiments, the sense strand comprises a phosphorothioate internucleotide bond between nucleotide positions 1 and 2 and between nucleotide positions 2 and 3, the antisense strand comprises a phosphorothioate internucleotide bond between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23, wherein the antisense strand contains at least one thermally destabilizing modification of the duplex located in the seed region of the antisense strand (i.e., positions 2 to 9 at the 5' end of the antisense strand), and wherein the dsRNA optionally further has at least one of the following features (e.g., one, two, three, four, five, six or all seven): (i) the antisense comprises 2, 3, 4, 5 or 6 2'-fluoro modifications; (ii) the sense strand is conjugated to a ligand; (iii) the sense strand comprises 2, 3, 4 or 5 2'-fluoro modifications; (iv) the sense strand comprises 3, 4 or 5 phosphorothioate internucleotide linkages; (v) the dsRNA comprises at least four 2'-fluoro modifications; (vi) the dsRNA comprises a duplex region of 12-40 nucleotide pairs in length; and (vii) the dsRNA has a blunt end at the 5' end of the antisense strand.
[0537] In some embodiments, the dsRNA molecules of the present disclosure comprise mismatches with the target, within the duplex, or a combination thereof. Mismatches may be present in the overhang region or in the duplex region. Base pairs can be ranked based on their propensity to promote dissociation or melt (e.g., based on the free energy of association or dissociation of a particular pairing, the simplest approach is to examine pairings individually, although neighbor or similar analysis may also be used). In terms of promoting dissociation: A:U is better than G:C; G:U is better than G:C; and I:C is better than G:C (I = inosine). Mismatches, such as non-canonical or extra-canonical pairings (as described elsewhere herein) are better than canonical (A:T, A:U, G:C) pairings; and pairings comprising universal bases are better than canonical pairings.
[0538] In some embodiments, the dsRNA molecules of the present disclosure include at least one of the first 1, 2, 3, 4, or 5 base pairs within the duplex region from the 5' end of the antisense strand, which can be independently selected from: A:U, G:U, I:C, and mispairing, such as non-canonical or extra-canonical pairing or pairing comprising universal bases, to promote dissociation of the antisense strand at the 5' end of the duplex.
[0539] In some embodiments, the nucleotide at position 1 from the 5' end of the duplex region of the antisense strand is selected from A, dA, dU, U and dT. Optionally, at least one of the first 1, 2 or 3 base pairs in the duplex region at the 5' end of the antisense strand is an AU base pair. For example, the first base pair in the duplex region at the 5' end of the antisense strand is an AU base pair.
[0540] It has been found that the introduction of a 4'-modified or 5'-modified nucleotide into the 3'-end of a phosphodiester (PO), phosphorothioate (PS) or phosphorodithioate (PS2) bond of a dinucleotide at any position of a single-stranded or double-stranded oligonucleotide can exert a steric effect on the internucleotide bond and thus protect or stabilize it from the action of nucleases. In some embodiments, a 4'-modified or 5'-modified nucleotide is introduced into the 3' end of a PO, PS or PS2 bond of a dinucleotide to modify the second nucleotide in the dinucleotide pair. In other embodiments, a 4'-modified or 5'-modified nucleotide is introduced into the 3' end of a PO, PS or PS2 bond of a dinucleotide to modify the nucleotide at the 3' end of the dinucleotide pair.
[0541] In some embodiments, 5'-modified nucleotides are introduced at the 3' end of a dinucleotide at any position of a single-stranded or double-stranded siRNA. For example, a 5'-alkylated nucleoside can be introduced at the 3' end of a dinucleotide at any position of a single-stranded or double-stranded siRNA. The alkyl at the 5' position of the ribose can be a racemic or chirally pure R or S isomer. An exemplary 5'-alkylated nucleotide is a 5'-methyl nucleoside. The 5'-methyl can be a racemic or chirally pure R or S isomer.
[0542] In some embodiments, a 4'-modified nucleotide is introduced at the 3' end of a dinucleotide at any position of a single-stranded or double-stranded siRNA. For example, a 4'-alkylated nucleoside can be introduced at the 3' end of a dinucleotide at any position of a single-stranded or double-stranded siRNA. The alkyl group at the 4' position of the ribose can be a racemic or chirally pure R or S isomer. Exemplary 4'-alkylated nucleotides are 4'-methyl nucleosides. The 4'-methyl group can be a racemic or chirally pure R or S isomer. Alternatively, a 4'-O-alkylated nucleoside can be introduced at the 3' end of a dinucleotide at any position of a single-stranded or double-stranded siRNA. The 4'-O-alkyl group of the ribose can be a racemic or chirally pure R or S isomer. Exemplary 4'-O-alkylated nucleotides are 4'-O-methyl nucleosides. The 4'-O-methyl group can be a racemic or chirally pure R or S isomer.
[0543] In some embodiments, 5'-alkylated nucleotides are introduced at any position on the sense strand or antisense strand of the dsRNA, and such modifications maintain or improve the effectiveness of the dsRNA. The 5'-alkyl can be racemic or chirally pure R or S isomers. Exemplary 5'-alkylated nucleotides are 5'-methyl nucleosides. The 5'-methyl can be racemic or chirally pure R or S isomers.
[0544] In some embodiments, 4'-alkylated nucleotides are introduced at any position on the sense strand or antisense strand of the dsRNA, and such modifications maintain or improve the effectiveness of the dsRNA. The 4'-alkyl can be racemic or chirally pure R or S isomers. Exemplary 4'-alkylated nucleotides are 4'-methyl nucleosides. The 4'-methyl can be racemic or chirally pure R or S isomers.
[0545] In some embodiments, 4'-O-alkylated nucleotides are introduced at any position on the sense strand or antisense strand of the dsRNA, and such modifications maintain or improve the effectiveness of the dsRNA. The 5'-alkyl can be racemic or chirally pure R or S isomers. Exemplary 4'-O-alkylated nucleotides are 4'-O-methyl nucleosides. The 4'-O-methyl can be racemic or chirally pure R or S isomers.
[0546] In some embodiments, the dsRNA molecules of the present disclosure may include a 2'-5' bond (having 2'-H, 2'-OH, and 2'-OMe, and having P=O or P=S). For example, the 2'-5' bond modification may be used to promote nuclease resistance or inhibit the binding of the sense strand to the antisense strand, or may be used at the 5' end of the sense strand to avoid activation of the sense strand by RISC.
[0547] In another embodiment, the dsRNA molecules of the present disclosure can include L sugars (e.g., L-ribose, L-arabinose with 2'-H, 2'-OH, and 2'-OMe). For example, these L sugar modifications can be used to promote nuclease resistance or inhibit the binding of the sense strand to the antisense strand, or can be used at the 5' end of the sense strand to avoid activation of the sense strand by RISC.
[0548] Various publications describe multimeric siRNAs, all of which can be used in the dsRNA of the present disclosure. Such publications include WO2007 / 091269, US 7858769, WO2010 / 141511, WO2007 / 117686, WO2009 / 014887, and WO2011 / 031520, which are hereby incorporated by reference in their entirety.
[0549] As described in more detail below, the RNAi agent containing one or more carbohydrate moieties and the conjugation of RNAi agent can optimize one or more characteristics of RNAi agent.In many cases, carbohydrate moieties are connected to the modified subunit of RNAi agent.For example, the ribose of one or more ribonucleotide subunits of dsRNA agent can be replaced by another part, for example, a non-carbohydrate (preferably, cyclic) carrier connected to a carbohydrate ligand.The ribonucleotide subunits wherein the ribose of subunits has been so replaced are referred to herein as ribose replacement modified subunits (RRMS).Annular carriers can be carbocyclic systems, i.e., all ring atoms are carbon atoms, or heterocyclic systems, i.e., one or more ring atoms can be heteroatoms, such as nitrogen, oxygen, sulfur.Annular carriers can be monocyclic systems, or can contain two or more rings, such as fused rings.Annular carriers can be fully saturated ring systems, or they can contain one or more double bonds.
[0550] The ligand can be connected to the polynucleotide by a carrier. The carrier comprises (i) at least one "main chain connection point", preferably two "backbone connection points" and (ii) at least one "tether connection point". As used herein, "main chain connection point" refers to a functional group, such as a hydroxyl group, or is generally available for and suitable for incorporating the carrier into the key in the main chain, such as the phosphate ester of ribonucleic acid or the modified phosphate ester (e.g., sulfur-containing) main chain. In some embodiments, "tether connection point" (TAP) refers to the composition ring atoms of the cyclic carrier connecting the selected part, such as a carbon atom or a heteroatom (different from the atom providing the main chain connection point). The part can be, for example, a carbohydrate, such as a monosaccharide, a disaccharide, a trisaccharide, a tetrasaccharide, an oligosaccharide and a polysaccharide. Optionally, the selected part is connected to the cyclic carrier by an intermediate tether. Therefore, the cyclic carrier generally comprises a functional group, such as an amino group, or generally provides a key suitable for incorporating or tethering another chemical entity (e.g., the ligand forming the ring).
[0551] The RNAi agent can be conjugated to the ligand through a carrier, wherein the carrier can be a cyclic group or an acyclic group; preferably, the cyclic group is selected from pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, [1,3] dioxolane, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinone, tetrahydrofuranyl and decahydronaphthyl; preferably, the acyclic group is selected from a serinol backbone or a diethanolamine backbone.
[0552] In certain specific embodiments, the RNAi agent used in the methods of the present disclosure is an agent selected from the group of agents listed in any one of Tables 2-5, 7 or 8. These agents may further include a ligand.
[0553] IV. iRNA conjugated to ligand
[0554] Another modification of the RNA of the disclosed iRNAs involves chemically linking to the iRNA one or more ligands, moieties, or conjugates that enhance the activity, cellular distribution, or cellular uptake (e.g., into cells) of the iRNA. Such moieties include, but are not limited to, lipid moieties, such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acid. Sci. USA, 1989, 86:6553-6556), cholic acid (Manoharan et al., Biorg. Med. Chem. Let., 1994, 4:1053-1060), thioethers, for example, hexyl (beryl)-S-tritylthiol (Manoharan et al., Ann. NY Acad. Sci., 1992, 660:306-309; Manoharan et al., Biorg. Med. Chem. Let., 1993, 3:2765-2770), thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20:533-538), an aliphatic chain, for example, dodecanediol or an undecyl residue (Saison-Behmoaras et al., EMBO J, 1991, 10: 1111-1118; Kabanov et al., FEBS Lett., 1990, 259: 327-330; Svinarchuk et al., Biochimie, 1993, 75: 49-54), phospholipids, for example di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycerol-3-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36: 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18: 3777-3783), polyamines or polyethylene glycol chains (Manoharan et al., Nucleosides & Nucleotides, 1995, 14: 969-973) or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36:3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264:229-237), or an octadecylamine or hexylamino-carbonyloxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277:923-937).
[0555] In certain embodiments, the ligand changes the distribution, targeting or lifespan of the iRNA agent into which it is incorporated. In some embodiments, for example, the ligand provides enhanced affinity for a selected target (e.g., a molecule, a cell or a cell type), a compartment (e.g., a cell or an organ compartment, a tissue, an organ or a body region) compared to a species in which such a ligand is not present. Typical ligands do not participate in duplex pairing in duplexed nucleic acids.
[0556] The ligand can include naturally occurring substances such as proteins (e.g., human serum albumin (HSA), low-density lipoprotein (LDL) or globulins); carbohydrates (e.g., dextran, pullulan, chitin, chitosan, inulin, cyclodextrin or hyaluronic acid); or lipids. The ligand can also be a recombinant or synthetic molecule, such as a synthetic polymer, for example a synthetic polyamino acid. Examples of polyamino acids include polylysine (PLL), poly-L-aspartic acid, poly-L-glutamic acid, styrene-maleic anhydride copolymer, poly-(L-lactide-co-glycolide) copolymer, divinyl ether-maleic anhydride copolymer, N-(2-hydroxypropyl) methacrylamide copolymer (HMPA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane, poly-(2-ethylacrylic acid), N-isopropylacrylamide polymer or polyphosphazene. Examples of polyamines include polyethyleneimine, polylysine (PLL), spermine, spermidine, polyamines, pseudopeptide-polyamines, peptidomimetic polyamines, dendrimer polyamines, arginine, amidine, protamine, cationic lipids, cationic porphyrins, quaternary salts of polyamines, or alpha helical peptides.
[0557] The part can also include a targeting group, such as a cell or tissue targeting agent, such as a lectin, a glycoprotein, a lipid or a protein (e.g., an antibody), which is combined with a specified cell type (e.g., a nephrocyte). The targeting group can be thyrotropin, melanocyte stimulating hormone, a lectin, a glycoprotein, a surfactant protein A, a mucin sugar, a multivalent lactose, a multivalent galactose, N-acetyl-galactosamine, N-acetyl-glucosamine multivalent mannose, a multivalent fucose, a glycosylated polyamino acid, a multivalent galactose, transferrin, a bisphosphonate, polyglutamic acid, polyaspartic acid, a lipid, cholesterol, a steroid, bile acid, folic acid, vitamin B12, biotin or an RGD peptide or an RGD peptide mimetic. In certain embodiments, the part is a multivalent galactose, such as N-acetyl-galactosamine.
[0558] Other examples of ligands include dyes, intercalators (e.g., acridine), crosslinkers (e.g., psoralen, mitomycin C), porphyrins (TPPC4, texaphyrin, Sapphyrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine), artificial endonucleases (e.g., EDTA), lipophilic molecules (e.g., cholesterol, cholic acid, adamantaneacetic acid, 1-pyrenebutyric acid, dihydrotestosterone, 1,3-bis-O (hexadecyl) glycerol, geranyloxyhexyl, hexadecyl glycerol, borneol, menthol, 1,3-propanediol, heptadecyl, palmitic acid, myristic acid, O3-(oleoyl) lithocholic acid, O3-(oleoyl) cholenoic acid, dimethoxytrityl or phenoxazine, and peptide conjugates (e.g., tentacles, Tat peptides), alkylating agents, phosphates, amino groups, sulfhydryl groups, PEG (e.g., PEG-40K), MPEG, [MPEG] 2 , polyamino, alkyl, substituted alkyl, radiolabeled markers, enzymes, haptens (e.g., biotin), transport / absorption enhancers (e.g., aspirin, vitamin E, folic acid), synthetic ribonucleases (e.g., imidazole, bisimidazole, histamine, imidazole clusters, acridine-imidazole conjugates, Eu3+ complexes of tetraazamacrocyclic compounds), dinitrophenyl, HRP or AP.
[0559] The ligand can be a protein (e.g., a glycoprotein) or a peptide (e.g., a molecule with a specific affinity for a co-ligand) or an antibody (e.g., an antibody that binds to a specific cell type such as a cancer cell, an endothelial cell, or a bone cell). The ligand can also include hormones and hormone receptors. The ligand can also include non-peptide substances such as lipids, lectins, carbohydrates, vitamins, cofactors, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-glucosamine multivalent mannose or multivalent fucose. The ligand can be, for example, a lipopolysaccharide, an activator of p38 MAP kinase, or an activator of NF-κB.
[0560] The ligand can be a substance, such as a drug, that can increase the uptake of the iRNA agent into the cell, for example, by disrupting the cytoskeleton of the cell, for example, by disrupting the microtubules, microfilaments or intermediate filaments of the cell. The drug can be, for example, paclitaxel (taxon), vincristine, vinblastine, cytochalasin, nocodazole, japlakinolide, latrunculin A, phalloidin, swinholide A, indanocine or myoservin.
[0561] In some embodiments, the ligand connected to the iRNA as described herein is used as a pharmacokinetic regulator (PK regulator). PK regulators include lipophiles, bile acids, steroids, phospholipid analogs, peptides, protein binders, PEG, vitamins, etc. Exemplary PK regulators include, but are not limited to, cholesterol, fatty acids, cholic acid, lithocholic acid, dialkyl glycerides, diacylglycerides, phospholipids, sphingolipids, naproxen, ibuprofen, vitamin E, biotin. It is also known that oligonucleotides comprising multiple thiophosphate bonds are combined with serum proteins, so short oligonucleotides (e.g., oligonucleotides with about 5 bases, 10 bases, 15 bases or 20 bases) comprising multiple thiophosphate bonds in the main chain are also suitable for the present disclosure as ligands (e.g., as PK regulating ligands). In addition, the aptamer in conjunction with serum components (e.g., serum proteins) is also suitable for use as the PK regulating ligand in the embodiments described herein.
[0562] The ligand-conjugated iRNAs of the present disclosure can be synthesized by using oligonucleotides carrying side reactive functional groups, such as oligonucleotides derived from linker molecules attached to the oligonucleotides (as described below). Such reactive oligonucleotides can react directly with commercially available ligands, synthetic ligands with any of a variety of protecting groups, or ligands having linker moieties attached thereto.
[0563] The oligonucleotides used in the conjugates of the present disclosure can be conveniently and routinely prepared by well-known solid phase synthesis techniques. Equipment for such synthesis is sold by several suppliers, including, for example, Applied (Foster City, Calif.). Any other means known in the art for such synthesis may additionally or alternatively be employed. It is also known to use similar techniques to prepare other oligonucleotides (such as phosphorothioate and alkylated derivatives).
[0564] In the ligand-conjugated oligonucleotides and ligand-molecules with sequence-specifically linked nucleosides of the present disclosure, the oligonucleotides and oligonucleosides can be assembled on a suitable DNA synthesizer using standard nucleotide or nucleoside precursors or nucleotide or nucleoside conjugate precursors that already carry a linking portion, ligand-nucleotide or nucleoside conjugate precursors that already carry a ligand molecule, or building blocks with non-nucleoside ligands.
[0565] When using a nucleotide conjugate precursor that already carries a linking moiety, the synthesis of sequence-specific linked nucleosides is generally completed, and then the ligand molecule reacts with the linking moiety to form a ligand-conjugated oligonucleotide. In some embodiments, the oligonucleotides or linked nucleosides of the present disclosure are synthesized by an automated synthesizer using phosphoramidites derived from ligand-nucleoside conjugates and standard phosphoramidites and non-standard phosphoramidites that are commercially available and routinely used for oligonucleotide synthesis.
[0566] A. Lipid Conjugates
[0567] In certain embodiments, the ligand or conjugate is a lipid or lipid-based molecule. Such lipids or lipid-based molecules can generally bind to serum proteins, such as human serum albumin (HSA). HSA binding ligands allow the conjugate to be distributed to target tissues, such as non-renal target tissues of the body. For example, the target tissue can be the liver, including parenchymal cells of the liver. Other molecules that can bind to HSA can also be used as ligands. For example, naproxen or aspirin can be used. Lipids or lipid-based ligands can (a) increase resistance to degradation of the conjugate, (b) increase targeting or transport to target cells or cell membranes, or (c) can be used to regulate binding to serum proteins, such as HSA.
[0568] Lipid-based ligands can be used to modulate, e.g., control (e.g., inhibit) the binding of a conjugate to a target tissue. For example, a lipid or lipid-based ligand that binds HSA more strongly is less likely to be targeted to the kidneys and, therefore, less likely to be cleared from the body. A lipid or lipid-based ligand that binds HSA less strongly can be used to target the conjugate to the kidneys.
[0569] In certain embodiments, the lipid-based ligand binds to HSA. For example, the ligand may bind to HSA with sufficient affinity so as to enhance the distribution of the conjugate in non-renal tissues. However, the affinity is generally not so strong that HSA ligand binding cannot be reversed.
[0570] In certain embodiments, the lipid-based ligand binds weakly or not at all to HSA, resulting in enhanced distribution of the conjugate in the kidney.Other moieties that target renal cells may also be used in place of or in addition to the lipid-based ligand.
[0571] On the other hand, the ligand is a moiety that is taken up by the target cell (e.g., a proliferating cell), such as a vitamin. These are particularly useful for treating diseases characterized by undesirable cell proliferation, such as malignant or non-malignant types, such as cancer cells. Exemplary vitamins include vitamins A, E, and K. Other exemplary vitamins included are B vitamins, such as folic acid, B12, riboflavin, biotin, pyridoxal, or other vitamins or nutrients taken up by cancer cells. HSA and low-density lipoprotein (LDL) are also included.
[0572] B. Cell Permeabilization Agents
[0573] On the other hand, the ligand is a cell permeating agent, such as a helical cell permeating agent. In certain embodiments, the agent is amphipathic. Exemplary agents are peptides, such as tat or tentacles. If the agent is a peptide, it can be modified, including peptidyl mimetics, invertomers, non-peptide or pseudopeptide connections and the use of D-amino acids. Helical agents are typically alpha-helical agents and can have lipophilic and lipophobic phases.
[0574] The ligand can be a peptide or a peptide mimetic. Peptide mimics (also referred to herein as oligopeptide mimics) are molecules that can be folded into a defined three-dimensional structure similar to a natural peptide. The connection of peptides and peptide mimics to iRNA agents may affect the pharmacokinetic distribution of iRNA, such as by enhancing cell recognition and absorption. The length of the peptide or peptide mimetic part can be about 5-50 amino acids long, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 amino acids long.
[0575] The peptide or peptide mimetic can be, for example, a cell permeable peptide, a cationic peptide, an amphipathic peptide or a hydrophobic peptide (e.g., mainly composed of Tyr, Trp or Phe). The peptide portion can be a dendrimer peptide, a constrained peptide or a cross-linked peptide. In another alternative, the peptide portion can include a hydrophobic membrane translocation sequence (MTS). An exemplary hydrophobic MTS-containing peptide is RFGF with an amino acid sequence of AAVALLPAVLLALLAP (SEQ ID NO: 14). An RFGF analog containing a hydrophobic MTS (e.g., an amino acid sequence of AALLPVLLAAP (SEQ ID NO: 15)) can also be a targeting portion. The peptide portion can be a "delivery" peptide that can carry large polar molecules across cell membranes including peptides, oligonucleotides and proteins. For example, sequences from HIV Tat protein (GRKKRRQRRRPPQ (SEQ ID NO: 16)) and Drosophila antenna foot protein (RQIKIWFQNRRMKWKK (SEQ ID NO: 17)) have been found to be able to act as delivery peptides. The peptide or peptide mimetic can be encoded by a random sequence of DNA, such as a peptide identified from a phage display library or a one-bead-one-compound (OBOC) combinatorial library (Lam et al., Nature, 354:82-84, 1991). Typically, the peptide or peptide mimetic tethered to the dsRNA agent by the incorporated monomer unit is a cell targeting peptide, such as an arginine-glycine-aspartic acid (RGD)-peptide or RGD mimetic. The length of the peptide portion can range from about 5 amino acids to about 40 amino acids. The peptide portion can have structural modifications, such as improving stability or guiding conformational properties. Any structural modification described below can be used.
[0576] The RGD peptides used in the compositions and methods of the present disclosure can be linear or cyclic and can be modified, such as glycosylated or methylated, to facilitate targeting to specific tissues. RGD-containing peptides and peptide mimetics can contain D-amino acids as well as synthetic RGD mimetics. In addition to RGD, other moieties that target integrin ligands can also be used. Preferred conjugates of this ligand target PECAM-1 or VEGF.
[0577] The RGD peptide portion can be used to target specific cell types, such as tumor cells, such as endothelial tumor cells or breast cancer tumor cells (Zitzmann et al., Cancer Res., 62:5139-43, 2002). The RGD peptide can promote the targeting of dsRNA agents to tumors of various other tissues, including the lungs, kidneys, spleen, or liver (Aoki et al., Cancer Gene Therapy 8:783-787, 2001). Typically, the RGD peptide promotes the targeting of iRNA agents to the kidney. The RGD peptide can be linear or cyclic and can be modified, such as glycosylated or methylated, to facilitate targeting to specific tissues. For example, a glycosylated RGD peptide can deliver an iRNA agent to a cell expressing α V β 3 of tumor cells (Haubner et al., Jour. Nucl. Med., 42:326-336, 2001).
[0578] "Cell penetrating peptides" can penetrate cells, such as microbial cells (such as bacteria or fungal cells) or mammalian cells (such as human cells). Microbial cell penetrating peptides can be, for example, α-helical linear peptides (e.g., LL-37 or Ceropin P1), disulfide bond-containing peptides (e.g., α-defensins, β-defensins or bovine antimicrobial peptides (bactenecin)) or peptides containing only one or two major amino acids (e.g., PR-39 or indolicidin). Cell penetrating peptides can also include a nuclear localization signal (NLS). For example, a cell penetrating peptide can be a dichotomous amphipathic peptide, such as MPG, which is derived from the fusion peptide domain of HIV-1gp41 and the NLS of the large T antigen of SV40 (Simeoni et al., Nucl.Acids Res.31:2717-2724, 2003).
[0579] C. Carbohydrate Conjugates
[0580] In some embodiments of the compositions and methods of the present disclosure, the iRNA further comprises a carbohydrate. Carbohydrate-conjugated iRNA is advantageous for the in vivo delivery of nucleic acids and compositions suitable for in vivo therapeutic use as described herein. As used herein, "carbohydrate" refers to a carbohydrate (which may be linear, branched or cyclic) (with oxygen, nitrogen or sulfur atoms bonded to each carbon atom) that is itself composed of one or more monosaccharide units with at least 6 carbon atoms; or a compound having a carbohydrate moiety (which may be linear, branched or cyclic) (with oxygen, nitrogen or sulfur atoms bonded to each carbon atom) composed of one or more monosaccharide units with at least six carbon atoms as a part thereof. Representative carbohydrates include sugars (monosaccharides, disaccharides, trisaccharides and oligosaccharides containing about 4, 5, 6, 7, 8 or 9 monosaccharide units) and polysaccharides such as starch, glycogen, cellulose and polysaccharide gum. Specific monosaccharides include sugars of C5 and above (eg, C5, C6, C7, or C8); disaccharides and trisaccharides include sugars having two or three monosaccharide units (eg, C5, C6, C7, or C8).
[0581] In certain embodiments, the carbohydrate conjugate includes a monosaccharide.
[0582] In certain embodiments, the monosaccharide is N-acetylgalactosamine (GalNAc). GalNAc conjugates including one or more N-acetylgalactosamine (GalNAc) derivatives are described in, for example, US 8,106,022, the entire contents of which are hereby incorporated by reference herein. In some embodiments, the GalNAc conjugate is used as a ligand for targeting iRNA to specific cells. In some embodiments, the GalNAc conjugate targets iRNA to hepatocytes, for example, by acting as a ligand for the asialoglycoprotein receptor of liver cells (e.g., hepatocytes).
[0583] In some embodiments, the carbohydrate conjugate comprises one or more GalNAc derivatives. The GalNAc derivatives can be connected by a joint, such as a divalent or trivalent branched joint. In some embodiments, the GalNAc conjugate is conjugated to the 3' end of the sense strand. In some embodiments, the GalNAc conjugate is conjugated to the iRNA agent by a joint, such as a joint described herein (e.g., to the 3' end of the sense strand). In some embodiments, the GalNAc conjugate is conjugated to the 5' end of the sense strand. In some embodiments, the GalNAc conjugate is conjugated to the iRNA agent by a joint, such as a joint described herein (e.g., to the 5' end of the sense strand).
[0584] In certain embodiments of the present disclosure, GalNAc or a GalNAc derivative is connected to an iRNA agent of the present invention via a monovalent linker. In some embodiments, GalNAc or a GalNAc derivative is connected to an iRNA agent of the present disclosure via a divalent linker. Also in other embodiments of the present disclosure, GalNAc or a GalNAc derivative is connected to an iRNA agent of the present disclosure via a trivalent linker. In other embodiments of the present disclosure, GalNAc or a GalNAc derivative is connected to an iRNA agent of the present disclosure via a tetravalent linker.
[0585] In certain embodiments, the double-stranded RNAi agent of the present disclosure comprises a GalNAc or GalNAc derivative connected to an iRNA agent. In certain embodiments, the double-stranded RNAi agent of the present disclosure comprises a plurality of (e.g., 2, 3, 4, 5 or 6) GalNAc or GalNAc derivatives, each of which is independently connected to a plurality of nucleotides of the double-stranded RNAi agent through a plurality of monovalent linkers.
[0586] In some embodiments, for example, when the two strands of the iRNA agent of the present disclosure are connected by an uninterrupted nucleotide chain between the 3' end of one strand and the 5' end of the corresponding other strand to form a hairpin loop containing multiple unpaired nucleotides, each unpaired nucleotide within the hairpin loop can independently contain GalNAc or a GalNAc derivative connected by a monovalent linker. The hairpin loop can also be formed by an extended overhang in one strand of the duplex.
[0587] In some embodiments, for example, when the two strands of the iRNA agent of the present disclosure are connected by an uninterrupted nucleotide chain between the 3' end of one strand and the 5' end of the corresponding other strand to form a hairpin loop containing multiple unpaired nucleotides, each unpaired nucleotide within the hairpin loop can independently contain GalNAc or a GalNAc derivative connected by a monovalent linker. The hairpin loop can also be formed by an extended overhang in one strand of the duplex.
[0588] In some embodiments, the GalNAc conjugate is
[0589]
[0590] In some embodiments, the RNAi agent is linked to the carbohydrate conjugate via a linker, as schematically shown in the following formula, wherein X is O or S.
[0591]
[0592] In some embodiments, the RNAi agent is conjugated to L96 as defined in Table 2, and as follows:
[0593]
[0594] In certain embodiments, the carbohydrate conjugates used in the compositions and methods of the present disclosure are selected from:
[0595]
[0596]
[0597]
[0598]
[0599]
[0600]
[0601] wherein Y is O or S, and n is 3 to 6 (Formula XXIV);
[0602] wherein Y is O or S, and n is 3 to 6 (Formula XXV);
[0603]
[0604] wherein X is O or S (Formula XXVII);
[0605]
[0606]
[0607] as well as
[0608]
[0609] In certain embodiments, the carbohydrate conjugate used in the compositions and methods of the present disclosure is a monosaccharide. In certain embodiments, the monosaccharide is N-acetylgalactosamine, such as
[0610]
[0611] Another representative carbohydrate conjugate for use in the embodiments described herein includes, but is not limited to:
[0612]
[0613] When one of X or Y is an oligonucleotide, the other is hydrogen.
[0614] In some embodiments, suitable ligands are those disclosed in WO 2019 / 055633, the entire contents of which are incorporated herein by reference. In one embodiment, the ligand comprises the following structure:
[0615]
[0616] In certain embodiments, the RNAi agents of the present disclosure may comprise a GalNAc ligand, even though such GalNAc ligands are presently expected to be of limited value for the preferred intrathecal / CNS delivery routes of the present disclosure.
[0617] In certain embodiments of the present disclosure, GalNAc or a GalNAc derivative is connected to an iRNA agent of the present disclosure via a monovalent linker. In some embodiments, GalNAc or a GalNAc derivative is connected to an iRNA agent of the present disclosure via a divalent linker. In yet other embodiments of the present disclosure, GalNAc or a GalNAc derivative is connected to an iRNA agent of the present disclosure via a trivalent linker.
[0618] In one embodiment, the double-stranded RNAi agent of the present disclosure comprises one or more GalNAc or GalNAc derivatives connected to the iRNA agent. GalNAc can be connected to any nucleotide through a joint on the sense strand or the antisense strand. GalNac can be connected to the 5' end of the sense strand, the 3' end of the sense strand, the 5' end of the antisense strand, or the 3' end of the antisense strand. In one embodiment, GalNAc is connected to the 3' end of the sense strand, for example, through a trivalent joint.
[0619] In other embodiments, the double-stranded RNAi agent of the present disclosure comprises multiple (e.g., 2, 3, 4, 5 or 6) GalNAc or GalNAc derivatives, each of which is independently linked to multiple nucleotides of the double-stranded RNAi agent through multiple linkers (e.g., monovalent linkers).
[0620] In some embodiments, for example, when the two strands of the iRNA agent of the present disclosure are part of a larger molecule connected by an uninterrupted chain of nucleotides between the 3' end of one strand and the corresponding 5' end of the other strand to form a hairpin loop comprising a plurality of unpaired nucleotides, each unpaired nucleotide within the hairpin loop can independently comprise GalNAc or a GalNAc derivative connected by a monovalent linker.
[0621] In some embodiments, the carbohydrate conjugate further comprises one or more additional ligands as described above, such as, but not limited to, a PK modifier or a cell penetrating peptide.
[0622] Additional carbohydrate conjugates and linkers suitable for use in the present disclosure include those described in WO 2014 / 179620 and WO 2014 / 179627, the entire contents of each of which are incorporated herein by reference.
[0623] D.Connector
[0624] In some embodiments, the conjugates or ligands described herein can be linked to an iRNA oligonucleotide using a variety of linkers that may be cleavable or non-cleavable.
[0625] The term "linker" or "linking group" means an organic moiety that connects two parts of a compound, for example, covalently connects two parts of a compound. Linkers generally include direct bonds or atoms such as oxygen or sulfur; units such as NR8, C(O), C(O)NH, SO, SO 2 、SO 2 NH or a chain of atoms such as, but not limited to, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aralkyl, aralkenyl, aralkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocycloalkyl, heterocycloalkenyl, heterocycloalkynyl, aryl, heteroaryl, heterocyclo, cycloalkyl, cycloalkenyl, alkylaralkyl, alkylaralkenyl, alkylaralkynyl, alkenylaralkyl, alkenylaralkenyl, alkenylaralkynyl, alkynylaralkyl, alkynylaralkenyl, alkynylaralkynyl, alkylheteroarylalkyl, alkylheteroarylalkenyl, alkylheteroaryl alkynyl, alkenylheteroarylalkyl, alkenylheteroarylalkenyl, alkenylheteroarylalkynyl, alkynylheteroarylalkyl, alkynylheteroarylalkenyl, alkynylheteroarylalkynyl, alkylheterocycloalkyl, alkylheterocyclylalkenyl, alkylheterocyclylalkynyl, alkenylheterocyclylalkyl, alkenylheterocyclylalkenyl, alkenylheterocyclylalkynyl, alkynylheterocyclylalkyl, alkynylheterocyclylalkenyl, alkynylheterocyclylalkynyl, alkylaryl, alkenylaryl, alkynylaryl, alkylheteroaryl, alkenylheteroaryl, alkynylheteroaryl, the one or more methylene groups may be interrupted or terminated by O, S, S(O), SO 2 , N(R8), C(O), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl; wherein R8 is hydrogen, acyl, aliphatic or substituted aliphatic. In certain embodiments, the linker is between about 1-24 atoms, 2-24, 3-24, 4-24, 5-24, 6-24, 6-18, 7-18, 8-18 atoms, 7-17, 8-17, 6-16, 7-16 or 8-16 atoms.
[0626] A cleavable linking group is a linking group that is sufficiently stable outside of a cell, but which is cleaved after entering a target cell to release the two parts of the linker that hold it together. In a preferred embodiment, the cleavage of the cleavable linking group in a target cell or under a first reference condition (which can, for example, be selected to simulate or represent intracellular conditions) is at least about 10 times, 20 times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times or more, or at least about 100 times faster than the cleavage rate in a subject's blood or under a second reference condition (which can, for example, be selected to simulate or represent conditions found in blood or serum).
[0627] Cleavable linking groups are susceptible to cleavage agents (e.g., pH, redox potential, or the presence of degradation molecules). In general, cleavage agents are more common inside cells than in serum or blood, or are found at higher levels or activities. Examples of such degradation agents include: redox agents selected for specific substrates or without substrate specificity, including, for example, oxidative or reductases or reductants present in cells, such as thiols, which can degrade redox cleavable linking groups by reduction; esterases; endosomes or agents that can produce an acidic environment, for example, those that produce a pH of five or less; enzymes, peptidases (which can be substrate-specific) and phosphatases that can hydrolyze or degrade acid cleavable linking groups by acting as generalized acids.
[0628] Cleavable bond groups, such as disulfide bonds, may be sensitive to pH. The pH of human serum is 7.4, while the average intracellular pH is slightly lower, ranging from about 7.1-7.3. Endosomes have a more acidic pH, ranging from 5.5-6.0, and lysosomes have an even more acidic pH, at about 5.0. Some linkers have a cleavable linking group that is cleaved at a preferred pH, thereby releasing the cationic lipid from the ligand inside the cell, or into a desired compartment of the cell.
[0629] The linker can comprise a cleavable linking group that can be cleaved by a specific enzyme. The type of cleavable linking group incorporated into the linker can depend on the cell to be targeted. For example, a liver targeting ligand can be connected to a cationic lipid via a linker comprising an ester group. Hepatocytes are rich in esterases, and thus the linker is more efficiently cleaved in hepatocytes than in cell types that are not rich in esterases. Other cell types that are rich in esterases include cells of the lung, renal cortex, and testis.
[0630] When targeting cell types rich in peptidases, such as hepatocytes and synoviocytes, linkers containing peptide bonds can be used.
[0631] In general, the suitability of a candidate cleavable linking group can be evaluated by testing the ability of a degradation agent (or condition) to cut a candidate linking group. It is also desirable to test the ability of a candidate cleavable linking group to resist cutting in blood or when contacting other non-target tissues. Therefore, the relative susceptibility to cutting can be determined between the first condition and the second condition, wherein the first condition is selected to indicate the cutting in the target cell, and the second condition is selected to indicate the cutting in other tissues or biofluids, such as blood or serum. Evaluation can be carried out in a cell-free system, in a cell, in a cell culture, in an organ or tissue culture, or in a whole animal. It may be useful to perform an initial evaluation under cell-free or culture conditions and to confirm by further evaluating in a whole animal. In preferred embodiments, useful candidate compounds are cleaved at least about 2-fold, 4-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, or about 100-fold faster in cells (or under in vitro conditions selected to mimic conditions within a cell) than in blood or serum (or under in vitro conditions selected to mimic conditions outside a cell).
[0632] i. Redox-cleavable linker
[0633] In certain embodiments, the cleavable linking group is a redox cleavable linking group that is cleaved when reduced or oxidized. The example of a reducible cleavable linking group is a disulfide linking group (-SS-). In order to determine whether a candidate cleavable linking group is a suitable "reducible cleavable linking group", or whether it is suitable for use with a specific iRNA portion and a specific targeting agent, the method described herein can be referred to. For example, a candidate can be evaluated by incubating with dithiothreitol (DTT) or other reducing agents using reagents known in the art, which simulates the cleavage rate observed in cells (e.g., target cells). Candidates can also be evaluated under conditions selected to simulate blood or serum conditions. In one embodiment, the candidate compound is cut up to about 10% in blood. In other embodiments, useful candidate compounds are degraded in cells (or under in vitro conditions selected to simulate intracellular conditions) at least about 2 times, 4 times, 10 times, 20 times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, or about 100 times faster than they are cleaved in blood (or under in vitro conditions selected to simulate extracellular conditions). The cleavage rate of a candidate compound can be determined using standard enzyme kinetic assays under conditions selected to simulate intracellular media and compared to conditions selected to simulate extracellular media.
[0634] ii. Phosphate-based cleavable linking groups
[0635] In certain embodiments, the cleavable linker includes a cleavable linking group based on a phosphate. The cleavable linking group based on a phosphate is cleaved by an agent that degrades or hydrolyzes the phosphate group. Examples of agents that cleave phosphate groups in cells are enzymes in cells, such as phosphatases. Examples of phosphate-based linking groups are -OP(O)(ORk)-O-, -OP(S)(ORk)-O-, -OP(S)(SRk)-O-, -SP(O)(ORk)-O-, -OP(O)(ORk)-S-, -SP(O)(ORk)-S-, -OP(S)(ORk)-S-, -SP(S)(ORk)-O-, -OP(O)(Rk)-O-, -OP(S)(Rk)-O-, -SP(O)(Rk)-O-, -SP(S)(Rk)-O-, -SP(O)(Rk)-O-, -SP(S)(Rk)-O-, -SP(O)(Rk)-S-, -OP(S)(Rk)-S-. Preferred embodiments are -OP(O)(OH)-O-, -OP(S)(OH)-O-, -OP(S)(SH)-O-, -SP(O)(OH)-O-, -OP(O)(OH)-S-, -SP(O)(OH)-S-, -OP(S)(OH)-S-, -SP(S)(OH)-O-, -OP(O)(H)-O-, -OP(S)(H)-O-, -SP(O)(H)-O, -SP(S)(H)-O-, -SP(O)(H)-S-, -OP(S)(H)-S-. Preferred embodiments are -OP(O)(OH)-O-. Methods similar to those described above can be used to evaluate these candidates.
[0636] iii. Acid cleavable linking group
[0637] In certain embodiments, the cleavable linker includes an acid cleavable linking group. An acid cleavable linking group is a linking group that is cleaved under acidic conditions. In a preferred embodiment, the acid cleavable linking group is cleaved in an acidic environment of about 6.5 or lower (e.g., about 6.0, 5.75, 5.5, 5.25, 5.0 or lower) or by a reagent (such as an enzyme) that can act as a general acid. In cells, specific low pH organelles such as endosomes and lysosomes can provide a cleavage environment for acid cleavable linking groups. Examples of acid cleavable linking groups include, but are not limited to, hydrazones, esters, and amino acid esters. The acid cleavable group can have the general formula -C=NN-, C(O)O or -OC(O). A preferred embodiment is the case where the carbon (alkoxy) connected to the oxygen of the ester is an aryl, substituted alkyl or tertiary alkyl such as dimethylpentyl or tert-butyl. These candidates can be evaluated using methods similar to those described above.
[0638] iv. Ester-based cleavable linking groups
[0639] In certain embodiments, the cleavable linker includes an ester-based cleavable linking group. The ester-based cleavable linking group is cleaved by enzymes such as esterases and amidases in the cell. Examples of ester-based cleavable linking groups include, but are not limited to, esters of alkylene, alkenylene, and alkynylene. The ester-cleavable linking group has the gener...
Claims
1. A double-stranded ribonucleic acid (dsRNA) agent for inhibiting the expression of 4R-Tau, wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double-stranded region, wherein the sense strand comprises at least 15 consecutive nucleotides that differ by no more than 3 nucleotides from the nucleotide sequence of nucleotides 1009-1053 of SEQ ID NO:3, and the antisense strand comprises at least 15 consecutive nucleotides that differ by no more than 3 nucleotides from the nucleotide sequence of nucleotides 1007-1053 of SEQ ID NO:
4.
2. The dsRNA agent of claim 1, wherein the sense strand comprises at least 15 consecutive nucleotides of nucleotides 1009-1053 of SEQ ID NO: 3, and the antisense strand comprises at least 15 consecutive nucleotides of nucleotides 1007-1053 of SEQ ID NO:
4.
3. A double-stranded ribonucleic acid (dsRNA) agent for inhibiting the expression of 4R-Tau, wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double-stranded region, wherein the antisense strand comprises a region of complementarity to an mRNA encoding 4R-Tau, and wherein the region of complementarity comprises at least 15 consecutive nucleotides that differ by no more than 3 nucleotides from the nucleotide sequence of nucleotides 1007-1053 of SEQ ID NO:
4.
4. The dsRNA agent of claim 3, wherein the complementary region comprises at least 15 consecutive nucleotides of nucleotides 1007-1053 of SEQ ID NO:
4.
5. The dsRNA agent of claim 4, wherein the complementary region exists entirely within nucleotides 1007-1053 of SEQ ID NO:
4.
6. A double-stranded ribonucleic acid (dsRNA) agent for inhibiting the expression of 4R-Tau, wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double-stranded region, The antisense strand comprises a region complementary to an mRNA encoding 4R-Tau, and the complementary region comprises at least 15 consecutive nucleotides that differ by no more than 3 nucleotides from any antisense nucleotide sequence in Table 7 or 8.
7. The dsRNA agent of claim 6, wherein the nucleotide sequences of the sense and antisense strands comprise any sense and antisense strand nucleotide sequences of any duplex in Table 7 or 8.
8. The dsRNA agent of any one of claims 1-7, wherein the sense strand comprises at least 15 consecutive nucleotides that differ by no more than three nucleotides from any one of the nucleotide sequences of nucleotides 1009-1029, 1016-1036, 1018-1038, 1020-1040, 1021-1041, 1022-1042, 1024-1044, 1027-1047, 1028-1048, 1029-1049, 1030-1050, 1032-1052, 1033-1053, 1014-1048, and 1022-1048 of SEQ ID NO: 3, and the antisense strand comprises at least 15 consecutive nucleotides of the corresponding nucleotide sequence of SEQ ID NO:
4.
9. The dsRNA agent of any one of claims 1-7, wherein the antisense strand comprises at least 15 consecutive nucleotides that differ by no more than three nucleotides from any antisense strand nucleotide sequence of a duplex selected from the group consisting of: (a) AD-2204877, AD-1597146, AD-2204883, AD-2204885, AD-2204886, AD-1597147, AD-1597148, AD-2126092, AD-2126093, AD-220 4890, AD-2204891, AD-1597149 and AD-2204893; or (b) AD-1423276, AD-1423283, AD-1423285, AD-1423287, AD-142 3288, AD-1423289, AD-1423291, AD-1423294, AD-1423295, AD-1423296, AD-1423297, AD-1423299 and AD-1423300.
10. The dsRNA agent of claim 9, wherein the antisense strand comprises at least 15 consecutive nucleotides that differ by no more than three nucleotides from any antisense strand nucleotide sequence of a duplex selected from: (a) AD-1597146, AD-1597148, AD-2126092, and AD-2126093; or (b) AD-1423283, AD-1423291, AD-1423294, and AD-1423295.
11. The dsRNA agent of claim 9, wherein the antisense strand comprises at least 15 consecutive nucleotides that differ by no more than three nucleotides from any antisense strand nucleotide sequence of a duplex selected from: (a) AD-1597146, AD-1597148, and AD-2126092; or (b) AD-1423283, AD-1423291, and AD-1423294.
12. The dsRNA agent of any one of claims 1-7, wherein the dsRNA agent is capable of reducing 4R-tau isoform mRNA expression by at least about 50%, 55%, 60%, 65%, 70%, or 75% in cells expressing both 3R-tau and 4R-tau isoforms, while reducing 3R-tau isoform mRNA expression by no more than about 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5%.
13. The dsRNA agent of any one of claims 1-7, wherein the dsRNA agent is capable of reducing 4R-tau isoform mRNA expression by at least about 70% while reducing 3R-tau isoform mRNA expression by no more than about 30% in cells expressing both 3R-tau and 4R-tau isoforms.
14. The dsRNA agent of any one of claims 1-13, wherein the sense strand, the antisense strand, or both the sense strand and the antisense strand are conjugated to one or more lipophilic moieties.
15. The dsRNA agent of claim 14, wherein the lipophilic moiety is conjugated to one or more internal positions in the double-stranded region of the dsRNA agent.
16. The dsRNA agent of claim 14 or 15, wherein the lipophilic moiety is conjugated via a linker or a carrier.
17. The dsRNA agent of any one of claims 14-16, wherein the lipophilicity of the lipophilic moiety is greater than 0 as measured by logKow.
18. The dsRNA agent of any one of claims 1-17, wherein the hydrophobicity of the double-stranded RNA agent as measured by the unbound fraction in a plasma protein binding assay of the double-stranded RNA agent exceeds 0.
2.
19. The dsRNA agent of claim 18, wherein the plasma protein binding assay is an electrophoretic mobility shift assay using human serum albumin.
20. The dsRNA agent according to any one of claims 1 to 19, wherein the dsRNA agent comprises at least one modified nucleotide.
21. The dsRNA agent of claim 20, wherein no more than 5 nucleotides of the sense strand and no more than 5 nucleotides of the antisense strand are unmodified nucleotides.
22. The dsRNA agent of claim 20, wherein all nucleotides of the sense strand and all nucleotides of the antisense strand are modified nucleotides.
23. The dsRNA agent of any one of claims 20-22, wherein at least one of the modified nucleotides is selected from the group consisting of deoxynucleotides, 3'-terminal deoxythymidine (dT) nucleotides, 2'-O-methyl modified nucleotides, 2'-deoxy-2'-fluoro modified nucleotides, 2'-deoxy modified nucleotides, locked nucleotides, unlocked nucleotides, 2'-5' linked nucleotides (3'-RNA), conformationally restricted nucleotides, constrained ethyl nucleotides, abasic nucleotides, 2'-amino modified nucleotides, 2'-O-allyl modified nucleotides, 2'-C-alkyl modified nucleotides, 2'-hydroxy modified nucleotides, 2'-methoxyethyl modified nucleotides, 2'-O-alkyl modified nucleotides, morpholino nucleotides, aminophosphoryl modified nucleotides, Acids, nucleotides containing non-natural bases, tetrahydropyran modified nucleotides, 1,5-anhydrohexitol modified nucleotides, cyclohexenyl modified nucleotides, nucleotides containing 5'-thiophosphate groups, nucleotides containing 5'-methylphosphonate groups, nucleotides containing 5' phosphate or 5' phosphate mimetics, nucleotides containing vinylphosphonate, nucleotides containing 5'-vinylphosphonate, glycol nucleic acids (GNA), glycol nucleic acid S-isomers (S-GNA), nucleotides containing 2-hydroxymethyl-tetrahydrofuran-5-phosphate, nucleotides containing 2'-deoxythymidine-3' phosphate, nucleotides containing 2'-deoxyguanosine-3'-phosphate, and terminal nucleotides connected to a cholesteryl derivative and a dodecanoic acid bisdecylamide group; and combinations thereof.
24. The dsRNA agent of claim 23, wherein the modified nucleotides are selected from 2'-deoxy-2'-fluoro modified nucleotides, 2'-deoxy modified nucleotides, 3'-terminal deoxythymidine nucleotides (dT), locked nucleotides, abasic nucleotides, 2'-amino modified nucleotides, 2'-alkyl modified nucleotides, morpholino nucleotides, phosphoramidates, and nucleotides containing non-natural bases.
25. The dsRNA agent of claim 23, wherein the modified nucleotides include a short sequence of 3'-terminal deoxythymidine nucleotides (dT).
26. The dsRNA agent of claim 23, wherein the modification on the nucleotide is selected from 2'-O-methyl modification, 2'-deoxy modification, GNA modification, and 2'-deoxy-2'-fluoro modification.
27. The dsRNA agent of any one of claims 1-26, further comprising at least one phosphorothioate internucleotide linkage.
28. The dsRNA agent of claim 27, wherein the dsRNA agent comprises 6-8 phosphorothioate internucleotide linkages.
29. The dsRNA agent of any one of claims 1-28, wherein each strand is no more than 30 nucleotides in length.
30. The dsRNA agent of any one of claims 1 to 29, wherein at least one strand comprises a 3' overhang of at least 1 nucleotide.
31. The dsRNA agent of any one of claims 1 to 30, wherein at least one strand comprises a 3' overhang of at least 2 nucleotides.
32. The dsRNA agent of any one of claims 1 to 31, wherein the double-stranded region is 15-30 nucleotide pairs in length.
33. The dsRNA agent of claim 32, wherein the double-stranded region is 17-23 nucleotide pairs in length.
34. The dsRNA agent of claim 32, wherein the double-stranded region is 17-25 nucleotide pairs in length.
35. The dsRNA agent of claim 32, wherein the double-stranded region is 23-27 nucleotide pairs in length.
36. The dsRNA agent of claim 32, wherein the double-stranded region is 19-21 nucleotide pairs in length.
37. The dsRNA agent of claim 32, wherein the double-stranded region is 21-23 nucleotide pairs in length.
38. The dsRNA agent of any one of claims 1-37, wherein each strand has 19-30 nucleotides.
39. The dsRNA agent of any one of claims 1-37, wherein each strand has 19-23 nucleotides.
40. The dsRNA agent of any one of claims 1-37, wherein each strand has 21-23 nucleotides.
41. The dsRNA agent of any one of claims 15-40, wherein one or more lipophilic moieties are conjugated to one or more internal positions on at least one strand.
42. The dsRNA agent of claim 41, wherein the one or more lipophilic moieties are conjugated to one or more internal positions on at least one strand via a linker or carrier.
43. The dsRNA agent of claim 42, wherein the internal positions include all positions except the terminal two positions at each end of the at least one strand.
44. The dsRNA agent of claim 42, wherein the internal positions include all positions except the terminal three positions at each end of the at least one strand.
45. The dsRNA agent of claims 42-44, wherein the internal position does not include the cleavage site region of the sense strand.
46. The dsRNA agent of claim 45, wherein the internal positions include all positions except positions 9-12 counted from the 5 '-end of the sense strand.
47. The dsRNA agent of claim 45, wherein the internal positions include all positions except positions 11-13 counted from the 3'-end of the sense strand.
48. The dsRNA agent of claims 42-44, wherein the internal position does not include the cleavage site region of the antisense strand.
49. The dsRNA agent of claim 48, wherein the internal positions include all positions except positions 12-14 counted from the 5 '-end of the antisense strand.
50. The dsRNA agent of claims 42-44, wherein the internal positions include all positions except positions 11-13 on the sense strand counted from the 3'-end and positions 12-14 on the antisense strand counted from the 5'-end.
51. The dsRNA agent of any one of claims 15-50, wherein the one or more lipophilic moieties are conjugated to one or more internal positions selected from the following: positions 4-8 and 13-18 on the sense strand, and positions 6-10 and 15-18 on the antisense strand, counted from the 5'-end of each strand.
52. The dsRNA agent of claim 51, wherein the one or more lipophilic moieties are conjugated to one or more internal positions selected from the group consisting of positions 5, 6, 7, 15, and 17 on the sense strand, and positions 15 and 17 on the antisense strand, counted from the 5'-end of each strand.
53. The dsRNA agent of claim 15, wherein the internal position in the double-stranded region does not include a cleavage site region of the sense strand.
54. The dsRNA agent of any one of claims 14-53, wherein the sense strand is 21 nucleotides in length, the antisense strand is 23 nucleotides in length, and the lipophilic moiety is conjugated to position 21, position 20, position 15, position 1, position 7, position 6, or position 2 of the sense strand or position 16 of the antisense strand.
55. The dsRNA agent of claim 54, wherein the lipophilic moiety is conjugated to position 21, position 20, position 15, position 1, or position 7 of the sense strand.
56. The dsRNA agent of claim 54, wherein the lipophilic moiety is conjugated to position 21, position 20, or position 15 of the sense strand.
57. The dsRNA agent of claim 54, wherein the lipophilic moiety is conjugated to position 20 or position 15 of the sense strand.
58. The dsRNA agent of claim 54, wherein the lipophilic moiety is conjugated to position 16 of the antisense strand.
59. The dsRNA agent of any one of claims 14-58, wherein the lipophilic moiety is an aliphatic, alicyclic, or polyalicyclic compound.
60. The dsRNA agent of claim 59, wherein the lipophilic moiety is selected from a lipid, cholesterol, retinoic acid, cholic acid, adamantaneacetic acid, 1-pyrenebutyric acid, dihydrotestosterone, 1,3-bis-O(hexadecyl)glycerol, geranyloxyhexanol, hexadecylglycerol, borneol, menthol, 1,3-propylene glycol, heptadecanyl, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl, and phenoxazine.
61. The dsRNA agent of claim 59, wherein the lipophilic moiety contains a saturated or unsaturated C4-C30 hydrocarbon chain, and an optional functional group selected from hydroxyl, amine, carboxylic acid, sulfonate, phosphate, thiol, azide, and alkyne.
62. The dsRNA agent of claim 61, wherein the lipophilic portion contains a saturated or unsaturated C6-C18 hydrocarbon chain.
63. The dsRNA agent of claim 61, wherein the lipophilic moiety contains a saturated or unsaturated C16 hydrocarbon chain.
64. The dsRNA agent of claim 62, wherein the saturated or unsaturated C16 hydrocarbon chain is conjugated at position 6 counted from the 5'-end of the chain.
65. The dsRNA agent of any one of claims 14-64, wherein the lipophilic moiety is conjugated via a carrier that replaces one or more nucleotides in the internal position or in the double-stranded region.
66. The dsRNA agent of claim 65, wherein the carrier is a cyclic group selected from pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, [1,3]dioxolanyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinonyl, tetrahydrofuranyl and decahydronaphthyl; or an acyclic moiety based on a serinol backbone or a diethanolamine backbone.
67. The dsRNA agent of any one of claims 14-64, wherein the lipophilic moiety is conjugated to the double-stranded iRNA agent via a linker containing an ether, thioether, urea, carbonate, amine, amide, maleimide-thioether, disulfide, phosphodiester, sulfonamide bond, the product of a click reaction, or a carbamate.
68. The double-stranded iRNA agent of any one of claims 14-67, wherein the lipophilic moiety is conjugated to a nucleobase, a sugar moiety, or an internucleoside linkage.
69. The dsRNA agent of any one of claims 14-68, wherein the lipophilic moiety or targeting ligand is conjugated via a biocleavable linker selected from DNA, RNA, disulfides, amides, functionalized monosaccharides or oligosaccharides of galactosamine, glucosamine, glucose, galactose, mannose, and combinations thereof.
70. The dsRNA agent of any one of claims 14-69, wherein the 3'-end of the sense strand is protected by an end cap, wherein the end cap is a cyclic group having an amine selected from pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, [1,3]dioxolanyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinone, tetrahydrofuranyl, and decahydronaphthyl.
71. The dsRNA agent of any one of claims 14-68, further comprising a targeting ligand that targets neuronal cells.
72. The dsRNA agent of any one of claims 1-71, further comprising: a terminal chiral modification of the phosphorus atom of the bond having an Sp configuration at the first internucleotide bond present at the 3' end of the antisense strand; a terminal chiral modification of the phosphorus atom of the bond having an Rp configuration at the first internucleotide bond present at the 5' end of the antisense strand; as well as A terminal chiral modification of the phosphorus atom of the bond having either an Rp configuration or an Sp configuration is present at the first internucleotide bond at the 5' end of the sense strand.
73. The dsRNA agent of any one of claims 1-71, further comprising: a terminal chiral modification of the phosphorus atom of the bond having an Sp configuration at the first and second internucleotide bonds present at the 3' end of the antisense strand; a terminal chiral modification of the phosphorus atom of the bond having an Rp configuration at the first internucleotide bond present at the 5' end of the antisense strand; as well as A terminal chiral modification of the phosphorus atom of the bond having an Rp or Sp configuration is present at the first internucleotide bond at the 5' end of the sense strand.
74. The dsRNA agent of any one of claims 1-71, further comprising: terminal chiral modifications of the phosphorus atoms of the bonds having an Sp configuration at the first, second and third internucleotide bonds present at the 3' end of the antisense strand; a terminal chiral modification of the phosphorus atom of the bond having an Rp configuration at the first internucleotide bond present at the 5' end of the antisense strand; as well as A terminal chiral modification of the phosphorus atom of the bond having an Rp or Sp configuration is present at the first internucleotide bond at the 5' end of the sense strand.
75. The dsRNA agent of any one of claims 1-71, further comprising: a terminal chiral modification of the phosphorus atom of the bond having an Sp configuration at the first and second internucleotide bonds present at the 3' end of the antisense strand; a terminal chiral modification of the phosphorus atom of the bond having an Rp configuration at the third internucleotide bond present at the 3' end of the antisense strand; a terminal chiral modification of the phosphorus atom of the bond having an Rp configuration at the first internucleotide bond present at the 5' end of the antisense strand; as well as A terminal chiral modification of the phosphorus atom of the bond having an Rp or Sp configuration is present at the first internucleotide bond at the 5' end of the sense strand.
76. The dsRNA agent of any one of claims 1-71, further comprising: a terminal chiral modification of the phosphorus atom of the bond having an Sp configuration at the first and second internucleotide bonds present at the 3' end of the antisense strand; a terminal chiral modification of the phosphorus atom of the bond having an Rp configuration at the first and second internucleotide bonds present at the 5' end of the antisense strand; as well as A terminal chiral modification of the phosphorus atom of the bond having an Rp or Sp configuration is present at the first internucleotide bond at the 5' end of the sense strand.
77. The dsRNA agent of any one of claims 1-76, further comprising a phosphate or phosphate mimetic at the 5' end of the antisense strand.
78. The dsRNA agent of claim 77, wherein the phosphate mimetic is 5'-vinylphosphonate (VP).
79. The dsRNA agent of any one of claims 1-78, wherein the base pair at position 1 of the 5' end of the antisense strand of the duplex is an AU base pair.
80. The dsRNA agent of any one of claims 1-79, wherein the sense strand has a total of 21 nucleotides and the antisense strand has a total of 23 nucleotides.
81. A cell containing the dsRNA agent of any one of claims 1-80.
82. A pharmaceutical composition for inhibiting the expression of a gene encoding 4R-tau, comprising a dsRNA agent according to any one of claims 1-80.
83. A pharmaceutical composition comprising a dsRNA agent according to any one of claims 1-80 and a lipid formulation.
84. A pharmaceutical composition for preferentially inhibiting MAPT transcripts containing exon 10, comprising a dsRNA agent according to any one of claims 1-80.
85. The pharmaceutical composition of any one of claims 82-84, wherein the dsRNA agent is in an unbuffered solution.
86. The pharmaceutical composition of claim 85, wherein the unbuffered solution is saline or water.
87. The pharmaceutical composition of any one of claims 82-84, wherein the dsRNA agent is in a buffered solution.
88. The pharmaceutical composition of claim 87, wherein the buffer solution comprises acetate, citrate, prolamine, carbonate or phosphate, or any combination thereof.
89. The pharmaceutical composition of claim 87, wherein the buffer solution is phosphate buffered saline (PBS).
90. A method of inhibiting 4R-tau expression in a cell, the method comprising contacting the cell with a dsRNA agent according to any one of claims 1-80 or a pharmaceutical composition according to any one of claims 82-89, thereby inhibiting 4R-tau expression in the cell.
91. A method for reducing abnormal expression of a MAPT transcript containing exon 10 in a cell, the method comprising contacting the cell with a dsRNA agent according to any one of claims 1-80 or a pharmaceutical composition according to any one of claims 82-89, thereby degrading the MAPT transcript containing exon 10 in the cell.
92. The method of claim 91, wherein the cell is in a subject.
93. The method of claim 92, wherein the subject is a human.
94. The method of claim 93, wherein the subject suffers from a 4R-tau associated disorder.
95. The method of claim 94, wherein the 4R-tau associated disorder is a neurodegenerative disorder.
96. The method of claim 95, wherein the neurodegenerative disorder is associated with abnormality of the protein 4R-tau encoded by the MAPT gene.
97. The method of claim 96, wherein abnormalities in the protein 4R-tau encoded by the MAPT gene result in aggregation of Tau in the subject's brain.
98. The method of claim 96, wherein the neurodegenerative disorder is a familial disorder.
99. The method of claim 96, wherein the neurodegenerative disorder is a sporadic disorder.
100. The method of claim 96, wherein the disorder is a 4R-tauopathy selected from the group consisting of progressive supranuclear palsy (PSP), progressive supranuclear palsy-Richardson syndrome (PSP-RS), corticobasal syndrome (CBD), argyrophilic grain disease (AGD), frontotemporal lobar degeneration caused by tau (FTLD-tau), FTLD-tau caused by MAPT mutations, multisystem tauopathy with Alzheimer's disease (MSTD), globular glial tauopathy (GGT), Parkinson's disease similar to Parkinson's disease, nonfluent variant of primary progressive aphasia (nfvPPA), behavioral variant of frontotemporal dementia (bvFTD), primary akinesia with freezing of gait (PAGF), primary lateral sclerosis (PLS), familial multisystem tauopathy with precocious dementia (FMSTD), familial progressive subcortical gliosis (familial pSG), pallidal-ponto-nigral degeneration (pPND), familial frontotemporal dementia (e.g., FTD-Kumamoto), N279K tauopathy, rapidly progressive Alzheimer's disease (rpAD), and sporadic Alzheimer's disease (spAD).
101. The method of claim 100, wherein the 4R-tauopathy is selected from progressive supranuclear palsy (PSP), progressive supranuclear palsy-Richardson syndrome (PSP-RS), corticobasal syndrome (CBD), argyrophilic grain disease (AGD), multisystem tauopathy with Alzheimer's disease (MSTD), globular glial tauopathy (GGT), rapidly progressive Alzheimer's disease (rpAD) and sporadic Alzheimer's disease (spAD).
102. The method of claim 101, wherein the 4R-tauopathy is progressive supranuclear palsy (PSP).
103. The method of claim 101, wherein the 4R-tauopathy is rapidly progressive Alzheimer's disease (rpAD).
104. The method of claim 101, wherein the 4R-tauopathy is sporadic Alzheimer's disease (spAD).
105. The method of any one of claims 90-104, wherein contacting the cell with the dsRNA agent inhibits expression of 4R-tau by at least 25%.
106. The method of any one of claims 90-104, wherein inhibiting the expression of 4R-tau reduces the level of 4R-tau protein in the serum of the subject by at least 25%.
107. A method for treating a subject suffering from a disorder that benefits from reduced 4R-tau expression, comprising administering to the subject a therapeutically effective amount of a dsRNA agent according to any one of claims 1-80 or a pharmaceutical composition according to any one of claims 82-89, thereby treating the subject suffering from the disorder that benefits from reduced 4R-tau expression.
108. A method for preventing at least one symptom in a subject suffering from a disorder that benefits from reduced 4R-tau expression, comprising administering to the subject a prophylactically effective amount of a dsRNA agent according to any one of claims 1-80 or a pharmaceutical composition according to any one of claims 82-89, thereby preventing at least one symptom in the subject suffering from the disorder that benefits from reduced 4R-tau expression.
109. The method according to claim 107 or 108, wherein the disease is associated with abnormality of the protein 4R-tau encoded by the MAPT gene.
110. The method of claim 109, wherein abnormalities in the protein 4R-tau encoded by the MAPT gene result in aggregation of 4R-tau in the subject's brain.
111. The method of claim 109, wherein the disorder is a 4R-tauopathy selected from the group consisting of progressive supranuclear palsy (PSP), progressive supranuclear palsy-Richardson syndrome (PSP-RS), corticobasal syndrome (CBD), argyrophilic grain disease (AGD), frontotemporal lobar degeneration caused by tau (FTLD-tau), FTLD-tau caused by MAPT mutations, multisystem tauopathy with Alzheimer's disease (MSTD), globular glial tauopathy (GGT) , Parkinsonism similar to Parkinson's disease, nonfluent variant of primary progressive aphasia (nfvPPA), behavioral variant of frontotemporal dementia (bvFTD), primary akinesia with freezing of gait (PAGF), primary lateral sclerosis (PLS), familial multisystem tauopathy with precocious dementia (FMSTD), familial progressive subcortical gliosis (familial pSG), pallidal-pontine-nigral dementia (pPND), familial frontotemporal dementia (e.g., FTD-Kumamoto), N279K tauopathy, rapidly progressive Alzheimer's disease (rpAD), and sporadic Alzheimer's disease (spAD).
112. The method of claim 111, wherein the 4R-tauopathy is selected from progressive supranuclear palsy (PSP), progressive supranuclear palsy-Richardson syndrome (PSP-RS), corticobasal syndrome (CBD), argyrophilic grain disease (AGD), multisystem tauopathy with Alzheimer's disease (MSTD), globular glial tauopathy (GGT), rapidly progressive Alzheimer's disease (rpAD) and sporadic Alzheimer's disease (spAD).
113. The method of claim 112, wherein the 4R-tauopathy is progressive supranuclear palsy (PSP).
114. The method of claim 112, wherein the 4R-tauopathy is rapidly progressive Alzheimer's disease (rpAD).
115. The method of claim 112, wherein the 4R-tauopathy is sporadic Alzheimer's disease (spAD).
116. The method of any one of claims 107-115, wherein the subject is a human.
117. The method of claim 116, wherein administration of the dsRNA agent or the pharmaceutical composition results in a reduction in Tau aggregation in the brain of the subject.
118. The method of any one of claims 107-117, wherein the dsRNA agent is administered to the subject at a dose of about 0.01 mg / kg to about 50 mg / kg.
119. The method of any one of claims 107-118, wherein the dsRNA agent is administered to the subject intrathecally (IT) or intracerebroventricularly (ICV).
120. The method of any one of claims 107-118, wherein the dsRNA agent is administered intracisternal to the subject.
121. The method of any one of claims 107-120, further comprising determining the level of 4R-tau in a sample from the subject.
122. The method of claim 121, wherein the 4R-tau level in the subject sample is the 4R-tau protein level in a cerebrospinal fluid sample.
123. The method of any one of claims 92-122, further comprising administering an additional therapeutic agent to the subject.
124. A kit comprising a dsRNA agent according to any one of claims 1-80 or a pharmaceutical composition according to any one of claims 82-89.
125. A vial comprising a dsRNA agent according to any one of claims 1-80 or a pharmaceutical composition according to any one of claims 82-89.
126. A syringe comprising a dsRNA agent according to any one of claims 1-80 or a pharmaceutical composition according to any one of claims 82-89.
127. An intrathecal pump comprising a dsRNA agent according to any one of claims 1-80 or a pharmaceutical composition according to any one of claims 82-89.
128. A solid composition prepared by lyophilizing the pharmaceutical composition according to any one of claims 82-89.
Citation Information
Cited By
Multi-valent oligonucleotide moldulator and use thereof
WO2026171282A1
